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Abstract 
This thesis studies techniques for maximising the effects of Cardiac 
Resynchronisation Therapy (CRT) which is a modern therapy for chronic heart 
failure. 
The ability of echocardiographic parameters of mechanical dyssynchrony to identify 
suitable candidate patients for CRT, and subsequently to optimise the interventricular 
delay, is disputed. In this study, I initially perform a systematic review to clarify the 
nature and extent of this problem. I then perform detailed mathematical simulations to 
understand what is feasible in an ideal setting. 
I then evaluate the realistic potential of several non-invasive approaches of optimising 
CRT devices by formal evaluation head-to-head. A fundamental requirement for any 
marker in optimisation of CRT devices, or in selection of patients for implantation, is 
that the marker must be reproducible and must change when the amount of 
dyssynchrony changes. 
I perform detailed experiments in patients where I interrogated a panel of 
echocardiographic parameters to answer the questions relating to the sensitivity of 
each parameter and looked at methods to improve this. I look at the effect of 
spontaneous variability, and the impact on each echocardiographic method including 
3D echocardiography, tissue Doppler imaging and pulsed Doppler techniques 
including velocity time integrals and pre-ejection times. 
Finally, I perform an invasive study of the beat to beat physiological changes which 
occur after intra cardiac timings are altered, to evaluate alternative approaches to 
changes in cardiac performance that might be easier to automate. 
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Introduction 
This thesis addresses the mechanistic question and practical challenge for the 
contemporary management of heart failure. Heart failure is a growing burden in the 
developed world, with an overall prevalence of 2-3% which rises further after 70 
years of age (Dickstein et al. 2008). The number of people living with heart failure 
will continue to increase due to a greater number of people surviving myocardial 
infarctions and an aging population (Cowie et al. 1999). Developments in the 
management of heart failure have led to treatment of these patients moving 
progressively from drug treatments alone, i.e. ACE inhibitors (1987; Flather et al. 
2000), beta blockers (Bristow et al. 1996), angiotensin II receptor blockers (Pitt et al. 
2000) and aldosterone antagonists (Pitt et al. 1999; Pitt et al. 2001); to the addition of 
cardiac resynchronisation devices (Bristow et al. 2004; Cazeau et al. 1994; Cleland et 
al. 2005) and now the beneficial effects of these devices can be maximised by fine 
tuning the different programmable settings (Duvall et al. 2010; Ellenbogen et al. 
2010; Perego et al. 2003; Vanderheyden et al. 2005; Whinnett et al. 2006a) 
In this thesis I have studied the evolving sciences of dyssynchrony assessment and 
optimisation of resynchronisation devices. I seek to understand whether the extensive 
claims in these areas should be accepted at face value. Improving ability to select 
patients for CRT by identifying those who are likely to respond would be clinically 
valuable if true. I have studied this in a critical quantitative literature review in 
Chapter 3. Once implanted, ensuring that we are getting the most from the device by 
changing the atrioventricular (AV) or ventriculo-ventricular (VV) delay is important 
however as described in Chapter 4, it is essential that we have a tool which is able to 
detect the small changes which occur when intra-cardiac settings are altered in a 
reproducible manner. 
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1.1 Origin of the dyssynchrony concept 
In normal subjects, the ventricular walls contract together simultaneously – easily 
observable be eyeball alone (Holloway et al. 2011). In heart failure however, it is 
equally evident by eyeball observation alone that some patients have very disrupted 
ventricular wall contraction which is dyssynchronous.  
Left bundle branch block (LBBB) is common in heart failure (Baldasseroni et al. 
2002; Hawkins et al. 2007; Xiao et al. 1991) and it is conceptually easy to understand 
why this disruption of normal electrical conduction would lead to disrupted 
mechanical contraction. Many studies demonstrated the link between LBBB and poor 
survival in heart failure, with a rise in mortality as the QRS duration becomes more 
prolonged (Baldasseroni et al. 2002; Hawkins et al. 2007; Hochleitner et al. 1990; 
Shamim et al. 1999; Stewart et al. 2011).  
As a consequence of the observation, innovative electrophysiologists introduced the 
concept of pacing the ventricles simultaneously at two distinct sites to alleviate the 
effect of LBBB (and of long PR intervals) (Auricchio et al. 1999a; Cazeau et al. 1994; 
Nelson et al. 2000). 
1.2 Development of criteria for selecting patients – 
problems and solutions  
The dramatic success of biventricular pacing seen in many studies propelled the field 
into the limelight and in its wake came the assumption that mechanical dyssynchrony 
– a frequent counterpart of LBBB – must surely be the true lesion being targeted. In 
parallel with studies reporting the mechanical counterpart of electrical dyssynchrony 
(LBBB), large scale clinical trials organised by manufacturers demonstrated clear 
effect on quality of life, 6 minute walk test, ejection fraction and symptoms (Cazeau 
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et al. 2001; Cleland et al. 2005; Higgins et al. 2003; Kapetanakis et al. 2011; Linde et 
al. 2002; Sutton et al. 2006a; Young et al. 2003) from CRT in patients with heart 
failure. CARE HF closed the debate on whether CRT was beneficial: the survival 
enhancement was large, unequivocal and incontrovertible. 
Initial selection criteria included wide QRS duration, and prolonged PR intervals 
(Bristow et al. 2004; Cazeau et al. 1994). Entry criteria for the majority of the studies 
included a long QRS duration, a reduced ejection fraction, and NYHA III/IV. There 
has also been work on NYHA class II (Adabag et al. 2011; Linde et al. 2010; Moss et 
al. 2009a) patients and those with a narrower QRS duration (Beshai et al. 2007; 
Cazeau et al. 2008; Ghio et al. 2004; van Bommel et al. 2010a) which have had varied 
results.   
At this stage the very large number of papers reporting associations between 
mechanical dyssynchrony and physiological response became the driver to encourage 
detailed assessment of patients for mechanical dyssynchrony as part of their 
evaluation for CRT implantation. Our centre was also caught up in this excitement 
and published recommended protocols for mechanical dyssynchrony assessment 
(Lane et al. 2004). A forest of papers soon followed. They showed that the 
identification of mechanical dyssynchrony could predict response (Bax et al. 2003a; 
Chung et al. 2008a; Kapetanakis et al. 2005; Kapetanakis et al. 2011; Yu et al. 2004a). 
The concept of identifying patients with dyssynchrony was championed by many, 
assisting in identifying patients who would benefit most from CRT implantation. 
Many techniques became available and are still continuing to come to light, with the 
reported ability to detect mechanical dyssynchrony in a manner that predicts response. 
Mostly at the forefront was tissue Doppler imaging and real time 3-dimensional 
echocardiography.  
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Unfortunately many patients in real life do not show a clear, favourable response 
(Auricchio & Prinzen 2011) as the published reports lead us to believe. Many 
individual centres could not reproduce reliable prediction, but assumed they were in 
error (and hence did not publish). What was the reason, and why could we not 
identify the cause of this problem? Is it because they are selected incorrectly? Do they 
require optimisation of their pacemaker settings? How do we then proceed to optimise 
these patients? Or is there a fundamental flaw in our understanding and expectation of 
CRT devices in heart failure patients? The hunt for suitable mechanical dyssynchrony 
marker to select patients for CRT implantation continued. Surely assessing many 
favourable markers head-to-head was the way forward?  
Only a few people pushed back by arguing that mechanical dyssynchrony was never 
the principal basis of the endpoint trials. Instead, because it is clinically obvious that 
electrical dyssynchrony surely can only be the mediate harm through mechanical 
dyssynchrony, and the CARE-HF pivotal endpoint trial had a mechanical 
dyssynchrony avenue of entry (albeit used by only a minority of patients), most 
accepted without hesitation that mechanical dyssynchrony ought to be worth 
assessing, if only we could fathom how, as part of selection of patients for CRT.  
1.3 The PROSPECT Crisis 
The PROSPECT study was a disaster for those in favour of mechanical dyssynchrony 
and people were forced to confront serious gaps within the reasoning (Chung et al. 
2008a). The arguments included statements that those centres involved in PROSPECT 
were not skilled or able to perform these measurements (even though these were the 
leading centres!), and that there were different ma
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However, these alone could not explain the abject failure of prediction by mechanical 
dyssynchrony. 
Looking back through the literature, despite the dominant reputation of a large 
number reporting that mechanical dyssynchrony controlled response almost 
exclusively (Bax et al. 2003a; Bleeker et al. 2007b; Kapetanakis et al. 2011), there 
was a smaller group of less highly cited papers contradicting these findings (Diab et 
al. 2011; Marcus et al. 2005). In the early phase of my thesis I worked with others to 
systematically review these to understand why this contradiction is in the literature. 
1.4 The next step… 
Many research centres are now focussing work on trying to reduce mechanical 
dyssynchrony by optimising the settings of the devices (Bax et al. 2003a; Chung et al. 
2008a; Duvall et al. 2010; Inoue et al. 2005a; Jansen et al. 2006a; Sawhney et al. 
2004; Scharf et al. 2005; Thomas et al. 2009; Turcott et al. 2010; Zhang et al. 2008; 
Zuber et al. 2008). This materialised due to a sizable proportion of patients not 
responding to CRT implantation (Reuter et al. 2002). The question arose…. Why do 
these patients not respond and benefit as expected? How do we handle this, as the 
device is already implanted? The immediate attractive answer once the device is 
implanted is to attempt to improve the settings and potentially improve the function of 
the device for that particular patient. Hence the consideration of optimising the 
settings: firstly altering the timings of the atrioventricular (AV) delay and secondly 
the ventriculo-ventricular (VV) delay. Shortening a prolonged AV delay by atrially 
sensed RV pacing has already been shown to be beneficial (Hochleitner et al. 1990), 
long before CRT devices were used; so AV adjustment was a potential avenue to 
consider in CRT also. 
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Optimising the intra-cardiac settings has potentially two mechanisms of action. First, 
changing the AV delay timings can result in improved filling of the ventricle if it 
permits long filling time while preventing atrial ejection being uninterrupted by 
ventricular systole (Ritter et al. 1999). Second, choosing the ideal VV delay setting 
should reco-ordinate the activation timings of the ventricle and improve mechanical 
dyssynchrony (Sogaard et al. 2002; Vanderheyden et al. 2005). 
After implantation of a resynchronisation device, in typical UK practice relatively few 
patients undergo routine optimisation even though guidelines recommend that AV and 
VV delay should be optimised, and even though clinical trials have only demonstrated 
survival benefit of individually-optimised CRT (Carluccio et al. 2011; Cleland et al. 
2005). Are we, as clinicians, right to cut corners from the trial-validated, guideline-
mandated process? To address this, I examine the basic science of optimisation in 
Chapter 4.  
Conflicting studies also emerged as to what was a reliable way to optimise intra 
cardiac timings of CRT devices successfully (Chung et al. 2008a; Duvall et al. 2010; 
Parreira et al. 2005; Thomas et al. 2009; Turcott et al. 2010; Vesely et al. 2008; 
Whinnett et al. 2006b).   
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1.5 The Problem 
There are two very large unanswered practical questions with regards to CRT which 
are inter-related. 
(1) Which patients are in need of resynchronisation and which are not i.e. what is 
a good measure of dyssynchrony out of the many that have been reported to be 
reliable predictors of benefit? 
(2) Once implanted, how should we determine the best timings of the two 
ventricular leads? 
Provided that CRT works by reducing mechanical dyssynchrony, there is a systematic 
solution to these questions. First we need to find a tool that can accurately, reliably 
and reproducibly measure small changes in mechanical dyssynchrony. We can then 
test this tool for its ability to identify patients who would benefit from CRT, by 
running a trial comparing CRT-on versus CRT-off, on a wide spectrum of values of 
this variable at baseline. Following implantation, we should then be able to optimise 
VV delay to minimise this marker of dyssynchrony. 
1.6 The different families for measuring mechanical 
dyssynchrony 
Measuring mechanical dyssynchrony has a wide variability and at present there is no 
single method that has been shown to be used in multiple centres which can reliably 
measure it, hence it is unclear as to what to do practically?  
Echocardiography has been widely studied and in Chapter’s 3 and 4 I have reviewed 
current literature to identify those parameters which have been used for both selecting 
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and predicting response to CRT implantation, and those feasible for guiding 
optimisation. 
For each of the imaging techniques, measurements may be made within the left 
ventricle, or as a comparison between the right and left ventricle.  
1.6.1 Measurements focusing between the right and left ventricle 
Doppler timings for guiding selection for CRT device implantation have included the 
difference between ejection of the right and left ventricle, namely the inter-ventricular 
ejection delay using pulmonary Doppler flow and aortic Doppler flow measurements. 
1.6.2 Measurements focusing within the left ventricle 
Tissue Doppler imaging conventionally is used for dyssynchrony assessment by 
looking at the left ventricular walls and establishing the timings for contraction of the 
different walls. Most commonly quoted in the literature is the 2 segment, 6 segment of 
12 segment model (Bax et al. 2003a; Diab et al. 2011; Notabartolo et al. 2004; van 
Bommel et al. 2010b; Vesely et al. 2008; Yu et al. 2004a).  
3 dimensional echocardiography is used for dyssynchrony assessment in some centres 
(Kapetanakis et al. 2005) and divides the left ventricle into multiple segments. 
Dyssynchrony assessment is performed on each of these segments reaching their 
minimal volume.  
Doppler timings are recommending in some local guidelines (Lane et al. 2004) and 
can be used as guide to selection for implantation. However, the aortic pre-ejection 
time is only half of the story, because it addresses the left ventricle only. 
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1.6.3 Final pathway echocardiographic measurements for 
optimisation 
Stroke volume can be assessed using Doppler and has been used in some centres to 
guide optimisation (Gorcsan et al. 2004b). This is the LVOT VTI measurement which 
is the resulting cardiac flow that is ejected and often used as a surrogate for cardiac 
output.  
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1.7 How do we evaluate a proposed marker for assessing 
dyssynchrony and guiding optimisation? 
Any marker proposed for this purpose must meet a series of criteria 
1) At bare minimum, the method proposed must be able to reliably detect 
changes which occur when intra-cardiac timings are changed experimentally 
within an individual with everything else kept constant. 
2) The measured outcome or marker should be independent from that which is 
used to optimise, so that individual samples of random error are not used to 
validate themselves. 
These are cheap and quick to perform on any technique which is proposed as a 
method for optimisation, and in fact should be mandatory before clinical studies 
and trials are performed as these will be doomed unless they are satisfied. 
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1.8 Aims of this thesis 
Within this thesis I shall probe the plausibility of the “dyssynchrony-response” 
hypothesis, and examine the basic science for developing echocardiographic protocols 
for CRT optimisation. My individual aims are as follows: 
1.8.1 To evaluate and understand the current literature on cardiac 
resynchronisation therapy. 
I critically review the world literature on CRT and methods of predicting those who 
may benefit from CRT implantation. I cover large and small studies to gain a full 
overview of the work that have been performed. I review our local data of 
echocardiographic variability of ejection fraction, a marker often used as an endpoint. 
I provide mathematical algorithms to understand the degree of correlation possible 
between measurements and outcomes, so that claims in the literature may be viewed 
in the context of actual possible findings. 
1.8.2 How can we ensure protocols for optimisation are not a waste 
of time, but in fact reliable? 
I perform a mathematical simulation to understand the effect of signal and noise on 
the reliability and reproducibility of optimisation methods. I evaluate the literature to 
determine how this relates to the methods employed currently for optimisation 
purposes and will suggest ways we can use protocols that are robust for clinical use. 
1.8.3 Are echocardiographic markers plausible candidates for 
measuring dyssynchrony that can be measured by CRT? 
Many echocardiographic markers have been proposed as potential criteria to select 
patients for CRT implantation. I aim to test a series of these markers for their ability 
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to detect changes in mechanical dyssynchrony for experimental manipulation of 
dyssynchrony i.e. alteration of VV delay. 
I assess the clinical implications of their various reproducibility values, not only for 
optimisation of CRT devices but also for selection of patients for CRT implantation. 
1.8.4 Assess the effect of changing atrioventricular delay on 
invasive flow, invasive pressure and non-invasive pressure. 
My thesis also addresses the interplay between blood flow and arterial blood pressure 
in the immediate aftermath of changes in AV delay 
I aim to identify the beat-by-beat changes which occur when AV delay is changed 
from a favourable to a non favourable AV delay setting. With high temporal precision 
I measure invasive and non-invasive pressure and invasive flow, to assess whether 
improvements in pressure and cardiac output persist following improvements in AV 
delay. 
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2  Methodology 
2.1 Patient recruitment 
Patients were recruited from the Imperial College NHS Healthcare trust if they met 
the selection criteria, mentioned in individual chapters. They were given the 
opportunity to discuss the study and provided with a letter and an information sheet 
(Appendix 1 and 2).  Patients who agreed to participate in the study signed consent 
forms (Appendix 3). Patients were free to withdraw from the study at any time. 
2.2 Equipment 
2.2.1 Echocardiography 
Echocardiography was performed in all patients using the Philips IE33 machine 
(Figure 2-1). This machine was chosen as it is able to perform both the advanced 3 
Dimensional (3D) echocardiography and tissue Doppler imaging (TDI) required for 
some sections of the study in addition to the more routine 2D spectral  Doppler 
necessary for the other sections of the study. 
The IE33 enabled me to acquire images which were compatible with the 3D analysis 
software Tomtec (4D analysis CAP, Tomtec GmBH, Unterschlessheim, Germany) 
and the tissue Doppler analysis software, Philips Qlab 8.1with cardiac motion analysis 
(CMQ). Echocardiographic imaging was performed in all the study patients in the 
outpatient setting, which meant that this machine was therefore an ideal choice given 
its features and locality for this use. 
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2.2.2 Transducers  
Both transducers which were used in this study have Purewave Crystal technology 
that is able to transfer energy with greater precision and efficiency and hence superior 
overall quality (Yu et al. 2009) compared to previous technology. A watery based gel 
is applied to all transducers to improve contact impedance between the probe and 
patients skin. 
2.2.2.1 Transthoracic Probe 2D 
2D studies and Doppler images were acquired using the Philips S5-1 sector ultrasound 
transducer (Figure 2-1).  This is a phased array probe with frequencies between 1 and 
5MHz. Phased array probes can be swept through a wide volume without physically 
needing to turn the probe. This is possible because of the multiple elements making 
up the probe and which can be pulsed at different times. 
2.2.2.2 Transthoracic probe 3D 
3D echocardiography was performed using a X3-1 matrix array transducer (Figure 
2-1) which is fully compatible with the IE33 machine and enables triggered full 
volume images required for the real time 3D images. Therefore, full volume pyramid 
shaped datasets are acquired and can be manipulated. Geometric assumptions can be 
corrected for. This probe operates at frequencies between 1 and 3MHz. A minimum 
frame rate of 20Hz has been used throughout this study.  
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Philips IE33 echocardiography machine 
 
 
Philips S5-1 transducer 
 
 
Philips X3-1 transducer 
 
Figure 2-1: Photograph of the Philips IE33 machine used for data acquisition 
(top panel), with the 2D probe (middle panel) and the 3D probe (bottom panel).  
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2.3 Echocardiographic measurements used throughout 
the studies for optimisation processes. 
All of the echocardiographic measures that I critically analysed in my studies have 
been used in previously published research into optimisation, and have been proposed 
as valuable tools for guiding the optimisation process both in the research arena and in 
routine clinical practice.   
A clear and visible ECG trace was recorded with all echocardiographic images to 
allow timings to be calculated with precision and reference to the QRS complex. 
2.3.1 Doppler assessment of VV delay 
Pulsed wave Doppler was used in both (a) ejection flow dyssynchrony and (b) 
velocity time integral measurements.  Both of these measures have been used in 
published studies of echocardiographic optimisation of biventricular pacemakers 
(Bertini et al. 2008; Duvall et al. 2010; Fischer et al. 2009; Lane et al. 2004; Parreira 
et al. 2005; Turcott et al. 2010; van Geldorp et al. 2011; Vanderheyden et al. 2005). 
2.3.1.1 Ejection flow dyssynchrony – acquisition 
Ejection flow dyssynchrony was measured in 2 ways. Firstly aortic pre-ejection time 
(APET), calculated from QRS onset to commencement of flow from left ventricular 
outflow tract (Figure 2-2) and, secondly, interventricular mechanical delay (IVMD) 
calculated as the difference between onset of LV ejection and RV ejection (Lane et al. 
2004). Both have been demonstrated to be suggestive of intraventricular and 
interventricular delay respectively (Cazeau et al. 2003). 
Firstly we acquired pulsed wave (PW) Doppler images in the left ventricular outflow. 
Images were taken from the apical 5-chamber view with the pulse wave Doppler 
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cursor at the left ventricular outflow tract approximately 1 cm below the aortic 
annulus with the PW-Doppler (Lopez-Candales & Edelman 2011). For the right 
ventricular outflow tract, the PW Doppler was suitably placed approximately 1cm 
distal to the pulmonary valve (Lopez-Candales & Edelman 2011). 
Eight beats were acquired at each VV delay namely RV excitation first at 40ms, 20 
ms, LV excitation first at 20ms, 40ms and 60ms, and simultaneous ventricular 
excitation at VV 0ms. All acquisitions were made at end-expiration to minimise 
respiratory variation.  
During spectral Doppler imaging the position of the transducer needs to allow the 
blood flow to be parallel to it (and hence parallel to the sound waves). Any different 
inclination of the probe will result in inaccurate blood velocity to be measured unless 
corrections are made. Therefore I took great care to ensure not only that the angle was 
correct, but also that the subsequent images also have the same careful consideration 
when acquiring Doppler on subsequent beats / days.   
2.3.1.2 Ejection flow dyssynchrony – analysis 
The analysis was performed by me, a single experienced operator, offline which 
ensured that there was no haste in the measurements with the patients present but 
instead time and a calm environment to analyse the data ensured an accurate and 
precise analysis. All images were stored in DICOM format to a specialised 
echocardiography image storage and analysis system, Medcon UK (Mc Kesson, CA). 
Offline analysis was performed here. 
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Figure 2-2 Measuring aortic pre-ejection time.  
In the top panel I have shown the image that is acquired with the QRS clearly seen 
and the pulsed wave Doppler trace shown below it. The lower panel demonstrates the 
measurement taken from the onset of the QRS (the blue vertical line) and the timings 
(the red horizontal line). This was performed for the pulmonary flow in a similar 
manner. 
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2.3.1.3 Velocity-time Integral – acquisition 
Images were taken from the left ventricular outflow tract as described above. A clear 
pulsed wave Doppler image was acquired as shown in Figure 2-3 and again 8 beats 
were acquired at each VV delay at end expiration.  
2.3.1.4 Velocity-time Integral – analysis 
Offline analysis was manually traced and resulted in digitised velocity time integral 
(VTI) tracings. These VTI values were measured for each patient, at each VV delay, 
at eight beats per VV delay. 
 
Figure 2-3 An example of a velocity time integral tracing of a pulsed wave 
Doppler image. 
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2.4 Segmental assessment of VV delay optimisation  
Routinely the left ventricle is divided into a 16 or 17 segment model (Flachskampf & 
Daniel 2010; Liodakis et al. 2009) for other uses such as reporting stress echo in 
addition to dyssynchrony assessment, and in a similar fashion for 3 dimensional echo 
this process has been adopted (Kapetanakis et al. 2005).  
For TDI imaging we are able to look at individual walls and adopt either a 2, 6 or 12 
segment model (Chung et al. 2008a; Yu et al. 2004a) this can be used either for intra 
ventricular dyssynchrony assessment (most commonly) or interventricular 
dyssynchrony. In some cases these are combined to give an overall value to consider 
dyssynchrony (Lane et al. 2004). 
2.4.1 3D echocardiography 
The development of real time 3D echocardiography enabled LV assessment to be 
performed in yet another way (Corsi et al. 2005; Kuhl et al. 2004; Soliman et al. 
2007a). Real time 3D echocardiography has the potential advantage of eliminating 
any geometric assumptions that may occur when taking measurements of the left 
ventricle. As such good results had been obtained in some centres; it has been 
assumed that other uses for this modality may also be beneficial.  
Real time 3 dimensional echocardiography considers all 16 segments of the ventricle 
separately (Figure 2-4) and therefore also enables the operators to assess the 
intraventricular delay of the LV by calculating the time to minimal volume of each 
segment as a percentage of the cardiac cycle. 
  
 
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4 Segmental division of the left ventricle.  
In the bottom left corner we can see the ventricle divided up into 16 segments (plus 
apex), each of which corresponds to a different coloured section of the ventricle. 
 42 
The systolic dyssynchrony index (SDI) (Gimenes et al. 2008; Kapetanakis et al. 2011; 
Monaghan 2006) is a value which is the standard deviation of the time to minimal 
volume of all 16 segments of the left ventricle. A lower value correlates to less 
dyssynchrony. In a synchronous ventricle, we would get a value of approximately 3% 
to 5%. As the ventricle becomes more dyssynchronous this will increase. Values 
above 10% are said to be predictive of response to biventricular pacing (Kapetanakis 
et al. 2011).  
Changing VV delay towards an optimal setting, should therefore lead to a lower SDI 
value, and therefore should theoretically be a potential tool for guiding optimisation 
of VV delay.  The use of 3D assessment of dyssynchrony has been used in some 
centres for predicting response to biventricular pacing (Kapetanakis et al. 2005), but it 
has not been fully assessed for VV optimisation 
2.4.1.1 3D echocardiography- acquisition 
Echocardiography was performed by myself using the X3-1 matrix array transducer. 
Full-volume datasets were acquired over 4 cardiac cycles using this matrix array 
transducer, each recorded over 4 consecutive beats. Patients were in the left lateral 
decubitus position and images were recorded from the apical 4 chamber view with the 
left ventricle clearly identified. Acquisitions had a minimum frame rate of 20 frame/s 
in keeping with ASE guidelines (Chung et al. 2008b; Gorcsan et al. 2004b), with the 
patient breath holding at end expiration. For each VV delay four replicate 
measurements were taken.  
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2.4.1.2 3D echocardiography- analysis 
Measurements of 3DE volumes were performed off-line using semi-automated border 
detection software (4D analysis CAP, Tomtec GmBH, Unterschlessheim, Germany), a 
method that has been well validated both for measurements of ejection fraction 
(Jenkins et al. 2009; Kuhl et al. 2004), and also for calculating the systolic 
dyssynchrony index (SDI), a method which attempts to predict response to CRT 
(Kapetanakis et al. 2011; Liodakis et al. 2009). 
The apical 4 chamber is used as the reference plane, with the apical 2 and 3 chamber 
views derived automatically from a 60 degree rotation between planes, using manual 
adjustments as required. I chose the frames for EDV and ESV measurement in 
accordance with American Society of Echocardiography guidelines. EDV 
measurements were taken at the frame following mitral valve closure and ESV were 
measured on the image with the smallest left ventricular cavity. Initial contours were 
set by tracing the endocardial borders end-diastolic and -systolic images in the apical 
views. I traced the contours using the automatic border detection (Figure 2-5). Further 
manual editing was performed to ensure the smoothest delineation in the border 
between diastole and systole. A 3D mesh and the segmental model of the 3D shell are 
created. From this data, the software created time-volume curves and determines the 
time to minimum volume for each of the 16 segments. The standard deviation of these 
timings is then calculated automatically by the software which gives the systolic 
dyssynchrony index. 
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Figure 2-5 An example of drawing around the endocardium which is shown here 
for the 4 chamber view. This is repeated for 2 chamber and 3 chamber, which then 
results in the 3D reconstructed ventricle. 
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Time-volume curves are produced (Figure 2-6) and the systolic dyssynchrony index 
was calculated with the analysis performed by myself for each VV delay. Four 
replicate measurements were taken at each VV delay – therefore 4 optimisation 
processes were performed. In Figure 2-7 I have drawn schematic diagrams of time 
volume curves of a synchronous ventricle along side a dyssynchronous ventricle so 
that it is clearly shown how the systolic dyssynchrony index is calculated. 
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Figure 2-6 The dyssynchrony curves of a normal synchronous ventricle as seen when analysis is performed.  All segments reach the time 
to minimum volume at a similar time. An SDI value is then calculated. 
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Figure 2-7 Schematic diagram showing the segmental analysis with each coloured line representing a segment of the ventricle.  
Each 16 segments have a black line that denotes the time to minimal regional volume. The SDI calculation is the standard deviation of all of 
these time points. On the left there is a synchronous ventricle, and hence would calculate a low SDI. On the right there is a dyssynchronous 
ventricle with a high standard deviation and hence high SDI.
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2.4.2 Tissue Doppler Imaging- technology 
For tissue Doppler imaging, the colour Doppler frame rates were at least 90 frames/s 
in all subjects, with pulse repetition frequencies of 500 Hz to 1 kHz, resulting in 
aliasing velocities of 16 to 32 cm/s.  
LV dyssynchrony using TDI has been proposed using several walls of the ventricle 
and several methods of calculating the maximum level of dyssynchrony (Chung et al. 
2008a; Yu et al. 2002). Since none of the methods currently available have been 
deemed to be able to recommend improvement in patient selection for CRT beyond 
current guidelines (Chung et al. 2008a), we tested and calculated various possible 
combinations including 2 segment, 6 segment and 12 segment analysis (Sogaard et al. 
2002; Yu et al. 2005). This therefore incorporated all walls and different levels within 
the ventricle. 
2.4.2.1 Tissue Doppler Imaging-acquisition 
Studies were performed using the IE33 and images were obtained using a 3.5MHz 
transducer. Apical images of the left ventricle including the level of the mitral annulus 
were acquired with a minimum frame rate of 90 Hz (Gorcsan et al. 2004b). Images 
were acquired with LV cavity positioned in the centre of the sector showing clear 
myocardial definition. 4 chamber, 3 chamber and 2 chamber views of the left 
ventricle were acquired with the patient holding their breath at end-expiration. A 
minimum of 4 cycles were acquired, triggered to the QRS complex and saved in 
cineloop format, allowing 4 separate analyses.  
2.4.2.2 Tissue Doppler Imaging-analysis 
We calculated offline (a) the time from onset of QRS to onset of S wave and (b) the 
time from onset of QRS to the peak of S wave for 2 segment, 6 segment and 12 
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segment tissue Doppler measurements. To obtain time–velocity curves, a sample 
volume was placed within the segments at the region of interest (Figure 2-8). 2 
segments involved the basal septum and basal lateral walls. 6 segments involved the 
basal septum, lateral, anterior, inferior, posterior and anteroseptal walls. 12 segments 
consisted of the 6 of the 6 segment model and their mid level counterpart. All 
measurements were taken at rest at end expiration.  
To assess LV dyssynchrony, the interval to-peak systolic velocities was obtained by 
placing sample volumes in desired walls.  The optima was defined by, firstly, the 
absolute range (maximum minus minimum) of times between segments of the left 
ventricle (Bleeker et al. 2007a; van Bommel et al. 2010b) and, secondly, the standard 
deviation of these dispersion times using 2-segment, 6-segment and 12-segment 
models. For the 2 segment model a cut-off of >60 ms has previously been quoted as a 
marker of dyssynchrony (Bax et al. 2003a).  For a 12-segment model often the Yu 
index is championed (Yu et al. 2002; Yu et al. 2005) with a cut off >32ms as the 
standard deviation between the 12 segments as the threshold for dyssynchrony. I 
considered that the more synchronous the ventricle, the smaller the value for the delay 
between the walls. The greater the dyssynchrony, the greater the delay between the 
walls.  
Colour coded TDI was chose in preference over pulsed wave TDI since you can get 
several segments analysed in the same heart beat and analyse offline (Bleeker et al. 
2007c). We used Philips Qlab 7.0 3DQ and 3DQ advanced software the QLAB Strain 
quantification plug-in which allowed segmental analysis of the tissue Doppler traces. 
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Figure 2-8 An example of a TDI trace where the region of interest is the basal 
septum which is where the cursor is positioned in the top panel.  
The subsequent tissue Doppler trace is seen in the bottom panel. Measurements are 
taken from (a) the time from onset of QRS to onset of S wave and (b) the time from 
onset of QRS to the peak of S wave. 
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2.5  QRS duration as a marker for optimisation of CRT 
QRS duration is used as a guide to help select patients for CRT implantation (Barnett 
et al. 2007). Therefore the question could be raised, that if it is a useful and 
recommended method for selection, could it also be used for optimisation? 
(Tamborero et al. 2011; Vidal et al. 2007). To add further weight to this we know that 
a longer QRS duration is associated with increased mortality (Shamim et al. 1999) 
and furthermore, even within the normal reference ranges it is associated with a 
greater LV mass, LVEDV and LVESV(Stewart et al. 2011; Yerra et al. 2006) 
2.6 Pacemaker programmers 
Patients had either Medtronic or Boston Scientific biventricular pacemakers /ICD’s 
implanted, therefore we used both these pacemaker programmers to manipulate both 
the AV and VV delay settings in order to perform these studies (Figure 2-9).  
In the non-invasive studies we used both programmers in the standard way to enable 
connection between the patient and the programmer. 
The patient’s pre study settings were recorded at the beginning of the study. We then 
changed the atrioventricular (AV) and ventriculo-ventricular (VV) delays as per each 
study protocol, documented in each chapter. We were also able to change the atrial 
rate of the pacemaker. At the end of each study visit the patients initial pacemaker 
setting were re-program
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Figure 2-9 A photograph of the Boston Guidant pacemaker used in the study (left panel) and a close up of the programmer screen (right panel) as 
programmed during one of my experiments. 
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2.7 Invasive study 
Temporary biventricular pacing was performed in eligible subjects. A quadripolar 
electrode catheter (Josephson Curve, Bard Viking) was placed in the right atrium 
(usually the right atrial appendage) and a pentapole electrode catheter was placed at 
the right ventricular apex. An AL1 and/or a channel sheath was used to gain access to 
the coronary sinus and an ATW wire was positioned in a lateral or posterior-lateral 
coronary sinus branch for LV temporary pacing(Lane et al. 2008). LV capture was 
verified using a 12 lead ECG.   
In this study a CRT pacemaker (Medtronic InSynch III 8042) was connected 
extracorporally and transitions made via a standard pacemaker programmer.  
2.7.1 Invasive study - acquisition 
The protocol consisted of a series of transitions from AV delay 40ms to 120 ms.  
Measurements were recorded for at least 100 beats before and 100 beats after the 
change in AV delay. To minimise the effect of random variation, triplicate runs of the 
experimental protocol were conducted so that each patient’s dataset was composed of 
an average of 3 runs, aligned by beat and registered to the time point of transition 
from 40 ms to 120 ms. Heart rate was fixed at 100bpm in all patients by atrially 
pacing. Stable pacing and sensing for all 3 pacing wires was monitored throughout the 
protocol in all patients. 
2.7.2 Invasive pressure and flow measurements 
Aortic pressure was measured using a fluid filled catheter positioned in the aorta 
approximately 5 cm from the aortic valve. The catheter pressure was initially 
normalised to the pressure wire signal with the pressure wire positioned at the tip of 
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the catheter. The aortic flow was measured with a flow wire (Volcano FloWire 1400) 
also approximately 5 cm from the aortic valve within the aorta. 
2.7.3 Non-invasive blood pressure measurements - Finometer 
technology 
Beat-by-beat blood pressure was recorded using the Finometer system (Finapres 
Medical Systems, Amsterdam, Holland). The blood pressure is measured based on the 
arterial-volume clamp method (Imholz et al. 1998; Penaz 1973), after a cuff is placed 
in the middle finger.  
This is a form of plethysmograph which uses light to non-invasively detect changes in 
microvascular blood volume (Dorlas & Nijboer 1985; Turcott & Pavek 2008). The 
main components within the cuff are an inflatable air bladder and a plethysmograph 
with an infra red light source and light detector. The front-end unit is connected to the 
air bladder by a hose and to the light source and detector by a cable (Bogert & van 
Lieshout 2005). This front-end unit is then connected to the main unit and pump, 
Figure 2-10.  
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Figure 2-10 A Finometer unit (top panel) which has the connections at the front as 
described: the main unit is strapped to the back of the patients arm with the cuff 
around the index finger (bottom panel).
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By applying a finger cuff and monitoring pressure it is able to detect the change in 
volume as the amount of pressure requires will vary. This is then digitised when there 
is a change in pressure which occurs i.e. when AV or VV delay settings are altered for 
example. Transient changes in both volume and pressure (which are proportional) will 
allow optima to be identified. This has been investigated by Whinnett et. al who have 
identified that the Finometer, an advanced plethysmograph, can indeed be used to 
optimise changes in both AV and VV delay (Whinnett et al. 2006a). Maximising 
blood pressure is the ultimate aim given low SBP readings are a predictor of mortality 
in the heart failure patient population (Abraham et al. 2008; Adams, Jr. et al. 2005). 
The pressure is recorded based on the amount of pressure required to keep a constant 
arterial diameter. Hence there is a pulsatile feeling on the patient’s middle finger 
although if the trace is not good, then the other fingers can be used. There is a balloon 
which is within the finger cuff that inflates and deflates in order to maintain a constant 
pressure. Prior to commencing the recordings, there is a calibration process that 
occurs. The amount of cuff pressure required to counteract the intra-arterial pressure 
is what gives the indirect measure of the change in intra-arterial pressure (Wesseling 
et al. 1985). 
The Finometer has been well validated for a method of monitoring blood pressure 
(Schutte et al. 2004) and is widely recommended as a valid technology for the 
measurement of changes in arterial blood pressure (Kurki et al., 1987; Smith et al., 
1985; Wesseling et al., 1985). It has also been used for recording changes during 
optimisation protocols in the research setting (Whinnett et al. 2006a).  
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2.7.4 Surface ECG 
A three lead ECG recording was continuously measured for all of the patients 
undergoing invasive testing (Figure 2-11). The leads were positioned (1) on the right 
side of the chest just below the right clavicle, (2) on the left side of the chest, just 
below the left clavicle and (3) on the lower chest, just above and left of the umbilicus 
(Pope 2002).  Those undergoing non-invasive echocardiography without the invasive 
protocol had the ECG recorded on the echocardiography machine only.  
 
 
Figure 2-11 An example of the ECG acquisition which occurs simultaneously with the 
invasive measurements
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2.7.5 Acquisition system 
Analogue output feeds of all the signals were taken via a National instruments DAQ-
Card AI-16E-4 (National Instruments, Austin, TX) and acquired in digital form using 
Labview (National Instruments, Austin, TX), Figure 2-12. All the raw data was stored 
in text files for use in the subsequent offline analysis. 
2.7.6 Analysis software 
The data for non-invasive blood pressure, invasive blood pressure and invasive flow 
was collected as mentioned and analysed with custom software based ion the Matlab 
platform (MathWorks, Natick, MA). 
This software allows automated analysis, therefore many more replicates can be 
analysed in a shorter space of time. This improves the signal-to-noise ratio. 
Automation also removes human error which can occur if measuring traces and 
recordings by manual methods.  
The Matlab platform was the platform upon which the simulation for AV and VV 
optimisation was performed. This is described in detail in Chapter 4. 
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Figure 2-12 A snap shot of the data acquisition system on Labview where all data is 
recorded 
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2.8 Exclusion of ectopic beats 
Throughout all the studies, I wanted to maximise the precision of all measurements to 
ensure that we are accurately and fairly assessing each of the measurement 
parameters. Ventricular ectopic beats were excluded and the beat following this 
ectopic was also excluded. This is because the ectopic beat had a cardiac output which 
was not representative of a normal beat i.e. too little or too much cardiac output as 
shown by echocardiography and the subsequent beat had the compensatory additional 
or lesser blood volume within it therefore a greater output. This can be seen by the 
echocardiographic images below which demonstrate this point, Figure 2-13. 
 
Figure 2-13 showing ectopic and a normal beat with VTI measured. We can see 
the final beat in the frame (on the right) is a normal beat following the ectopic. The 
difference in VTI is visibly noticeable. 
 
This is also reflected in the end product of output i.e. the blood pressure which is 
being measured (Figure 2-14) and hence these beats in the Finometer non-invasive 
and aortic invasive blood pressure tracings should be excluded in a similar fashion. 
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Figure 2-14 An example of an ectopic beat whilst recording ECG, invasive blood pressure and non invasive blood pressure. 
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3D echocardiography measured the dyssynchrony index by superimposing 4 beats to 
create a full volume image which is only reliable if there are at least 4 beats of similar 
RR lengths. Therefore ectopic beats will lead to “stitching artefacts” and these 
therefore needed to be excluded. AF patients and patients with arrhythmias could not 
therefore be included in the study as the technology here does not allow accurate 
recordings and readings which are truly representative of the hypothesis we are trying 
to demonstrate. 
During invasive data collection there were times when the patient would move due to 
discomfort of being on the catheter laboratory table for a length of time. Therefore, on 
the matlab traces we can see that these are artefacts and not true recordings. Hence I 
have excluded these anomalies from the analysis to ensure that what is calculated and 
measured is a true reflection of the intra cardiac timing manipulations. I am aware that 
the beat-to-beat variability that is present is inherent and cannot be eliminated, but by 
ensuring we have a dataset which is firstly free of artefact i.e. either movement or 
equipment failure but still includes all other data, we can then get a true understanding 
of physiological changes and answers to the hypothesis we have queried. 
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2.9 Methods of Analysis – Acquiring data 
2.9.1 Single measurements 
When performing each of the studies, individual measurements were taken at each 
AV or VV delay. This was then repeated multiple times when using advanced echo 
modalities of 3D echocardiography (Chapter 5), TDI (Chapters 5 and 6), PW Doppler 
measurements (Chapters 5 and 7) and invasive measurements (Chapter 8). 
These single measurements were analysed to assess agreement between replicate 
measurements within the same modality and between the different modalities. I then 
analysed this data to calculate the agreement, intra class correlation and scatter 
between replicate optimisations processes. 
2.9.2 Averages of multiple measures 
A major component of my study hinged on the concept of improving the signal-to- 
noise of the measurements to ensure optimisation is performed in the best way 
possible rather than randomly performed and hoping to improve patient outcomes 
according to chance. I have shown in Figure 2-15 in this schematic diagram how I 
have measured beats and averaged them.  
A well know phenomenon to reduce the noise component is to average multiple 
values and hence improve the signal-to-noise quality (Le Cam L 1986; Pabari et al. 
2011). This is the rationale for the many images I have acquired and analysed in this 
study. The theory behind this is explained in Chapter 4, and will demonstrate the 
effect on actual measurements in Chapters 5, 6 and 7. 
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Figure 2-15 Schematic diagram showing how we measured single beats, average-of-two and averages-of-three to ensure each beat was 
independent. We then calculated the standard deviation from the optimum derived.
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2.10 Calculation of Intraclass Correlation Coefficient  
The intraclass correlation coefficient (ICC) quantifies the extent to which 
measurements differ between settings because of genuine difference between settings 
versus random biological variation.  I used the ICC to quantify how well each 
modality could detect a genuine improvement arising from a change in VV delay, as 
distinct from background spontaneous beat-to-beat variability. An ICC close to 1 
indicates that changes in settings make a relatively large difference to the 
measurement in comparison to random beat-to-beat variability. An ICC close to 0 
indicates that random beat-to-beat differences are relatively large in comparison to the 
genuine effect of changing settings, Figure 2-16. 
 66 
 
 
  
Figure 2-16 Intuitive description of intraclass correlation coefficient, as applied 
to dyssynchrony measures. 
Replicate measures at the same setting are likely to have slightly different values 
(small dots). Averaging the measures from the setting gives the means (large blue 
dots). If the scatter between the means is of similar size to the scatter between all raw 
individual measurements (top panel), then reproducibility is very good i.e. ICC = 1. If 
the scatter between the means is much smaller than the scatter between all raw 
individual measurements, then reproducibility is poor i.e. ICC = 0 (bottom panel).  
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3 Limits to predictability of response to 
biventricular pacing from dyssynchrony 
indices, and systematic analysis of 
impact of study design on findings    
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3.1 Abstract   
3.1.1 Background 
Can markers of mechanical dyssynchrony strongly determine ventricular remodelling 
by biventricular pacing (cardiac resynchronisation therapy, CRT)?  The aim of this 
chapter is to quantify the fundamental limits on the consistently-observable 
coefficient of determination (R2), arising from variability between repeat 
echocardiographic measurements and between successive mechanical dyssynchrony 
measurements. It examines the literature and induces a small retrospective study in the 
test-retest distributions of changes in Ejection Fraction (EF) over time, when no 
intervention has occurred. 
3.1.2 Method and Results 
First, I quantified the mathematical depression of observable R2 between 
dyssynchrony criteria and response arising from spontaneous biological variability of 
response markers over time, and test-retest variability of dyssynchrony measurements.   
Second, I compared actual published R2 values, between externally-monitored 
randomised controlled trials (EMRCTs) and highly-skilled-single-centre studies 
(HSSCSs).   
Inherent variability in dyssynchrony markers and measures of ventricular remodelling 
such as ∆LVEF, ∆ESV or ∆EDV means that even if a perfect dyssynchrony predictor 
of response is found (underlying R2=1), observable R2 between dyssynchrony and 
∆LVEF cannot sustainably exceed 0.33 (for ∆ESV, ≤0.34;  for ∆EDV, ≤0.27).  
Interestingly, many R2 values published in HSSCS exceed these mathematical limits 
whereas none in externally-monitored studies did so.  Overall HSSCSs seem to 
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overstate R2 by >5 to 20-fold (p=0.002), whether response is ∆LVEF, ∆ESV or 
∆EDV. 
Finally, I assessed the spread of repeated ∆EF in a real-life population of general 
cardiology patients undergoing follow-up in a tertiary centre. We found 1298 patients 
reporting the distribution of ∆EF on measurements 3 to 12 months apart within a 5 
year period. The standard deviation of ∆EF for these patients was 18.6%. This is 
wider than the scatter seen in the control arms of the RCT’s.  
3.1.3 Conclusions 
Even in an elaborately conducted prospective study, it is not realistic to expect to find 
a significant correlation between ∆EF achieved by CRT and outcomes (or baseline 
dyssynchrony).  It is unlikely to happen however skilled the operator, whatever the 
method of measuring EF and even if an alternative parameter to EF is used.   
Even more unrealistic is to hope that analysis of routine clinical measurements will 
show responses that can be predicted. Overall, our findings suggest HSSCSs often 
overstated the predictability of response by mechanical dyssynchrony markers.  In 
many cases they report values exceeding the mathematical limits imposed by 
spontaneous variability.  Even if they continue to arise in the literature, markedly 
positive results will fail to be replicated in independent, blinded hands with neutral 
external monitoring.  These results favour testing of mechanical dyssynchrony 
markers using scientific quality standards as strict as externally monitored RCTs, and 
suggest that prediction will be poor. 
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3.2 Background 
There are questions raised regarding the ability and the reliability of dyssynchrony 
markers to predict response to biventricular pacemakers. In this study I have 
collaborated with my colleague Dr S. Nijjer, to perform a systematic review of the 
literature to assess the degree to which dyssynchrony markers can predict response to 
biventricular pacemakers. We evaluated both externally-monitored randomised 
controlled trials (EMRCTs) and highly-skilled-single-centre studies (HSSCSs).   
I then reviewed our local datasets of echocardiograms performed in patients to 
identify and assess commonly measured echocardiographic parameters, such as 
ejection fraction to assess their test- retest reproducibility.  
Biventricular pacing is thought to deliver its benefits in heart failure through 
resynchronisation of dyssynchronous cardiac mechanical function, hence the term 
“cardiac resynchronisation therapy” (CRT) (Abraham et al. 2002; Bristow et al. 2004; 
Cazeau et al. 2001; Cleland et al. 2005; Gras et al. 2002; Young et al. 2003) The 
correlation coefficient (r) and its square, the coefficient of determination (R2), are 
commonly used to quantify the strength of the association between variables such as a 
baseline parameter and an outcome measure; for example, baseline mechanical 
dyssynchrony and the degree of reverse remodelling after biventricular pacing.  The 
R2 statistic is important because it indicates how much of the variability of future 
outcomes between patients can be correctly predicted from baseline information.  R2 
is always positive, with values close to 1 indicating that all the differences in 
outcomes between patients are fully predictable from the baseline marker, and values 
close to 0 indicating no predictive value.  Some studies (Bax et al. 2003a; Bleeker et 
al. 2007a; Yu et al. 2004c) demonstrate high R2 values between baseline mechanical 
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dyssynchrony and echocardiographic outcome measures whereas other (Chung et al. 
2008a; Marcus et al. 2005; Miyazaki et al. 2010) show much weaker relationships.   
The failure of dyssynchrony markers to consistently predict response to biventricular 
pacing is a cause of concern.  Unsurprisingly, mechanical dyssynchrony is not 
included in guidelines which instead rely on electrical dyssynchrony as denoted by 
wide QRS (Hawkins et al. 2009). Nonetheless, the quest for new and more robust 
mechanical dyssynchrony markers or more complex selection algorithms continues, in 
the hope of giving higher R2 values. 
In this study I test whether the current processes, of examining patient sets for 
variables that predicted outcomes well, is a rational strategy to solve to the problem of 
unreliable prediction of response.  In particular, if a marker (or combination index) is 
found with excellent prediction of response, how high can its R2 be when 
independently re-tested beyond the initial cohort or, when in real clinical practice? 
The answer cannot be R2=1 because of unavoidable variability or uncertainty in 
measurements.  But the precise impact of this variability has never been addressed.  
Both mechanical dyssynchrony markers (Palmieri et al. 2010; Vesely et al. 2008) and 
commonly used outcome markers of reverse remodelling have variability when re-
tested in the same patient as opposed to re-analysis of a stored image. The clinically 
relevant measure of variability of any diagnostic test must capture all sources of 
variability.  The complete test must be performed afresh, conducted and analysed with 
blinding to the first result.   
I calculate the limit on R2 by using randomised controlled studies and test-retest 
studies to determine for the first time the impact of these variability’s on R2.  In this 
study I calculated the R2 that one should realistically expect and provide a simple, 
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usable tool for clinicians and researchers to understand to what extent low test-retest 
reproducibility, and spontaneous changes in markers of LV function, attenuate 
associations in studies of biventricular pacing response.  
Having reviewed the world literature, I also wanted to test whether data in my local 
hospital showed the same properties of surprisingly wide test retest reproducibility of 
repeated echocardiographic EF assessments. I found that in my hospital 
reproducibility was very wide meaning that there was certainly no chance of defining 
echocardiographic responders in any meaningful way, any therefore all claims of 
others saying that they have done so should be viewed sceptically. 
This evaluation is fundamental in understanding and further unravelling to puzzle of 
dyssynchrony and response to cardiac resynchronisation therapy.
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3.3 Methods 
3.3.1 Quantitative separation of device-mediated, versus 
spontaneous, changes in LVEF 
Patients undergoing biventricular pacing have two drivers that affect the pre-to-post 
change in the chosen echocardiographic outcome measure (e.g. change in ejection 
fraction, ∆LVEF).  Firstly, inherent phenomena will contribute to individual patients’ 
∆LVEF even without device implantation.  This includes true biological variability 
and measurement error intrinsic to the assessment technique.  The size of this effect 
can be assessed by size of the variance (the square of standard deviation) in the 
control population in randomised controlled trials assessing biventricular pacing.  
Secondly, the device itself will impose an effect on outcome measure, over and above 
the inherent variation.  Individual patients have differing responses to the device, 
some improving and some worsening.  Therefore, the variance of the ∆LVEF should 
be larger in the device population of a randomised trial (Figure 3-1).  If the variance 
of ∆LVEF is the same as in the control population, then the device had a perfectly 
uniform effect on that chosen marker across all patients.   
 74 
 
 
 
 
 
Figure 3-1 The variance of the intervention group is only partly due to the 
intervention.   
Control populations in randomised controlled trials of biventricular pacing have 
changes in their outcome markers, such as LVEF, LVESV and LVEDV even without 
intervention.  This change is measured by the variance (SD2) of the change in LVEF 
(∆LVEF) and represents inherent or unpredictable change (left panel).  Those 
undergoing biventricular pacing will have a further change in LVEF over and above 
inherent changes and therefore have a wider variance in ∆LVEF (right panel).  This is 
shown schematically as the grey section.  Only this component is related to the device 
and therefore only this section of ∆LVEF is potentially predictable by any baseline 
marker. 
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Baseline dyssynchrony markers are typically only measured once but will also have 
an inherent variability within a given patient and across the population being studied.  
Only test-retest reproducibility studies can reveal the extent of this.   
When correlating two variables such as mechanical dyssynchrony and 
echocardiographic outcome (r), or determining the predictive value of one on the 
other (R2), then the variance of both combines in an additive fashion to depress the 
relationship (Equation 3-1). We have termed this the R2 contraction factor.  This is the 
maximal R2 that can be calculated between those variables for that population.  Below 
I have shown the derivation of the formula for contraction factor. Appendix 4 shows 
the derivation of the formula. 
The contraction factor can be calculated easily if the standard deviation of the ∆ in the 
outcome measure is known for both the control arms and device arms of a randomised 
control trial are known.  It is not sufficient to know the distribution of the initial and 
final LVEFs.  Rather, the distribution of the change, i.e. the standard deviation of ∆, is 
needed.  This can be used in the following calculation: 
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Equation 3-1  R2 contraction factor caused by inherent variability in LVEF, where σ 
is standard deviation and σ2 is variance. 
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This formula can also be used for the baseline mechanical dyssynchrony measure.  
The two contraction factors are then multiplied to determine the combined contraction 
factor. The observed R2 is then calculated as shown in Equation 3-2. 
 
 
 
 
Observed R2 = Underlying R2 x
R2 contraction factor
imposed by 
Dyssynchrony Marker
R2 contraction factor
imposed by 
Response Marker
x
Combined R2 Contraction Factor
 
 
 
 
Equation 3-2 The combined contraction factor which takes into consideration the R2 
contraction factor due to the dyssynchrony marker and the response marker 
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ΔEF
ΔEF
C
ΔEF
A. Imaginary noise-free measurement  
ofdyssynchrony and of delta EF
Dyssynchrony 
Marker
Dyssynchrony 
Marker
ΔEF
D
Dyssynchrony 
Marker
Dyssynchrony 
Marker
r2 = 1 
r2 = 0.56r2 = 0.7
r2 = 0.8
B. Imaginary noise-free measurement of 
dyssynchrony, but some measurement 
noise in delta EF
C. Imaginary noise-free measurement of delta 
EF, but some measurement noise in 
dyssynchrony
D. Measurement noise in both 
dyssynchrony anddelta EF
  
 
 
Figure 3-2 How inherent variability in two measures reduces the maximum 
achievable R2 between them.   
Imagine a dyssynchrony marker that can perfectly predict response, as long as 
measurement noise could somehow be eliminated (panel A). In practice there is 
natural variability in measurements of EF (panel B) and of the dyssynchrony marker 
(panel C). These noise properties combine together multiplicatively to depress the 
actually-observable R2 value (panel D). In this example case, it is mathematically 
impossible for R2 value over 0.56 to be observed sustainably. 
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The following provides a worked example.  In the MIRACLE-ICD II trial (St John 
Sutton et al. 2003), in the control arm ∆LVEF has a standard deviation of 6.2. In the 
biventricular pacing arm, ∆LVEF has a standard deviation of 8.  The SD of ∆LVEF is 
larger in the device arm, because additional change is occurring over and above the 
inherent variability in LVEF.  The effect of spontaneous, inherent variation in LVEF 
can be calculated by measuring the R2 contraction factor as 1-(6.2/8) 2 = 0.40.  That is, 
in the MIRACLE-ICD population, if one attempted to assess any baseline marker as a 
predictor of ∆LVEF, the maximum R2 that could be determined would be 0.40. 
If a mechanical dyssynchrony marker was used to predict the ∆LVEF, then we must 
assess the contraction factor applied by the variability in the mechanical dyssynchrony 
marker and multiply together with the 0.40 already calculated. For example, if the 
mechanical dyssynchrony marker has a contraction factor of 0.50, then the maximum 
observable R2 between ∆LVEF and the mechanical dyssynchrony marker will be 0.40 
× 0.50 = 0.20.  Therefore, regardless of the true underlying relationship between 
dyssynchrony and the ∆LVEF, the maximum R2 that can be measured will be 0.20 
with these example figures.   
This calculation is distinct from the proportion of the mean effect that is caused by the 
device: that proportion is simply 1 minus the ratio of the mean effect in the control 
arm divided by the mean effect in the device arm. This may be as high as 100%, even 
if the proportion of between-patient variability caused by different responses to the 
device is far lower. The two are independent phenomena. 
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3.3.2 Data extraction from published studies 
A systematic review of studies assessing the response to biventricular pacing was 
performed using EMBASE and Medline databases (Figure 3-3).  The terms ‘cardiac 
resynchronisation therapy’, ‘biventricular pacing’ and ‘dyssynchrony’ were used and 
abstracted reviewed for relevance.  Further papers were identified through review of 
citations including the extensive review by Hawkins et al, 2009 (Hawkins et al. 2009).   
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1286 records:
EMBASE 306
Medline 377
706 records screened
Limit to English: 104 excluded
Limit to Human: 127 excluded
349 Duplicates removed
“Cardiac 
resynchronisation 
therapy” OR 
“biventricular pacing” 
AND “dyssynchrony 
marker”
168 Full-text articles 
assessed for eligibility
538 excluded: not relevant, not 
present sufficient data, review
55 included articles
 
Figure 3-3 Systematic search strategy 
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All published studies that assessed mechanical dyssynchrony markers against the 
change in LVEF (∆LVEF), ∆LVESV and ∆LVEDV were analysed in detail and data 
extracted (Abraham et al. 2004; Bank et al. 2009; Bax et al. 2003a; Bleeker et al. 
2007a; Bleeker et al. 2007b; Bordachar et al. 2010; Conca et al. 2009; De Boeck et al. 
2008; Delgado et al. 2008; Deplagne et al. 2009; Diaz-Infante et al. 2007; Duncan et 
al. 2006; Faletra et al. 2009; Gorcsan et al. 2004a; Gorcsan et al. 2007; Kaufman et al. 
2010; Liodakis et al. 2009; Marcus et al. 2005; Marsan et al. 2008; Mele et al. 2006; 
Norisada et al. 2010; Notabartolo et al. 2004; Park et al. 2010; Penicka et al. 2004; 
Pitzalis et al. 2002; Pitzalis et al. 2005; Porciani et al. 2006a; Sassone et al. 2007; 
Soliman et al. 2007b; Soliman et al. 2009; St John Sutton et al. 2003; Suffoletto et al. 
2006; van Bommel et al. 2010b; Van de Veire et al. 2007; Wang et al. 2010; Yu et al. 
2003; Yu et al. 2004a; Yu et al. 2005; Yu et al. 2007). We extracted R2 or calculated it 
from the correlation coefficient between the mechanical dyssynchrony marker and 
outcome measure, using the published data in tabular, text or graphical form.  The 
weighted averages of the R2 were calculated using the size of the study.   
The landmark EM-RCTs of biventricular pacing were also assessed, specifically to 
compare the spread (standard deviation) of ∆LVEF, ∆LVESV and ∆LVEDV in the 
control and intervention arms (Abraham et al. 2004; Beshai et al. 2007; Cappola et al. 
2006; Cleland et al. 2008; Cleland et al. 2005; Foley et al. 2011; Ghio et al. 2006; 
Ghio et al. 2009; Linde et al. 2008; Lubitz et al. 2010; Moss et al. 2009b; Solomon et 
al. 2010; St John Sutton et al. 2003; Sutton et al. 2006b; Wikstrom et al. 2009).  The 
spread of the ∆ in the control arm shows the intrinsically unpredictable element of the 
spread of ∆ in the intervention arm.   
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3.3.3 Data from my hospital’s database assessing ejection fraction 
at repeated studies 
1298 patients who attended a general cardiology clinic at a teaching hospital in 
London who had more than one echocardiogram were included.  All the 
echocardiograms were stored on Medcon systems with LV measurements and 
calculated ejection fractions at each attendance were compared. I looked to see how 
∆EF changed with each successive measurement. Each measurement was compared 
to the first measurement and each preceding measurement. 
 Patients were included if they had repeat echocardiograms which enabled me to 
calculate the EF. This was not a study designed to perform the most robust and 
reproducible measurements using a study protocol, but rather a review of the 
echocardiograms performed in standard clinical practice. All patients had at least two 
echocardiograms performed. Some had further echocardiograms - up to 3, 4, 5 or 6 
echocardiograms between July 2004 and June 2009. 
To find the data, a search was performed on the Medcon database using the 
instructions shown in Figure 3-4. 
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3.3.4 Medcon search utility 
Go to http://connserver/crn   Log on using Username and Password 
Click Query Studio (top left) 
3.3.4.1 Part I: Create report layout 
Under the ‘Insert Data’ tab, drag and drop fields that you want to be in your final 
report. This should include fields that you will be searching in, as well as patient 
identifiers and any other Echo data you may need.  
To locate fields, go to ‘Echo 2’ 
For demographic details, look under Common 
For echo data, look under Echo 
When you drag and drop them across to the main frame, a new column will form. 
3.3.4.2 Part II: Create search 
1. To search, click Edit Data in the top left 
2.  Click the column you wish to search in 
3.  Click Filter 
4.  Search criteria will come up at the bottom of the main frame.  
5. You can add multiple search criteria.  
6.  The search will then run automatically. 
7. When finished, click ‘Manage File’ and export to a CSV or XLS sheet.  
Figure 3-4 Step by step method to search Medcon to perform searches for 
echocardiograms as performed in this study   
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3.3.5 Statistics 
Values are shown as mean (95% confidence interval), except where otherwise 
indicated. Comparisons between classes of study were made using Student’s unpaired 
t test and the Mann-Whitney U test.  A p value of <0.05 was predefined as statistically 
significant. Stata/SE 10.0 for Windows (Stata Corp LP; College Station, Tex) were 
used to perform the statistical analysis.   
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3.4 Results 
3.4.1 Reported R2 for echocardiographic response in EMRCTs and 
HSSCs 
52 reports were identified and assessed.  The majority were retrospective cohort 
studies either with or without matched controls, performed in highly skilled single 
centres (HSSC) with specific interest in echocardiographic dyssynchrony markers and 
a track record of innovation in the field (Abraham et al. 2004; Bank et al. 2009; 
Bleeker et al. 2007b; Bordachar et al. 2010; Conca et al. 2009; De Boeck et al. 2008; 
Delgado et al. 2008; Deplagne et al. 2009; Diaz-Infante et al. 2007; Duncan et al. 
2006; Faletra et al. 2009; Gorcsan et al. 2004a; Kaufman et al. 2010; Liodakis et al. 
2009; Marcus et al. 2005; Marsan et al. 2008; Mele et al. 2006; Norisada et al. 2010; 
Notabartolo et al. 2004; Park et al. 2010; Penicka et al. 2004; Pitzalis et al. 2005; 
Porciani et al. 2006b; Sassone et al. 2007; Soliman et al. 2007b; Soliman et al. 2009; 
St John Sutton et al. 2003; Suffoletto et al. 2006; van Bommel et al. 2010b; Van de 
Veire et al. 2007; Wang et al. 2010; Yu et al. 2003; Yu et al. 2005). The R2 reported 
in these studies between individual dyssynchrony markers and echocardiographic 
response to biventricular pacing (∆LVEF, ∆LVESV or ∆LVEDV) are tabulated in 
Table 3-1.    
 
 86 
 
Table 3-1 A comparison of the baseline dyssynchrony variables found to predict 
response in externally monitored randomised controlled trials with those found 
highly skilled single centre studies.  Correlation coefficients and coefficient of 
determination (R2) are presented.  Abbreviations are those used in the original 
publication 
 
 
The externally-monitored randomised controlled trials establishing the use of 
biventricular pacing were identified.  Primary and secondary publications from these 
major landmark studies have examined a wide variety of potential R2 between the 
outcome of biventricular pacing and baseline measures of dyssynchrony.54-70  The R2 
values found in EM-RCTs were significantly smaller than those found in the HSSC 
studies (p=0.02) for response in ∆LVEF (0.40 v 0.07), ∆LVESV (0.24 v 0.05); 
∆LVEDV (0.53 v 0.02). 
3.5 Impact of R2 contraction factor arising from the 
response variable: the mandatory statistical ceiling 
on observable R2 values 
The large EM-RCTs provided sufficient data to calculate the maximum achievable R2 
between the assessed mechanical dyssynchrony measures and the outcome measures 
used (Table 2a).  These are large populations with carefully performed 
echocardiographic studies with rigorous monitoring by external bodies.  Whilst only a 
few have specifically sought correlation of ∆LVEF, or other outcome markers with 
baseline mechanical dyssynchrony markers, the maximum R2 values calculable are 
those shown in Table 4a.  Using other common markers of response to biventricular 
pacing used in the EM-RCTs does not produce any higher ceiling on the achievable 
R2 values (Table 2b).   
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Table 3-2 Calculation of the contraction factor for ∆LVEF, ∆LVESV and 
∆LVEDV in externally monitored randomised controlled trials assessing 
biventricular pacing.  The maximum possible R2 for any parameter to the ∆EF in 
each study is presented for each study.   ∆ represents change.  SDD – standard 
deviation of difference (∆) 
Response 
measure
Study
Unpredictabl
e element of 
variabil ity
Total  
variability in 
intervention 
arm
Calculation
Total N
SDD of 
control arm
SDD of 
intervention 
arm
ΔLVESV MIRACLE ICD II 153 57 77 1-(57/77)
2 0.45
CARE-HF 735 42.8 66.6 1-(42.8/66.6)
2 0.59
MADIT-CRT 1366 16.3 31.2 1-(16.3/31.2)
2 0.73
REVERSE 487 23.4 29.5 1-(23.4/29.5)
2 0.37
RETHINQ 142 5.1 5.61 1-(5.1/5.61)
2 0.17
RESPOND 55 44.1 46.9 1-(44.1/46.9)
2 0.12
Variance Weighted Average 0.50
ΔLVEDV MIRACLE ICD II 154 62 76 1-(62/76)
2 0.33
CARE-HF 735 50.7 74.5 1-(50.7/74.5)
2 0.54
MADIT-CRT 1366 14.4 33.2 1-(14.4/33.2)
2 0.81
REVERSE 487 28 33.4 1-(28/33.4)
2 0.3
RETHINQ 142 7.14 5.36 1-(7.14/5.36)
2 -0.77
RESPOND 55 47.6 51.9 1-(47.6/51.9)
2 0.16
Variance Weighted Average 0.40
ΔLVEF CONTAK-CD 490 10.3 10.4 1-(10.3/10.4)
2 0.02
MIRACLE ICD II 153 6.2 8 1-(6.2/8)
2 0.4
CARE-HF 735 4.5 8.5 1-(4.5/8.5)
2 0.72
MADIT-CRT 1366 3 5 1-(3/5)
2 0.64
REVERSE 487 6.5 9.3 1-(6.5/9.3)
2 0.51
RETHINQ 142 0.99 1.22 1-(0.99/1.22)
2 0.34
RESPOND 55 11.7 15.7 1-(11.7/15.7)
2 0.44
Variance Weighted Average 0.48
Breakdown of variability
Mandatory ceiling on R
2
 value 
imposed solely by 
unpredictable variability in 
response measure  
Point 
estimate of 
maximal 
achievable R
2  
value
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The ∆LVESV, ∆LVEDV, ∆LVEF values in RETHINQ had distinctive properties that 
make them potentially unsuitable for this analysis.  First, the test-retest reproducibility 
(i.e. delta in the control arm) had a variance that was an order of magnitude smaller 
than that of all of the other studies.  Second, the distributions of delta values for these 
echo markers where observers had a choice of beat to analyse, were skewed, with a 
relative curtailment of tail trending towards deterioration, and relative extension of the 
tail trending towards improvement.  These phenomena were not present in the 
markers that were continuous variable where only a single measurement was 
realistically possible, such as exercise duration.  Although the study carefully blinded 
assessors to allocation, the report did not state that it blinded them to prior 
measurements. Reluctance to state values far from prior measurements, together with 
the understandable preference in real-life clinical practice to prefer to document 
improvement, might have been the reason for these anomalies.  
I calculated the contraction values for ∆LVESV, ∆LVEDV and ∆LVEF from the 
externally monitored RCT’s and have shown the maximum R2 values in Table 3-2. 
This formula can also be applied to non echocardiographic markers of response as 
shown in Table 3-3. 
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Table 3-3 R2 contraction factor for non-echocardiographic markers of response 
to biventricular pacing. The maximal achievable R2 column shows the maximum R2 
that any predictor could find when correlated against any of these outcome measures.  
∆ represents change. SDD - standard deviation of difference (∆). Abbreviations: 
6MWD - six minute walk distance; peak VO2 - peak oxygen consumption; VE/VCO2 - 
ratio of minute ventilation (VE) and minute production of CO2 (VCO2), a measure of 
ventilatory response to exercise.  
 
 
Response measure Study
Unpredictable 
element of 
variabil ity
Total 
variabil ity in 
intervention 
arm
SDD of control 
arm
SDD of 
intervention 
arm
6MWD (m) COMPANION 93 96 1-(93/96)
2 0.06
CONTAK 103.8 104.8 1-(103.8/104.8)
2 0.02
MIRACLE 98 109 1-(98/109)
2 0.19
Peak VO2 (ml/kg/min) CONTAK 4.3 4.4 1-(4.3/4.4)
2 0.05
MIRACLE 3.2 3.2 1-(3.2/3.2)
2 0.00
Quality of Life Score CONTAK 30 30.6 1-(30/30.6)
2 0.04
MIRACLE 21.7 25.1 1-(21.7/25.1)
2 0.03
Quality of Life Improvement (%) COMPANION 23 26 1-(23/26)
2 0.22
VE/VCO2 MIRACLE 5.2 6.2 1-(5.2/6.2)
2 0.30
Breakdown of variability
Mandatory ceiling on R
2
 value 
imposed solely by 
unpredictable variability in 
response measure  
Point 
estimate of 
maximal 
achievable 
R
2  
Value
Calculation
 
 90 
3.5.1 Impact of R2 contraction factor arising from the dyssynchrony 
variable 
I assessed the published variability of mechanical dyssynchrony markers between 
repeated echocardiograms in the same patient (test-retest reproducibility, Table 3-4). 
The full variability is not reflected in simple re-measurements of identical previously-
acquired images because this omits biological variability over time. 
There are two studies reporting in detail the test-retest inherent variability of 
mechanical dyssynchrony on entirely separate echocardiograms (Table 3-4).  In one 
study (Palmieri et al. 2010) within-patient variation and between-patient variation was 
small when performed in specialist hands. The data for SD within one patient is from 
their Table 3, and the SD across the population is from their Table 1.  From these, the 
R2 contraction factor due to the mechanical dyssynchrony marker can be calculated as 
1-(SDwithin patient / SDbetween patient)2.  The other study (Vesely et al. 2008) assessed test-
retest reliability of TDI mechanical dyssynchrony markers and presents the R2 
contraction factor directly.  Where test-retest variability of a baseline variable is 
known in the form of a correlation coefficient r, that coefficient is a suitable estimate 
of the R2 contraction factor if that variable is used as a predictor of a response. In 
(Vesely et al. 2008), r between test and retest of 2-segment dyssynchrony is 0.26 for 
reader A, and 0.43 for reader B, giving an averaged test-retest r value of 0.35 (Table 
3-4).   
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Table 3-4 Test-retest variability of dyssynchrony markers within individuals, in 
populations who are candidates for biventricular pacemaker implantation. Most 
studies did not report test-retest reproducibility.   
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3.6 True limits to correlation between baseline and delta 
response: Combined contraction factor from both 
sources of variability 
Published studies provide only limited information to fully determine the combined 
contraction factor (calculated from the product of contraction factors imposed by the 
outcome marker and the mechanical dyssynchrony marker predictor).  We therefore 
provide a theoretical contraction factor based on the data available, in Table 3-5.    
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R2 contraction 
factor imposed 
R2 contraction factor imposed by variability in dyysynchrony marker
by variability in 
∆LVEF 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
0.1 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09
0.2 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18
0.3 0.03 0.06 0.09 0.12 0.15 0.18 0.21 0.24 0.27
0.4 0.04 0.08 0.12 0.16 0.20 0.24 0.28 0.32 0.36
0.5 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45
0.6 0.06 0.12 0.18 0.24 0.30 0.36 0.42 0.48 0.54
0.7 0.07 0.14 0.21 0.28 0.35 0.42 0.49 0.56 0.63
0.8 0.08 0.16 0.24 0.32 0.40 0.48 0.56 0.64 0.72
0.9 0.09 0.18 0.27 0.36 0.45 0.54 0.63 0.72 0.81
1 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90
Table 3-5  The true limit to the observed R2 for the correlation between ∆LVEF and dyssynchrony markers is a product of their two R2 
contraction factors.  Shaded rows represent the R2 contraction factor arising from variability in ∆LVEF (range 0.34-0.44). Shaded columns 
represent the estimated range of R2 contraction factor arising from variability in the dyssynchrony markers for which data is available (0.35-
0.90).  The resulting ceiling on observable R2 values (total shaded region) is modest. Arrows represent values quoted in published studies 
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3.6.1 Echocardiographic data from my local hospital database 
All 1298 patients had undergone at least 2 scans. The distribution of the first scan 
across all 1298 patients had mean 60.6 percentage units and SD 19.0. For the second 
scan, mean was 60.5 and SD 17.5. There was no significant trend in the mean from 
the first to the second, p = 0.923.  
Of these, 337 patients had undergone a third scan, as shown in Table 3-6.This subset 
too, showed no significant difference in means between the first and last scans p = 
0.800. Likewise, in the progressively smaller subsets of patients who had 4, 5 and 6 
scans, there was no significant difference between first and last scans (p >0.05 for all 
comparisons, Table 3-7).   
This dataset showed that the passage of time was not causing a progressive increment 
or decrement in average EF, neither in the full cohort nor in any of the sub cohorts 
who had had a larger number of scans. 
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Table 3-6 The distribution of EF for patients who had 2, 3, 4, 5 or 6 scans performed.  
 
 
 
LVEF (%) n
mean SD mean SD mean SD mean SD mean SD
Scan 1 60.6 19.0 63.6 16.5 63.8 15.7 64.5 15.5 64.0 17.7
Scan 2 60.5 17.5 63.0 16.1 63.1 16.0 64.0 16.0 66.0 20.0
Scan 3 X X 62.2 19.2 64.1 16.2 65.5 16.8 64.6 19.9
Scan 4 X X X X 62.4 15.3 64.6 12.1 63.9 13.7
Scan 5 X X X X X X 65.3 13.5 67.9 9.7
Scan 6 X X X X X X X X 64.6 16.3
All patients, 2 scans
1298
Patients with 3 scans Patient with 4 scans Patients with 6 scans
337 136 45 16
Patients with 5 scans
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Table 3-7 The scatter (SD) between the first scan and each subsequent scan. This shows that the scatter does not change significantly 
whether the first scan is compared to the 2nd or to the 6th, hence the passage of time is not a factor. Instead it is the variability of measurement 
which is causing the wide scatter (SD). 
 
 
 
 
Δ LVEF
mean SD mean SD mean SD mean SD mean SD
Δ (Scan 1 → Scan 2) 0.0 18.6 -0.5 18.0 -0.7 17.0 -0.5 16.1 1.9 19.0
Δ (Scan 1 → Scan 3) X X X -1.4 20.2 0.3 15.6 1.0 16.4 0.5 20.7
Δ (Scan 1 → Scan 4) X X X X X X -1.4 16.0 0.1 16.0 -0.1 18.7
Δ (Scan 1 → Scan 5) X X X X X X X X X 0.9 18.3 3.8 16.4
Δ (Scan 1 → Scan 6) X X X X X X X X X X X X 0.6 16.7
Patients with 6 scans
1298 337 136 45 16
All patients, 2 scans Patients with 3 scans Patient with 4 scans Patients with 5 scans
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The change in EF, i.e. ∆EF, between immediately successive scans therefore had a 
value of approximately zero. Of interest was its standard deviation across the patient 
population, which is an index of reproducibility of the variable. As shown in Table 
3-8, this SD of ∆EF had values between 15.7 and 21.1 in all the reasonably sized 
cohorts of patients. There was no tendency for the SD of ∆EF to become narrower 
later in any sequence of scans. This supports the concept that this variability is 
random. I have not calculated the F test p value for thee comparisons of the standard 
deviations because the interlinking of the successive SD’s would break Fisher’s 
original assumption. 
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Table 3-8 The scatter (SD) of ∆EF between immediately successive scans is shown below 
 
 
Δ LVEF
mean SD mean SD mean SD mean SD mean SD
Δ (Scan 1 → Scan 2) 0.0 18.6 -0.5 18.0 -0.7 17.0 -0.5 16.1 1.9 19.0
Δ (Scan 2 → Scan 3) X X X -0.9 21.1 1.0 16.9 1.5 15.8 -1.4 12.9
Δ (Scan 3 → Scan 4) X X X X X X -1.7 16.3 -0.9 15.7 -0.6 15.3
Δ (Scan 4 → Scan 5) X X X X X X X X X 0.8 15.8 3.9 12.8
Δ (Scan 5 → Scan 6) X X X X X X X X X X X X -3.2 16.3
16
All patients, 2 scans Patients with 3 scans Patient with 4 scans Patients with 5 scans Patients with 6 scans
1298 337 136 45
 
 
 
 
 
 
 
 
 
 99 
3.7 Discussion 
In this study I present a method for calculating the ceiling on the achievable R2 values 
between any baseline echocardiographic marker of electromechanical dyssynchrony 
and subsequent response to biventricular pacing.  It may be a surprise how low this 
ceiling is for both dyssynchrony markers in widespread use, and echocardiographic 
measures of long term response.  This mandatory ceiling applies even if a new 
mechanical dyssynchrony marker is found that perfectly encapsulates all aspects of 
dyssynchrony status.  The sustainable R2 will never exceed this ceiling.  Even 
supplanting individual variables with a combination index will not evade this limit 
because it arises from spontaneous variability inherent in individual patients and in 
the measurement processes.   
Reports of new dyssynchrony markers and combination indexes with strong 
predictive powers may continue to arise, but this analysis shows with certainty that 
when tested in independent environments the sustainable R2 will be small.  A different 
approach to improving our selection for CRT may be required.  
3.7.1 The fundamental ceiling on observable R2 
Regression dilution is a well-recognised concept in statistics but less so in medical 
literature (Hutcheon et al. 2010). With any outcome variable and any predictor 
variable, the greater the test-retest variability in the predictor and/or the response — 
whether due to biological factors, measurement error or random noise — the more the 
observed R2 between predictor and response must be diluted towards zero except in 
exceptionally rare chance circumstances.  Even if the underlying ‘true’ relationship 
(i.e. between imaginary versions of the variables in which the random variability had 
been stripped away) is a perfect correlation of 1.00, this can never be observed in 
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practice unless the variability’s are vanishingly small (Francis et al. 1999; Hutcheon et 
al. 2010). 
Studies of prediction of response have assumed that the variability of predictors and 
of outcome measures was small and statistically unimportant.  This study 
demonstrates that this not true, and that therefore our community’s expectation of 
predictability of CRT response from current study designs is set far too high.  
3.7.2 Minimising contraction in R2 values 
Critics of the PROSPECT study suggested that poor echocardiographic technique was 
responsible for poor predictive ability of mechanical dyssynchrony markers.  The 
present study shows that variability is important, but highlights that all sources of test-
retest variability conspire to limit predictability of response. Data on test-retest 
variability between separate echocardiographic sessions are surprisingly sparse, but 
are fundamental to knowing the maximum credible limit of the ability of a variable 
(or index constructed from such variables) to predict response. Our data from the 
echocardiograms analysed, showed results for ejection fraction reproducibility in 
keeping with findings in 1997 (Otterstad et al. 1997). 
A vital step before embarking on a clinical study of the predictive value of a 
mechanical dyssynchrony marker should be assessment of its test-retest 
reproducibility in formal, blinded conditions. Both test and re-test acquisitions should 
be performed on separate days at the very least and preferably with longer intervals 
between measurements.  
Ideally this test-retest reproducibility should be conducted by a group independent of 
the originators of the marker because even small biases destroy the scientific value of 
the result.  Many candidate indices will fail at this stage, allowing the effort and 
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expense of trials to be expended fully on a smaller set of indices which have passed 
basic scientific testing. 
It is not sufficient to analyse intra-observer and inter-observer ability to reproduce 
measurements from the same acquired images (Zhang et al. 2011), because this omits 
biological and other temporal sources of variability such as subtle differences in (for 
example) probe position.  Such image re-analysis is inexpensive and needs no 
additional patient effort, and may be a useful early preliminary step to identify a few 
highly unsuitable modalities where observers cannot agree on interpretation of even 
identical digital images. Conducting entirely separate scans is necessary to capture the 
true test-retest reproducibility that is relevant to limiting predictability of response.  
The test-retest reproducibility of both the baseline mechanical dyssynchrony markers 
and the response variables should then be evaluated in the context of Table 3-4.  
Unless they are much narrower than the population distribution of these variables, the 
methods should be refined before any major study is initiated.  Effort expended on 
maximising the ratio of signal (between-patient variability) to noise (within-patient 
variability), is indispensable to improving prediction of response.   
Spontaneous variability of measurements across time in my hospital was measured. 
The data from my centre shows variability no better that that of formal 
reproducibility. My study is retrospective and the operators concerned were not 
acquiring data with reproducibility in mind, but in a way this makes it a more 
favourable representation of clinical practice. 
The fact that successive pairs of several EF’s showed no greater scatter is not 
surprising. What is surprising is that the scatter between two echoes many sessions 
apart was same as those sequentially. This proves that this is not due to evolution of 
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biological processes which would have taken much longer to take effect but instead 
due to measurement variability. 
3.7.3 Opportunities and limits of replicate averaging 
One may not always have the luxury of starting with a better marker. If a marker has 
substantial noise variability, contraction of R2 by noise can be minimised by making 
multiple measurements of each variable and then using an average of these as the 
patient’s final value.  However, although noise would be reduced (Pabari et al. 2011), 
signal would not be increased. Thus sustainable R2 value will not rise above the 
underlying value which indicates how much the underlying (between patient) 
variability in response is genuinely due to underlying (between patient) variability in 
the marker.  For markers with no relationship to response, no degree of replication 
could make their R2 value with response high, sustainably.  Increased replication can 
only improve R2 contraction due to noise.  
Simply increasing the number of patients recruited will not raise the ceiling on R2, 
rather it will enforce the same mathematical ceiling all the more firmly, since there is 
less scope for fluke high values.   
Often when making multiple replicates for averaging, it is conventional to attempt to 
make each replicate as similar to each other as possible.  However, it is actually 
preferable for measurements to be made without reference to each other.  Thus the 
random disturbances in the replicates are statistically independent of each other.  
Fundamentally, cardiovascular variables may fluctuate over periods of hours or days 
in a manner that is not captured in recordings a few seconds apart but which becomes 
important when measurements days or weeks apart are compared. This means that if, 
say, 10 measurements are to be averaged, the average might be more repeatable if the 
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measurements were done on 10 separate days than on 10 successive beats.  This 
extreme example illustrates the principle that replicate measures which fail to fully 
sample the intrinsic variability give less helpful averages than those that do.  In 
reality, resources preclude multiple days of measurements, but one should adopt the 
principle by giving as much opportunity as possible for different noise elements in 
each of the multiple measurements: using the full range of echocardiographs, 
sonographers, times of day, prior rest or activity, etc.  Equally, intolerably elaborate 
markers of mechanical dyssynchrony or response that cannot be replicated under the 
pressures of clinical practice will not be applicable to clinical practice or the 
generality of patients.   
The final advantage of replicate measurement, if conducted “another day, other hands, 
other eyes”, it can expose irreproducibility of some markers allowing their early 
dismissal such that efforts can be focused on the few with adequate properties.  
Whilst readily available and convenient, repeated echocardiography has significant 
variability.  Otterstad et al (1997) showed that repeated echocardiograms a week apart 
in post infarct patients without change in therapy, had a coefficient of variation of 7-
19%.  Serial echocardiographic recordings and LV measurements are influenced by 
small differences in angulation and placement of the transducer.  Loading conditions, 
adrenergic drive and the post-absorption state after a meal also interact.  Obesity and 
COPD, common in the heart failure population also limit image quality.  Adjustment 
needs to be made when considering apparent changes in an echocardiographic 
variable considering ascertainment error.   
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This data demonstrates that the variability between 2 echocardiograms, measuring 
ejection fraction, is between 15% and 20%. This is above the 10% or 15% threshold 
for detecting response which is the cut-off in many studies (Deplagne et al. 2009). 
At least a 10% error should be expected if looking for a one-way change.  Thus, 
setting a 15% change as cut-off for response, this may be too close to change 
occurring due to error and natural variation.  Furthermore, it is known that whilst both 
very low and high LVEFs can be accurately determined, echocardiography is less 
accurate in determine LVEFs between 30-50% - the range expected in this patient 
population (McGowan & Cleland 2003).   
Dyssynchronous ventricles are also harder to accurately measure the LVEF. Ghio et al 
(2009) has suggested that dysynchronous ventricles appear worse than they are – that 
is the measured LVEF is lower than what is generally being produced.  Thus CRT 
may just allow measurement of this true LVEF, and thus show an apparent 
improvement. 
3.7.4 Why some HSSCSs report higher R2 than EMRCTs (and higher 
than mathematically sustainable limits) 
Several factors may have contributed to HSSCSs reporting significantly higher R2 
values than the sustainable values found in EMRCTs (Table 3-2).  
(a) Chance association:  the apparently high R2 values found may represent 
statistical chance, which have been noticed and published with preferential 
enthusiasm.  This could occur as submission bias from research groups and/or 
acceptance bias from journals. 
(b) Russian-doll publication:  Successive HSSCSs publications from the same site 
may have overlapping patient cohorts.  Patients might understandably be 
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added to a growing database, from which publications naturally arise.  High R2 
occurring by chance in early cohorts would repeatedly contribute to 
subsequent publications.  
(c) Preferential recruitment of patients:  Selection of extra patients who have 
unusually severe or mild mechanical dyssynchrony, or who have unusually 
large changes in the response variable will have significant impact on the R2.   
(d) Lack of blinding:  The R2 between mechanical dyssynchrony markers and 
response markers can only reliably inform real-life prospective clinical 
practice if each measurement is performed by observers blinded to the other 
relevant measurements in that patient.  For example, mechanical dyssynchrony 
should be measured without knowledge of the LVEF, and vice versa.  
Concealment of ECG (which shows biventricular pacing spikes) is essential 
during analysis if unbiased ∆LVEF is sought. The majority of the EMRCTs 
report some degree of blinding; almost all of the HSSCSs did not (OR 81, 
95% CI 6.3-1046.0, p<0.01 for response markers; OR 37.5, CI 3.5-399.4, 
p<0.01 for dyssynchrony markers). 
(e) Selective inclusion or exclusion of particular patients:  HSSCSs may receive 
unusual referral patterns distorting the distribution of dyssynchrony markers 
away from the pattern typically seen by future clinical practice and in 
EMRCTs. Finally, HSSCSs, if done without the advantage of formal, 
sequentially-numbered, prospective enrolment of patients may end up 
analysing an incomplete subset of the population at that centre: patients with 
notably strong concordance between physiological expectation and clinical 
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response are especially unlikely to be forgotten, but their preferential 
recollection would persistently bias R2 upwards. 
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Table 3-9 Differences in study design between highly skilled single centre studies 
(HSSCS) and externally monitored randomised control trials (EMRCTs).  
 
Study
EF /LVESV / LVEDV 
measurements 
stated to be 
blinded
Dyssynchrony 
measurement 
stated to be 
blinded
Study 
measurements 
only made after 
formal enrolment
CONTAK (Marcus 2005) Yes Yes Yes
MIRACLE (Sutton 2003) Yes Yes Yes
CARE-HF (Ghio 2009) Yes Yes Yes
REVERSE (Linde 2009) Yes Yes Yes
MADIT-CRT (Solomon 2010) Yes Yes Yes
MADIT-CRT (Pouleur 2011) Yes Yes Yes
RETHINQ No No Yes
RESPOND Yes Yes Yes
86% 86% 100%
Pitzalis et al  2002 No No Yes
Bax et al  2003 No Yes Unknown
Yu et al  2003 (AJC) No No Yes
Gorcsan et al  2004 No No Yes
Notabartolo et al  2004 No No Yes
Penicka et al  2004 Yes Yes Unknown
Yu et al  2004 No No Unknown
Pitzalis et al  2005 No No Yes
Yu et al  2005 (JACC) No No Yes
Mele et al  2006 No No Unknown
Porciani et al  2006 No No Unknown
Suffoletto et al  2006 No No Yes
Yu et al  2006 No No Yes
Gorcsan et al  2007 No No Yes
Soliman et al  2007 No No Unknown
Yu et al  2007 No No Yes
Delgado et al  2008 No No Unknown
Jansen et al  2008 No No Yes
Masan et al  2008 No No Yes
Van de Veire et al  2008 No No Unknown
Deplagne et al  2009 Yes Yes Unknown
Soliman et al  2009 No No Yes
Park et al  2010 No No Yes
Bordachar et al  2010 No No Unknown
Kaufmann et al  2010 No No Unknown
Norisada et al  2010 No No Unknown
Van Bommel et al  2010 No No Unknown
Wang et al  2010 No No Unknown
Shanks et al  2010 No Yes Unknown
7% 14% ≥50%
Highly skilled single centre studies
Externally monitored randomised controlled trials
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Figure 3-5 Comparison of highly skilled single centre studies (HSSCSs) and externally monitored randomised controlled trials 
(EMRCTs) for reported R2 values between baseline dyssynchrony markers and echocardiographic markers of response to biventricular 
pacing 
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3.7.5 Clinical Implications 
Clinicians are skilled in handling biological variability. It may be difficult for 
clinicians to believe that variability of a size readily accommodated in clinical 
practice can have such serious implications for prediction of response.  But clinicians 
appropriately merge technical knowledge with human skill, for example one might 
enthuse patients who show even a small positive ∆LVEF (saying it is a small 
improvement, giving them the benefit of placebo) while refraining from dismaying 
patients who show a small negative ∆LVEF (saying it is essentially unchanged, 
protecting them from nocebo). Statistics of prediction of response cannot, however, 
apply this doublethink. Variability imposes a remarkably low ceiling on sustainable 
predictability of response which our discipline’s present clinical research strategy is 
unlikely to dissolve.  
The R2 contraction factor arising from variability in ∆LVEF had a weighted average 
of 0.48.  Even if there was a dyssynchrony marker with a very high R2 contraction 
factor from its own variability, the resulting ceiling on the total R2 contraction factor 
is at most modest. This means that no matter what one tries to use to predict response 
to biventricular pacing, the predictive value of that method would be at most modest, 
and in danger of being almost no clinical value.  The predicament would persist for 
any response marker with wide blinded test-retest variability. 
While individual dyssynchrony markers continue to have their own proponents, other 
workers are seeking combined indices to give better prediction of response. Our study 
shows that failure of prediction will occur even with a perfect index of propensity to 
benefit which might include all aspects of dyssynchrony and all other aspects of 
clinical status, assembled perfectly into a single ideal score. Failure of prediction is 
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guaranteed due to spontaneous variability in the outcome measure and test-retest 
uncertainty in the predictor value itself.  
Even if all within-patient variability could be eliminated in a dyssynchrony marker 
(and in the response variable) this would not automatically make it possible to predict 
response reliably. Any given marker (or combination predictor variable) may or may 
not contain the information necessary to predict benefit. This paper does not quantify 
this particular restraint on prediction because currently the information is not yet 
available. This paper does show that the only reliable source of such information is 
carefully-blinded studies such as EMRCTs. 
Our current research efforts and resources expended in indentifying strong predictors 
of response in longitudinal studies, would be better expended first screening 
predictors (single or conjoint) for test-retest reproducibility and outcome markers to 
eliminate from consideration those with substantial spontaneous variability with time. 
If this “first stage” takes forever, then at least we will not have wasted effort on 
premature reports of strong predictions of response which will be universally found 
not to stand the test of time. 
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3.8 Limitations 
This study is limited by the nature of published data available for analysis.  Not all 
studies present sufficient information to determine the distribution of the change 
induced by biventricular pacing.  Few studies present test-retest reproducibility of 
either predictors or outcome measures.  I have used rigorously performed EM-RCTs 
which have control populations not undergoing biventricular pacing to ensure I have 
accurately determined the inherent variability of response markers over the time 
periods over which response to implantation is normally calculated.   
3.9 Conclusions 
This study shows that no externally-monitored trial will have reliable prediction (e.g. 
R2>0.5) by any current baseline marker of mechanical dyssynchrony of any current 
marker of response to biventricular pacing, across a representative range of patients, 
with measurements carried out in the currently conventional manner. This can be 
deduced confidently from the inherent variability in these measurements, which 
mandatorily contract the R2 value.  
It may by these reasons be time to critically reassess the HSSCS literature on 
echocardiographic prediction of response to mechanical dyssynchrony. The 
overstatement of relationship strength, of the order of 5 to 20-fold, and indeed the 
large proportion of the studies showing relationship strengths exceeding the 
mathematically achievable limits indicates this approach of HSSCSs to identifying 
predictive markers of response is highly unsatisfactory.  
It would be preferable to see a suspension of the natural, but misguided, competition 
to describe high correlations between baseline markers of mechanical dyssynchrony 
and response, until two conditions are met: 
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(1) Techniques for measuring mechanical dyssynchrony become available which have 
high test-retest reproducibility in the hands of multiple centres beyond their prime 
developers; 
(2) Techniques for measuring “response” are available which consistently show 
minimal between-individual scatter in patients who undergo no intervention, over the 
time periods similar to those over which biventricular pacing response is typically 
measured, and with analyses blinded and externally monitored.  
The latter is essentially biologically impossible suggesting the current approach 
should be set aside.  Fascination with, and uncritical acceptance of, near-perfect 
prediction of individual-patient ∆LVEF from baseline characteristics has evolved 
uniquely in the environment of cardiac dyssynchrony. Lack of a solid ceiling on what 
can be claimed, and perhaps perception by authors and journals that the competition is 
for highest (and not the most reliable) value, may have conspired to yield the present 
glut of excessive assertions.  
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4  The Puzzle of Optimisation: When is an 
optimisation not an optimisation?  
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4.1 Abstract 
4.1.1 Background  
Impact of variability in the measured parameter is rarely considered in designing 
clinical protocols for optimisation of atrioventricular (AV) or interventricular (VV) 
delay of cardiac resynchronisation therapy (CRT). In this article I approach this 
question quantitatively using mathematical simulation in which the true optimum is 
known, and examine practical implications using some real measurements. 
4.1.2 Method and Results 
I calculated the performance of any optimisation process that selects the pacing 
setting which maximises an underlying signal, such as flow or pressure, in the 
presence of overlying random variability (noise).  
If signal and noise are of equal size, for a 5-choice optimisation (60,100,140,180,220 
ms), replicate AV delay optima are rarely identical but rather scattered with a standard 
deviation of 45 ms. 
This scatter was overwhelmingly determined (ρ = -0.975, p <0.001) by Information 
Content, NoiseSignal
Signal
+
, an expression of signal-to-noise ratio. Averaging multiple 
replicates improves information content.  
In real clinical data, at resting heart rate information content is often only 0.2–0.3; 
elevated pacing rates can raise information content above 0.5. Low information 
content (e.g. < 0.5) causes gross overestimation of optimisation-induced increment in 
VTI, high false positive appearance of change in optimum between visits and very 
wide confidence intervals of individual patient optimum.  
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4.1.3 Conclusions 
AV and VV optimisation by selecting the setting showing maximum cardiac function 
can only be accurate if information content is high. Simple steps to reduce noise such 
as averaging multiple replicates, or to increase signal such as increasing heart rate, can 
improve information content, and therefore viability, of any optimisation process.  
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4.2 Background 
After implantation of a resynchronisation device (biventricular pacemaker or 
defibrillator) not all patients undergo optimisation even though guidelines recommend 
that AV and VV delay should be optimised, and even though clinical trials have only 
demonstrated survival benefit of individually-optimised CRT. Are clinicians right to 
cut corners from the trial-validated, guideline-mandated process? To answer this, the 
basic science of optimisation needs to be examined. 
For optimisation of atrioventricular (AV) delay, commonly a range of AV settings is 
tested, while monitoring a marker of cardiac function such as echocardiographic 
velocity-time integral (Scharf et al. 2005; Thomas et al. 2009; Valzania et al. 2008) 
VTI, a surrogate of stroke volume (Barold et al. 2008) or left ventricular dP/dt (Gold 
et al. 2007; Kass et al. 1999) The pacemaker setting that gives the best cardiac 
function is then defined as the optimum. A similar process can also be carried out for 
the delay between activation of left and right ventricular leads (VV delay). 
However, every measurement has uncertainties, which might conceal the true 
optimum.  This uncertainty in our measurement of VTI (or of any other marker for 
monitoring cardiac function (De Boeck et al. 2008; Turcott et al. 2010; Zhang et al. 
2008) arises from numerous factors including natural biological variability (Turcott et 
al. 2010). Therefore, repeating the “optimisation protocol” often provides different 
optima, as shown in Table 4-1.  
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Optimization
AV 40
AV 80
AV 120
AV 140
AV 160
16.67
15.94
16.24
13.78
18.01
16.61
16.47
15.85
13.79
16.08
16.42
16.58
16.36
15.02
15.75
# 1
Optimization VTI
Apparent AV optimum: 160ms 40ms 80ms
# 1 #  2 # 3
VTI VTI
# 2 # 3
Optimization
 
Figure 4-1: An example of clinical data from typical patient undergoing three 
separate Doppler optimisation processes (#1, #2 and #3) a few minutes apart, 
using one heartbeat of velocity-time integral as the measurement to be 
maximised. In this patient, the small differences in velocity-time integral between the 
three optimisation processes are enough to cause different AV delay settings to be 
identified as apparently optimal on the three occasions. 
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There are several clinically important questions. First, if the optimum is not 
necessarily the ‘true’ underlying optimum, can we at least express its precision, for 
example as a 95% confidence interval?  
Second, can we trust the measured increase in VTI as a good estimate of the ‘true’ 
average underlying increase in VTI? 
Third, if optimisations 6 months later show that many patients’ optima have changed, 
would this imply that patients require more frequent re-optimisation (Barold et al. 
2008; Porciani et al. 2006a; Zhang et al. 2008)?  
Finally, how can the precision of the optimisation protocol be maximised?  
It would be difficult and contentious to attempt to answer these questions by doing 
clinical studies. This is partly because in clinical practice it is normally assumed that 
the apparent optimum is indeed the true optimum (or at least the nearest of the tested 
settings to the true optimum). Persons other than the operator conducting the 
optimisation process itself rarely entertain the possibility that spontaneous variability 
of the monitored measurement during the optimisation procedure arising from beat-to-
beat variability and inherent measurement uncertainty has caused the optimum to be 
misidentified. Confidence intervals are not reported for individual clinical patients’ 
optima (Anselmino et al. 2009; Gold et al. 2007; Scharf et al. 2005; Valzania et al. 
2008).  
In this study, therefore, I created mathematical simulation having properties exactly 
like real-life studies, but in which I could truly know the underlying optimum, despite 
the presence of overlying noise. To understand the realistic balance between 
underlying optima and overlying noise we looked at published studies of optimisation.  
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4.2.1 Information content 
A convenient way of quantifying in real-life optimisations the relative contributions of 
underlying true signal information versus overlying random noise (illustrated in Table 
4-2) is using “information content”. Signal, in this context, is the genuine underlying 
between-setting difference in VTI, which for computational convenience can be 
expressed as a variance (average of the squared deviate between the underlying value 
of each setting and the mean of all settings). Noise, correspondingly, is the unwanted 
variability that occurs when measures are repeated at the same setting. This too can be 
expressed as a variance (average of the squared deviate between individual replicate 
measurements at a setting and the underlying value of that setting). The advantage of 
using variances is that their sum is the total observed variance.  The variance observed 
over a series of settings can be decomposed into the variance arising from the genuine 
between-setting differences (signal magnitude) and the remainder which is noise 
variance. The proportion of the total variance which is signal, can be called 
“information content”, Equation 4-1.     
  
Equation 4-1 
 
 
The reasons to use information content rather than simply signal-to-noise ratio are 
three-fold. First, the information content conveniently varies between 0 and 1, rather 
than extending to infinity. Second, it is symmetrical: noise content is 1 minus 
information content, which makes it clear that there are two contributors to observed 
differences between settings. Third, it is numerically identical to the intraclass 
correlation coefficient, a simple index of reproducibility used in biological research. 
VarianceNoiseVarianceSignal
VarianceSignalContentnInformatio
+
=
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4.3 Published data 
Information content can be calculated in any study for which both the overall 
variability and the noise variability are available. I present, in Table 4-1, information 
content for three detailed physiological studies conducted in research environment 
where special attention was given to accuracy (Auricchio et al. 1999a; van Geldorp et 
al. 2011; Whinnett et al. 2006a).  For each row of this table, I calculated for each 
patient the signal size (expressed as a variance) and the noise size (expressed as a 
variance), and displayed the average values across all patients. Each study had 
measurements at more than one heart rate, or via more than one monitoring technique, 
and so had more than one row. Where raw data of multiple replicates was available to 
us (Whinnett et al. 2006a), noise variance was quantified directly. Where data of only 
a single replicate was available (van Geldorp et al. 2011), noise variance was defined 
as the dispersion (expressed as a variance) of raw data away from a best-fit regression 
parabola between the observed measurements and the AV delay. Where noise 
variance was published graphically (Auricchio et al. 1999a), it was read off the graph. 
Signal variance was defined as the total observed variance of that patient minus noise 
variance. Because the protocols differed between studies, this table should not be used 
to compare optimisation technologies, but rather just to obtain an idea of the realistic 
range of information content achievable. It should be remembered that these were 
conducted in ideal research environments when there was effectively no time 
pressure. Routine clinical practice, because of time pressure, typically falls short of 
such ideal protocols that might require as many as 1500 beats to be acquired and 
analysed (Auricchio et al. 1999b).
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Table 4-1 : Information content calculated from published studies of optimisation (Auricchio et al. 1999b; van Geldorp et al. 2011; 
Whinnett et al. 2006a). 
 
Average 
heart 
rate 
(bpm) 
Pacing 
parameter 
being 
optimised 
Study 
Definition of 1 
replicate 
Number of 
replicates 
( R) 
Parameter 
used for 
optimisation 
Number of 
patients with 
sufficient raw 
optimisation 
data 
Signal size, 
expressed 
as a 
variance 
The noise 
size
,  expressed 
as a 
variance 
Information content of 
parameter, when used 
as an n -replicate 
average (mean ± 
sem) 
resting AV 5 
% change in 
aortic pulse 
pressure 
4 (pts 18, 5, 
17 and 13) 10.74 % 
2 45.76 % 2 0.20 ± 0.15 
resting AV 5 
% change in LV 
dP/dt 
4 (pts 18, 5, 
17 and 13) 18.21 % 
2 19.44 % 2 0.32 ± 0.05 
90 AV 1 
Relative 
change in 
stroke volume 
by Nexfin 
20 21.78 % 2 8.70 % 2 0.63 ± 0.05 
90 AV 1 
Relative 
change in 
stroke volume 
by echo 
20 40.31 % 2 23.84 % 2 0.71 ± 0.05 
90 AV 8 
Relative 
change in 
systolic blood 
pressure 
10 
29.06 
mmHg 2 
3.81 
mmHg 2 
0.51 ± 0.09 
110 AV 8 
Relative 
change in 
systolic blood 
pressure 
10 
35.58 
mmHg 2 
2.44 
mmHg 2 
0.86 ± 0.02 
130 AV 8 
Relative 
change in 
systolic blood 
pressure 
10 
55.07 
mmHg 2 
4.60 
mmHg 2 
0.90 ± 0.01 
Average of first 10 
beats at an AV delay 
setting, minus 
average of previous 
10 beats at reference 
setting (AV 120ms) 
Whinnett 
et al 
Average of first 5 
beats at an AV delay 
setting, minus 
average of previous 6 
beats at reference 
setting (intrinsic 
Auricchio 
et al 
van 
Geldorp 
et al 
Average of first 8 
beats at an AV delay 
setting, minus 
average of previous 
10 beats at reference 
setting (intrinsic 
conduction) 
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In this study I present a simple way to establish the impact of spontaneous beat-to-
beat variability, by simulating an optimisation in which there is a known underlying 
optimum setting at which cardiac function is best, and alternative settings at which 
cardiac function decays away. In the simulation I can then superimpose random 
variability simulating clinical beat-to-beat variability (the “noise”). This simulation 
gives information whose applicability is completely general across any method of 
optimisation that is based on selecting the settings which gives the most favourable 
value of a cardiovascular measure.  
I aimed to determine:  
• how reliable optimisation is  
• how one can quantify the confidence interval of any observed optimum 
• whether one should trust an apparent increment in cardiac function  
• whether the observation that optima change over time is a good reason to 
increase the frequency of repeat optimisation, and finally  
• whether there are any straightforward steps we can take to improve the quality 
of the optimisation process. 
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4.4 Methods 
4.4.1 Observed measurement = underlying signal + superimposed 
noise  
I constructed a simulation to identify the impact of noise variance, which is the 
random variability occurring between one beat and another. This noise is 
superimposed on the signal, which is the “true” underlying effect of the pacemaker 
setting changes in real patient data.  In clinical practice signal and noise cannot be 
separated in individual raw data points because each such observed measurement 
contains both contributions mixed together. (However, if replicate measurements are 
made, their inter-replicate variance can be subtracted from the total variance of the 
observed raw data to reveal the signal variance). 
4.4.2 Simulation 
In keeping with real patient data, the underlying signal in this model was constructed 
as an inverted parabola with its peak – the underlying optimum – at 140 ms. The 
vertical size of the parabola was scaled to have the desired signal magnitude. The 
magnitude was defined as the average of the squared deviation from the mean: this 
definition is computationally identical to that of variance. Separately, we programmed 
noise as normally-distributed random values with mean zero and variance as desired. 
The signal and noise were added together to create the simulated observations.  This 
process was repeated separately for each simulated patient. For each analysis in this 
study, 1000 patients were simulated.   
I tested signal and noise sizes over a wide range, but for clarity in this paper I have 
presented a limited number of values, ensuring that the full spectrum of relative sizes 
of signal magnitude and noise variance are encompassed. 
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4.4.3 Identification of optimum 
I defined the optimal setting as the one which gave the highest measurement of 
cardiac function (Barold et al. 2008; Nishimura et al. 1995; Zhang et al. 2008). 
Because of the presence of noise, the measured value of this optimum may not be the 
same as the underlying optimum. The measured hemodynamic parameter is not 
specified, but it could represent VTI (Barold et al. 2008), blood pressure or dP/dt. The 
measurement is expressed without physical units, for simplicity and generality. 
Because signal and noise always will have the same unit, the choice of the unit has no 
impact on reliability of optimisation. 
4.4.4 Confidence intervals of the optimum 
I simulated repeat optimisations within the same individual, and collected the 
resulting optima in order to see how widely these optima were scattered. I defined the 
95% confidence interval of a single optimisation as 1.96 × the standard deviation of 
this collection of observed optima. This is the confidence interval that would be 
appropriate to report for each patient’s individual optimisation, although by this 
method it is of course necessary to carry out several optimisations per patient in order 
to calculate the confidence interval.  
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Figure 4-2 Observed measurements are composed of underlying true difference 
between settings (“signal”, top panel) and beat-to-beat variability (“noise”, 
middle panel) which may be small (left) or large (right) relative to the signal.  
The relative sizes of underlying signal and overlying noise determine whether the 
observed measurements (bottom panel) reflect the underlying signal faithfully (left) or 
not (right). When the noise variability is relatively large (right), the observed optimum 
(arrow) is often not the true optimum (140 ms in all cases in this figure). 
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4.5 Results 
4.5.1 Impact of information content on consistency of detecting 
optimum, using a single beat at each setting. 
With signal and noise both configured to be the same size, the underlying curved 
shape of the signal was not always evident in the observed measurements (signal + 
noise). Nevertheless inevitably, in each run, one of the settings yielded the highest 
measurement and was duly selected as the observed “optimum”. Since this was not 
always the true underlying optimum, the observed optima showed some scatter (as 
shown schematically in Figure 4-2). 
For each combination of signal and noise size, I quantified the observed scatter of 
optimisation as the standard deviation of difference between the optima obtained on 
two successive optimisations of the same patient. I calculated the information content 
from the known sizes of signal and noise. 
When signal and noise were equal, there was an optimisation scatter (standard 
deviation) of 45 ms. Making the signal magnitude small, made the scatter of the 
observed optimum wider. Making the signal larger, made the scatter of the observed 
optimum narrower (Figure 3, Spearman rank correlation coefficient ρ = 0.973, p = 
0.021). When the noise was made smaller, the scatter of the observed optimum 
narrowed. When the noise was made larger, the scatter of the observed optimum 
widened (Figure 3, ρ = 0.991, p = 0.0017).  
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Figure 4-3 Scatter between successive optima increases when noise variance is 
increased (Top panel) and decreases when signal magnitude is increased (Middle 
panel). Information content, encompassing the relative sizes of signal and noise, has a 
powerful effect on the scatter between successive optima. The bottom panel shows the 
effect of information content (the proportion of variance that arises from signal) on 
the scatter between successive optima. 
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The information content was the overwhelming determinant of the scatter of optima 
(ρ = 0.979, p<0.001, Figure 4-3). In the worst case scenario, i.e. information content 
near zero, the scatter of optimisation was ~80 ms, the implied range, 60 – 220 ms, 
covers the full range of settings over which the simulations are performed.  
This can be compared to the expected behaviour of an entirely worthless optimisation 
method which would be to use no physiological information but simply to select one 
of the settings (60, 100, 140, 180, 220 ms) at random and announce it to be the 
optimum. From first principles, the mean “optimum” expected from such an approach 
is 140 ms, and the expected variance (average square of deviate from that mean) is 
simply (802+402+02+402+802)/5 = 3200 ms2, giving an expected optimisation scatter 
(SD of difference, SDD) of √2 × √3200 = 80 ms. This forms an effective limit on how 
poorly reproducible any optimisation amongst these settings can be: SDD can never 
be more than 80 ms, for this range of tested settings. 
Figure 4-3 shows that the information content needs to be rather high before the 
scatter of optimisation even comes close to values that clinicians may consider 
acceptable. Even to get the SDD of successive optima down to 25 ms, for example, 
we need information content of 0.91, i.e. signal-to-noise ratio of 10:1. 
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4.5.2 Size of confidence interval of the observed optimum 
I calculated the size of the confidence interval of the observed optimum for a range of 
possible signal and noise size combinations (and therefore information content) as 
shown in Table 4-2. 
4.6 Impact of averaging multiple replicates on reproducibility 
I tested the impact of changing a clinic’s optimisation policy to making, not just a 
single measurement at each pacemaker setting, but several raw replicates (3, 10, 30 or 
100), with average of all those replicate raw measurements in that patient being 
plotted and used to select that patient’s optimum setting. This process improved the 
fidelity with which the observed measurements reflected the underlying physiological 
value.  
Effectively, the absolute impact of noise was reduced. For example, using averages of 
3 replicate raw measurements reduced effective noise variance to one-third (Table 
4-2). With this elevation of the signal-to-noise ratio, the shape of the underlying signal 
was more faithfully depicted in the observed measurements (Figure 4-4, left panels), 
and the true optimum more likely to be detected (Figure 4-4, right panels). 
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Table 4-2 Effect of signal and noise on the information content, and on widths of 95% confidence limits.  
For simplicity the confidence intervals are shown centred on the “true” value. Greater information content gives narrower confidence intervals. 
The effect of averaging multiple replicate measurements is to reduce the effective noise and therefore narrow the confidence interval. 
 
Properties of isolated measurements Effective properties of averaged replicate measurements
Signal 
magnitude
Noise 
variance
Information 
content
Number of 
replicate 
measurements
Effective 
noise 
variance
Effective 
information 
content
Scatter of 
optima, SDD 
(ms)
1 1 0.50 1 1.00 0.50 45 ± 62
1 1 0.50 3 0.33 0.75 37 ± 51
1 1 0.50 10 0.10 0.91 24 ± 33
1 1 0.50 30 0.03 0.97 12 ± 16
1 1 0.50 100 0.01 0.99 0 ± 0
1 10 0.09 1 1.00 0.50 66 ± 91
1 10 0.09 3 0.33 0.75 58 ± 80
1 10 0.09 10 0.10 0.91 42 ± 58
1 10 0.09 30 0.03 0.97 35 ± 49
1 10 0.09 100 0.01 0.99 26 ± 36
1 100 0.01 1 1.00 0.50 74 ± 103
1 100 0.01 3 0.33 0.75 74 ± 102
1 100 0.01 10 0.10 0.91 68 ± 94
1 100 0.01 30 0.03 0.97 57 ± 79
1 100 0.01 100 0.01 0.99 43 ± 60
Size of 95% 
confidence interval of 
an observed optimum
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Figure 4-4  Impact of switching from single measurements to average of multiple 
measurements for the optimisation process. 
For simplicity of presentation, the simulated patients all have the same underlying 
optimum (140 ms) and the signal magnitude and the noise variance for a single 
measure, is set to be 1. The top panel simulates optimisation with a single 
measurement made per setting per patient. The lower two panels simulate multiple 
measurements made for each setting in each patient, each patient’s optimum being 
determined using the averages of that patient’s replicate measurements. I display 
detailed optimisation curves in 10 example patients (left) and the overall distribution 
of the observed optimum in 1000 patients (right). 
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4.6.1 Apparent versus true size of improvement on optimisation 
I measured the apparent size of the increase in the measured variable upon 
optimisation. To make the results easy to interpret, I simulated patients to arrive in the 
optimisation clinic with a reference setting of 100 ms and undergo an optimisation 
procedure. In each case the underlying true optimum is 140 ms, but because of noise 
variability, the setting selected as optimum may be this or another setting.  
I calculated several aspects. First, the proportion of patients in whom the observed 
optimum was a correct reflection of the underlying true optimal AV delay.  
Second I calculated by how much the observed optimum appeared to be better than 
the reference state. In reality I also knew how much the underlying optimum was 
better than the underlying reference state, and I reported this value too, for 
comparison. This enabled me to report the extent to which the apparent increase over- 
or under-estimated the underlying benefit. It was always an over-estimation, as shown 
in the column “Extent of Illusion” in Table 4-3. The size of this illusion was strongly 
determined by the information content, with lower information contents leading to 
larger illusory improvements (ρ = –0.975, p <0.001).  
Third, I calculated the observed difference between the “best” setting and “worst” 
setting. Because I knew the underlying difference between the true best and worst, I 
was able to report this too, for comparison. Again I was thereby able to calculate the 
illusory element. 
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Figure 4-5  Relation between variability and apparent benefit of optimisation.  
The presence of noise on its own does not consistently inflate the apparent difference 
between 2 predetermined settings, since the noise effect is sometimes positive and 
sometimes negative. However, it can inflate the difference between a predetermined 
setting and the apparently-best setting. When there is sufficient noise to cause a 
setting which is not the underlying optimum to appear to be the optimum (because it 
happens to have had a positive noise element) then we are effectively selecting the 
setting whose noise is most positive. This introduces a consistent, positive, bias whose 
size increases as the noise becomes more dominant because the most positive noise 
element is larger, and because in noisier environments there is a larger group of 
settings amongst which the apparent optimum might plausibly be drawn. As a result, 
larger noise consistently inflates the difference between the apparent optimum and 
any reference setting. Likewise the difference between maximum and minimum is 
also artefactually inflated by increases in noise. 
80 120 160 200 240
Reference Underlying
optimum
Underlying 
signal
with 
small 
noise
with 
larger 
noise
with 
large 
noise
Apparent 
improvement
Apparent 
max-min
Underlying 
improvement
Underlying 
max-min
 134 
Table 4-3  Impact of information content on the size of the apparent benefit of optimisation.  
For each combination of signal and noise variance, we show the apparent benefit of optimisation (calculated from the measured data including 
noise) and the true benefit (calculated from the underlying benefit with no noise). The illusory element is also shown, defined as the degree to 
which the apparent measured increase overstates the true increase. 
 
Benefit from optimization: Benefit from optimization:
optimum minus worst optimum minus reference
Signal 
magnitude
Noise 
variance
Information 
content
Apparent 
measured 
increase
True 
underlying 
increase
Extent of 
illusion
Apparent 
measured 
increase
True 
underlying 
increase
Extent of 
illusion
1 1 0.50 3.3 2.1 + 54% 1.1 0.5 + 105%
1 10 0.09 7.8 2.1 + 263% 3.2 0.5 + 497%
1 100 0.01 23.7 2.1 + 1008% 11.2 0.5 + 2002%
10 1 0.91 7.5 6.8 + 11% 1.9 1.7 + 10%
10 10 0.50 10.4 6.8 + 54% 3.3 1.7 + 98%
10 100 0.09 24.8 6.8 + 267% 10.5 1.7 + 522%
100 1 0.99 21.9 21.4 + 2% 5.4 5.3 + 0%
100 10 0.91 23.6 21.4 + 10% 5.6 5.3 + 6%
100 100 0.50 32.9 21.4 + 54% 11.2 5.3 + 110%
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4.6.2 Apparent change in optimum over time 
I simulated repeating the optimisation process after the passage of time, keeping the 
underlying optimum the same between sessions. I calculated whether the observed 
optima seemed to change between sessions, and by how much. 
For each signal and noise combination, I observed the resulting distribution of 
differences between the optima found at the 1st and 2nd optimisation visits. Figure 4-6 
shows these distributions which have information content of 0.91, 0.50 and 0.09 
respectively.  Since the true underlying optimum did not change between visits, all 
changes in observed optimum were false. The proportion of patients of patients giving 
this false apparent change in optimum is shown by dark shading.  
Low information content was strongly linked to the likelihood of false-positive 
detection of change in optimum (ρ = 0.975, p < 0.001) 
When signal and noise were of equal size (information content ~ 0.50) about two-
thirds of the patients have spurious apparent changes in optimum between visits. Even 
when the signal-to-noise ratio was 10:1, giving an information content of 0.91, still 
one-third of patients had spurious apparent changes in optimum. Only when signal-to-
noise ratio reached 30:1 (information content ~ 0.97), did the proportion of patients 
getting false-positive apparent change in optima fall to a clinically respectable 7% 
(top panel, Figure 4-6). 
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Figure 4-6  Impact of information content on the probability of falsely detecting 
a change in optimum.  
A group of patients is simulated attending the optimisation clinic twice, with their 
underlying optima truly unchanged between visits. We calculate the apparent change 
in optimum between visit 1 and visit 2. The table shows the percentage who have a 
spurious apparent change depending on the information content. Graphically we can 
see that when information content is high (top panel) only 33% of patients have a 
spurious apparent change in optimum. When information content is slower (middle 
and bottom panels), the proportion of patient having a spurious apparent change in 
optimum becomes much higher. It should be noted that simply randomly choosing 
between 5 settings, gives an 80% (4/5) rate of spurious detection of change in 
optimum, which is no worse than the bottom panel.  
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4.7 Discussion 
In this study I have shown that uncritically selecting the pacemaker setting which 
gives the best value of a monitored variable might be little better than random 
selection amongst a set of AV settings. These findings are generally applicable to any 
optimisation method that relies on testing a series of settings while monitoring some 
measure of cardiac function (such as echocardiographic velocity-time integral or 
pressure or any other cardiovascular marker) and then picking the setting that gives 
the highest measurement.  
It is overwhelmingly important for signal-to-noise ratio (information content) to be 
high, otherwise a series of illusions automatically arise in any clinical data analysis.  
4.7.1 Illusion 1: “We have selected the true underlying optima” 
One tends to assume that the setting which gives the highest measurement is the best. 
However, our study shows that only a very small amount of variability is enough to 
seriously compromise this assumption because the true biological effect may also be 
very small. With signal and noise of equal size for example, in ~ 50% of cases (Figure 
4-6) the optimum detected will not be the true optimum but an erroneous alternative. 
The confidence interval of a clinical optimisation is never reported and (surprisingly) 
rarely asked for. A wide confidence interval will have immediate comprehensibility to 
any clinician reviewing the result. The simplest way to calculate the confidence 
interval of optimisation is to carry it out on several occasions (e.g. immediately, one 
after the other) and calculate the standard deviation. The 95% CI would be the mean ± 
1.96×standard deviation. To make this reasonably valid, one would need to perform at 
least 3 or 4 optimisations. Of course this would be extremely time-consuming, and is 
therefore not realistic for routine clinical practice with current monitoring techniques.   
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Alternatively one can determine information content of the clinic’s optimisation 
process in general. This could be calculated once and then applied to all similar 
patients without having to carry out multiple replicate optimisations in each new 
clinical patient. Fortunately, information content is easy to calculate: it is essentially 
the intraclass correlation coefficient. This can be calculated quickly for a 
representative group of patients by any laboratory. This is similar, in principle, to 
using concepts of statistical power analysis to routine clinical practice.  
4.7.2 Illusion 2: “The optimisation increased flow (or pressure) by X 
and was therefore worthwhile” 
It is tempting to average the apparent increments in velocity-time integral (or 
whatever measure was used for optimisation) achieved in an optimisation service, and 
believe that, first, (a) the process is almost always increasing stroke volume, (b) the 
size of the average increase in stroke volume is ‘X’ which sounds clinically 
worthwhile and (c) that since the increment in statistically significant it is not likely to 
be a chance finding.  
This study reveals all three of these tempting conclusions to be wrong. First, the 
setting selected as apparently optimum will always have a higher measured cardiac 
function than the reference setting (except where the reference setting happens to be 
selected as the optimum). Even if an optimisation method was just roulette amongst n 
tested settings, then in (n-1)/n cases (i.e. almost always) it would be selecting an 
optimum different from reference. Therefore, the statement that stroke volume is 
higher on the optimal setting is meaningless.  
Second, ironically, the worse the optimisation method, the larger the illusionary 
increase in stroke volume. 
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Third, unless carefully constructed (Turcott et al. 2010), the statistical test is assessing 
whether or not changes in stroke volume are randomly distributed (some positive, 
some negative) with a mean of zero. But each patient’s increment will always be 
either positive or zero (never negative), so the average increment will always be 
statistically significantly positive unless the sample size is very small. Indeed, the 
worse the optimisation method, the more likely the apparent increment is to be 
statistically significantly positive. 
4.7.3 Illusion 3: “The optimum has changed between X months and 
now” 
A well established and indispensable optimisation clinic may start to consider how 
often these optimisations should be carried out (Porciani et al. 2006a; Zhang et al. 
2008). Is the contrast between patients’ optima on subsequent visits a useful guide? 
My analysis now shows that if a technology has poor information content (low signal-
to-noise ratio) reproducibility will be poor. For example when signal and noise are 
approximately equal (information content = 0.5) at 6 months (or any other time) the 
optimum will falsely appear to have changed, purely through noise, 65% of the time 
(Figure 4-6). Ironically, the worse the optimisation process, the more the data will 
seem to encourage more frequent optimisations. The giveaway clue to this would be 
that however frequently we re-optimise, there would still be a similar proportion who 
would seem to need a change in setting. 
4.7.4 Illusion 4: “We should not waste time making multiple 
replicate measurements at each setting in clinical practice” 
In a busy clinical department, it may seem an unnecessary multiplication of work to 
make more than one measurement at each setting. Instead, it may seem rational to 
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concentrate on ensuring that each measurement is acquired and analysed properly by 
well-trained staff. Unfortunately, the reasons for beat-to-beat variability in 
measurement are many, and inadequate skill on the part of the sonographer or 
interpreter is typically not the dominant contribution. Rather, there is substantial beat-
to-beat variability in transvalvular blood flow, ventricular volumes, arterial blood 
pressure and dP/dt. These variations may be due to respiration and numerous other 
less-easily monitored physiological processes that take place over periods of seconds 
and minutes. They will not disappear through wishful thinking alone. Instead, 
averaging multiple replicate acquisitions gives us a powerful method to reduce the 
effective noise. Effective noise (the variance of the averaged value from R replicate 
raw measurements) falls in direct proportion to 1/R, providing a simple way to 
improve the information content. Another strategy for blood pressure recordings, is to 
elevate heart rate, since this increases the size of the signal (Whinnett et al. 2006a). 
4.7.5 Illusion 5: “We should optimise using whatever measurement 
method we are most familiar with” 
Inter- and intra-observer variability may not be the dominant source of noise, rather 
there may well be genuine biological variation between beats. Even with excellent 
clinical acquisition and measurement technique, if the biological variability is large in 
comparison to the true signal between settings, information content will be low. One 
should quantify information content directly and not assume that the technique with 
which we are most familiar has a high information content. 
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4.7.6 Illusion 6: “Between separate beats, variability in my 
laboratory is only X%, therefore this measure is suitable for 
use in optimisation”  
That X%, being the ratio between variability and mean measurement, is not the 
relevant ratio for quality of optimisation. Reliability of optimisation depends on the 
ratio between beat-to-beat variability (noise) and between-setting variability (signal). 
The ratio is much less favourable than X%. For example, a VTI measurement might 
have a mean value of 10 cm, and a standard deviation of 1 cm, giving a coefficient 
variance of 10%. However, the relevant signal is not 10 cm but the standard deviation 
between-settings which may only be (for example) 1 cm, In this case, the information 
content would be 11
1
+
 = 0.5. The naive figure of 10% variability, in isolation, is of 
no relevance. 
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4.8 A simple method of calculating information content of 
a cardiovascular measure used clinically for 
optimisation 
Because this study was carried out using computer simulation, it was possible to know 
the size of the true underlying signal, as well as the size of the noise, and thereby state 
the information content directly.  
In vivo, one can calculate information content by measuring total variance and noise 
variance, since although the underlying signal magnitude cannot be directly observed, 
it is the difference between them. We need to carry out several optimisations in the 
same patients. Suppose one carries out R replicate sets of optimisations in one patient. 
First calculate the variance of all the raw measurements (Vraw). Then one can calculate 
the mean measurement at each pacemaker setting, and then the variance (Vm) of these 
means. Vm will tend to be smaller than Vraw, because the impact of noise is reduced by 
the averaging process. The lower the information content in the measurement, the 
larger its noise in comparison to its signal, and therefore the more markedly Vm will 
differ from Vraw. In brief, the information content is approximately the ratio Vm / Vraw, 
when R is large. More elaborately, accommodating for R not always being large 
(Equation 4-2).  
 
Equation 4-2    
 Information content = 1
1
1 −
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R
raw
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 143 
An example of how to calculate information content in a single patient, using only 
standard spreadsheet software, is shown in Figure 4-7 Calculation of information 
content using raw clinical data from a single patient.. 
 
 
 
Figure 4-7 Calculation of information content using raw clinical data from a 
single patient. 
In this example of real-life data from one patient, 4 replicates of measurements at 5 
settings are entered into a table (columns E to H), and the mean at each setting 
calculated (column K). The variance of the raw data is calculated (Cell H21) using the 
formula shown immediately below it; the same is done for the variance of the means 
(Cell K21). Information content is calculated in cell K26 using the formula shown 
immediately below it. The formulae shown are in appropriate form for standard 
spreadsheet software such as OpenOffice or Microsoft Excel. In particular, 
information content for several early patients (who would need to undergo replicate 
measurements) can be averaged to allow the laboratory to calculate typical confidence 
intervals to be reported alongside optimal settings in future patients.   
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In practice, the examples of published data on information content in Table 4-1 show 
that even with time-consuming methodology including a high number of replicates 
and many beats measured per replicate, information content can still be low. 
4.9 How many replicates are really needed in clinical 
practice? 
Clinicians cannot afford to waste time in clinical practice on performing unnecessary 
numerous measurements during optimisation. Nor, though, can they waste time 
performing apparent optimisations that they should know will be worthless before the 
patient even lies down on the couch. To choose rationally the number of replicates to 
perform it is vital to decide how precisely the patient’s optima is to be identified. 
In clinical practice each individual physician can decide what level of precision is 
suitable in their context and can easily calculate the number of replicates required to 
achieve this as long as the information content of a single replicate of their local 
method is known. The numbers of replicates required for a range of such 
combinations is shown in Table 4-4.  
For example, a clinician may wish to know the AV optimum with a 95% confidence 
interval of  ± 10 ms. How many replicates are needed depends on the heart rate at 
which optimisation is to be carried out (Table 4-1). Studies at resting heart rate have 
found rather low information contents around 0.3.  
If a confidence interval of optimisation of  ±10 ms is wanted in this context, from 
Table 4-4 it can be seen that the number of replicates needing to be conducted at each 
setting is 59. 
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Table 4-4 The number of replicates required when optimisation is performed to reduce the scatter of AV optima obtained to a range of 
acceptable confidence intervals. 
 
 
For 95% confidence interval of an 
individual-patient optimum to be:
±5ms ±10ms ±15ms ±20ms ±30ms
Required "effective ICC" of the multiple replicates
0.974 0.962 0.93 0.877 0.56
Number of replicates required to achieve this
0.02 1836 1240 651 349 62
0.05 712 481 252 135 24
0.1 337 228 120 64 11
0.2 150 101 53 29 5
0.3 87 59 31 17 3
0.4 56 38 20 11 2
0.5 37 25 13 7 1
0.6 25 17 9 5 1
0.7 16 11 6 3 1
ICC of single 
replicate
Actual  behaviour 
of AV optimisation 
algorithms which 
average 18 - 20 
beats per single 
replicate (Table 1)
Projected 
behaviour of VV 
optimisation 
algorithms which 
average 18 - 20 
beats per single 
replicate
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At higher heart rates such as 90 bpm, information content is approximately 0.5 to 0.7 
for several methods (Table 4-1). Achieving a confidence interval of ± 10 ms now only 
requires 11-25 replicates, as shown in Table 4-4, which might be achievable. At 
higher heart rates still, the number of replicates needed continues to fall as 
information content increases (Figure 4-8).  
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Figure 4-8 The effect of heart rate on information content from datasets of published 
studies regardless of method used for AV optimisation 
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Adjustment of VV delay, in contrast, exerts a much smaller signal effect on 
physiological measurements than AV adjustment; by a factor of about 5-7 fold 
(Whinnett et al. 2006b). Even if the variation in blood pressure is just 5-fold smaller, 
the information content is roughly 25-fold smaller – because it is the variances 
(squared deviates) that matter. Therefore, even assuming a favourably elevated (90 
bpm) heart rate, a favourable range of AV optimisation information contents of 0.5-
0.7, and a possible relative signal variance for VV of (1/7)2 to (1/5)2, the information 
content for VV would lie between 0.01 and 0.03. It can be seen from Table 4-4 that 
this necessitates well over 500 replicates at each setting to achieve the desired 
precision of optimisation.  
Although there are detailed descriptions of meticulous protocols (Auricchio et al. 
1999b) even putting together 1500 beats of data does not give high information 
content. Multi beat averages reduce noise, but if signal is small, information content 
may still be small. High heart rate raises signal magnitude (Whinnett et al. 2006a) and 
has allowed a higher information content to be obtained.  
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4.10 Clinical Implications 
No clinical optimisation protocol currently specifies a number of replicates to be 
carried out, while giving a quantitative reasoning. This may be because the impact of 
noise has not been considered or measured. It may not be rational to conduct an 
optimisation without ensuring adequate precision of the optimum. Although there may 
be a clinical imperative to be seen to be doing something, we should not necessarily 
give in to perceived pressure to conduct a placebo procedure. Worse still, if the 
apparent optimisation is in fact no different to randomisation amongst a constrained 
range, it is inescapable that half of all such procedures worsen cardiac efficiency 
rather than improve it. 
If we want our optimisation service to be delivering clinical valuable results, there are 
three generic steps we should take. First, it is important to have as large an underlying 
signal as possible. For blood pressure changes, it has been reported that the signal is 
larger in absolute terms at higher heart rates than at lower heart rates (Whinnett et al. 
2006a).  
Second, noise should be as small as possible. We should not criticise operators for 
inadequate care when they may simply be correctly measuring biological variability. 
Instead the measured variable and protocol should be designed to have a high 
information content. 
Third, we can take averages of multiple replicate measurements of cardiac function at 
each AV delay setting. An R-fold replication will have the same beneficial effect as 
reducing the noise variance of individual measurements by R-fold. This can be 
applied to any measurement technique, but of course carries the cost of increased 
labour. 
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Realisation of these inherent properties of optimisation, should encourage us all to 
mandatorily report the noise and information content of our monitored variable in our 
hands. We should be able to therefore present the confidence interval with every 
optimisation we carry out. This may be uncomfortable. 
I emphasize that in this article I am not recommending one method of measurement 
(e.g. VTI or pressure) over another, nor suggesting whether measurement should be 
invasive or non-invasive.  The choice of measurement modality for optimisation 
should be prejudged by personal preference or based on whim, but rather selected on 
the balance of relevant properties. The most important property of optimisation (a 
process that recommends small adjustments to pacemaker settings) is the precision 
with which the recommendation is given. This chapter is neutral and simply provides 
a language to rationally evaluate, discuss and improve this precision. 
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4.10.1 Practical Recommendations 
This analysis is completely general to all optimisation schemes which test a range of 
settings and select the one with the greatest measurement. Any laboratory conducting 
optimisation can use Equation 4-2 and Figure 4-7 to calculate their typical 
information content. In concert with device physicians, who can recommend an 
acceptable confidence interval, the laboratory can see how many replicates are 
required. 
Such an estimated number of replicates required only applies to an “average” patient 
in the population. The size of the signal may vary between patients. For example one 
patient may have a particularly critical dependency on AV setting, and another a 
below-average amount of dependency. The former would need fewer replicates to 
identify the optimum within a given size of confidence interval, and the later would 
need more. Similarly, one patient may have more noise for one of many reasons, 
including deeper respiration due to acute physiological distress; chronic lung disease 
that enhances ventilatory fluctuation in haemodynamics; obesity impairing image 
quality; agitation impairing probe position maintenance. This would necessitate more 
replicates. 
But while individual patients may have different strict needs for replication, all 
patients will need more replicates if the optimisation technique has poor information 
content. Any protocol document (which specifies an optimisation technique) to be 
credible must at least give quantatively sound guidance as to the number of replicates 
needed for an average patient to obtain optimisation with a level of precision widely 
considered reasonable. If a protocol does not give such guidance, clinical time 
pressures may lead to all patients having optimisations that are, on average, worthless 
(helping half slightly, and harming half slightly). 
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4.11 Conclusions 
Information content, the proportion of the observed differences in the measurements 
at different settings that is genuinely due to the change in settings, has an 
overwhelmingly important impact on the meaningfulness of the pacemaker 
optimisation processes. Although easy to measure, it is rarely reported or commented 
on, and may be surprisingly low unless steps are taken to improve it. 
Low information content leads to frequent misidentification of the optimum. 
However, worse than this, it inflates the apparent benefit of optimisation: counter-
intuitively, the worse the optimisation method, the better it will superficially appear 
(unless one asks about information content). 
Worst of all, because low information content makes apparent optima more variable, 
the poorer the optimisation method, the more frequently one will feel compelled to re-
optimise the patient (unless we ask about information content). 
Information content is easy to improve for any technique. All that is needed is (a) to 
use a technique where the underlying difference between settings is as large as 
possible, (b) to use a technique with beat-to-beat variability as small as possible and 
(c) to make multiple measurements at each setting and calculate the average.  
If, despite these steps, information content is still low, clinical resources could be 
saved by selecting a setting arbitrarily or even at random, with no additional loss to 
the patient’s physiology. We do not make this suggestion for fun but to point out the 
seriousness of the present situation. Optimisation is not optimisation when it is 
roulette. 
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5 Validating markers of mechanical 
dyssynchrony by experimental 
manipulation of interventricular 
timings: What is needed to make them 
a reasonable prospect for Cardiac 
Resynchronisation Therapy selection? 
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5.1 Abstract  
5.1.1 Background  
In optimisation of CRT (and even selection for implantation) we may be 
underestimating the impact of beat-to-beat variation in echocardiographic 
measurements.  
A simple screening test of a proposed dyssynchrony marker is that its value should be 
stable between heartbeats but change dramatically when interventricular delay is 
experimentally manipulated across a wide range; another is that an optimal 
interventricular delay should minimise dyssynchrony. 
The optimisation process exposes this most clearly, because genuine small changes in 
cardiac function (signal) must be detected amongst potentially large beat-to-beat 
variation (noise).  
5.1.2 Methods and Results 
In this study of biological variability, I performed 2592 echocardigraphic 
measurements in 13 patients with CRT. I performed separate, replicate measurements 
at a series of interventricular delays using several potential optimisation modalities.  
These were (i) 3D systolic dyssynchrony index, (ii) Tissue Doppler imaging, (iii) 
aortic pre-ejection time, (iv) interventricular mechanical delay, (v) LVOT VTI and 
(vi) QRS duration. Variability in acquisition or between observers over time is 
eliminated. 
Agreement between successive optimisations was low with Kappa values of 0.24 for 
SDI, 0.02 for TDI, 0.36 for aortic pre-ejection time, 0.14 for IVMD, 0.40 for LVOT 
VTI and 0.47 for QRS duration  
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The intraclass correlation coefficient (ICC), which quantifies measurement 
reproducibility, was low for all methods when single measurements were taken 
(ranging from 0.32 to 0.63), but improved when pairs of measurements were averaged 
(0.51 to 0.74, p=0.0008). The scatter between replicate optima obtained is lower when 
pairs of measurements were taken, p=0.007 across all methods. 
5.1.3 Conclusions   
The relative sensitivity of these dyssynchrony markers to detect even large changes in 
VV delay (as distinct from spontaneous beat-to-beat variability) appears to be very 
poor. Under these blinded conditions these mechanical dyssynchrony markers cannot 
reliably discriminate even large changes in interventricular delay, and can be quickly 
rejected as candidates for predicting clinical benefit from CRT.   
VV delay optimisation by any of the echocardiographic techniques is not realistic 
unless multiple replicates are performed and averaged. More concerningly, even 
dyssynchrony assessment to select patients for implantation may need averaging of far 
more replicate measurements than is currently described, to have any hope of success.  
It would save time and expense if markers considered for clinical trialling under 
formal scientific conditions first underwent screening for plausibility by such a stage 
of inexpensive, active experimentation. 
 
 155 
5.2 Background 
What properties should a marker of dyssynchrony have? First, it should be stable from 
one beat to the next, which can readily be tested. Second, it should change when the 
amount of dyssynchrony changes: this can be tested by changing the VV delays 
settings of a Cardiac Resynchronisation Therapy (CRT) pacemaker. For a marker of 
dyssynchrony to have any hope of being diagnostically useful, the impact of changes 
in VV delay setting must be much greater than the impact of random beat-to-beat 
biological variability. This “signal-to-noise” information should be helpful in 
evaluating potential markers of dyssynchrony (Pabari et al. 2011), and may be pivotal 
for designing approaches to optimisation of VV delay. 
There are several echocardiographic markers which might be used to detect 
dyssynchrony or be used to optimise the atrioventricular or interventricular delay 
settings of a CRT device once implanted. Potential techniques for VV optimisation 
include maximisation of LVOT VTI (Mortensen et al. 2004; Thomas et al. 2009), 
minimisation of 3D dyssynchrony (Kapetanakis et al. 2005; Liodakis et al. 2009) or 
minimisation of the differences in tissue Doppler timings (Yu et al. 2004b). The latter 
techniques are of special interest because they are dyssynchrony markers also used for 
selecting patients for implantation.   
In this study I carry out an acid test of markers of dyssynchrony. I eliminate between-
patient variability, between-observer variability and gradual changes in clinical status. 
With all these kept constant, I experimentally manipulate dyssynchrony through a 
wide range of values to confirm or refute the ability of individual dyssynchrony 
markers to detect this. 
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I have systematically quantified the discriminant power of these echocardiographic 
indices in a formal head-to-head evaluation to reproducibly detect changes in 
mechanical dyssynchrony elicited by changes in VV delay. Specifically, I distinguish 
the genuine changes caused by change in VV delay from the natural random 
biological variation occurring between beats. To do this I measure several 
independent beats, at each of several VV delays, in each patient. 
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5.3 Methods 
5.3.1 Study Population 
13 outpatients with biventricular pacemakers or biventricular defibrillators previously 
implanted for clinical indications (Barnett et al. 2007) were invited to enter this 
detailed study of approximately 10 hours of echocardiographic recording per patient. 
All patients were free from decompensation for greater than 3 months and no changes 
to medication were made 4 weeks prior to entering the study and until all data had 
been collected. All patients had intrinsic sinus rhythm, heart rate 70 ± 17bpm,  with 
100% biventricular pacing (AsVp) and a fixed AV delay programmed to the standard 
nominal setting of 120ms. 
At the time of the study, 1 patient was NYHA class I, 4 were NYHA II and 8 were 
NYHA III. Time between implantation and enrolment was 32 months (range 8 months 
to 63 months. 5 subjects were male and 8 female, age 69 years ± 8 years (mean ± sd). 
The cause of heart failure was ischemic in 5 subjects and idiopathic dilated in 8 
subjects. 11 patients were taking angiotensin-converting enzyme inhibitors or 
angiotensin-II receptor antagonists, 10 were taking beta-blockers, 6 were taking 
spironolactone and 6 were taking a diuretic (loop or thiazide). Patients gave informed 
consent for this study which was approved by the local ethical committee. 
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5.4 Protocol 
In each patient optimisation of VV delay was performed using each of the potential 
markers: (i) 3D systolic dyssynchrony index (SDI), (ii) Tissue Doppler imaging 
(TDI), (iii) aortic pre-ejection time, (iv) interventricular mechanical delay (IVMD), 
(v) LVOT VTI and (vi) QRS duration .  The range of VV delays investigated was RV 
first 40ms, 20ms, VV 0ms, LV first 20ms, 40ms and 60ms. and replicate 
measurements were performed as described below.  Continuous ECG monitoring 
from limb leads confirmed that all patients were 100% AsBiVp throughout the 
measurements. 
For most patients this required 3 or 4 visits of several hours each, which were carried 
out within 2 weeks of each other. All the measurements using a particular modality 
(e.g. tissue Doppler) across all replicates and all pacemaker settings were conducted 
within one visit by one experienced operator for each patient. This ensured that the 
only variability being quantified was beat-to-beat biological variability, a variation 
that cannot be attributed to between-operator disagreements or to a substantial change 
in patient status. 2592 measurements were made in total and I analysed all results. 
5.5 Echocardiography 
Echocardiography was performed in all patients using the Philips IE33 machine able 
to acquire the advanced images for 3 dimensional and tissue Doppler 
echocardiography, in addition to the more common practice Doppler measurements. 
Tissue Doppler studies and pulsed wave (PW) Doppler images were acquired using 
the Philips S5-1 sector ultrasound transducer. 3D echocardiography was performed 
using a X3-1 transducer. 
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5.5.1 Modalities used for optimising VV delay 
5.5.1.1 LVOT – Velocity Time Integral 
LVOT VTI images were taken from the apical 5-chamber view with the pulse wave 
Doppler cursor at the left ventricular outflow tract approximately 1 cm below the 
aortic annulus. Eight beats were acquired at each VV delay, by a single operator, at 
end expiration. Offline analysis was manually traced and resulted in digitised VTI 
tracings.  The optimal VV delay setting was defined as that at which the LVOT VTI 
was greatest in magnitude.   
5.5.1.2 Ejection flow dyssynchrony 
Ejection flow dyssynchrony was measured in 2 ways. Firstly aortic pre-ejection time 
(APET) by measuring the time delay from onset of QRS to onset of flow (Lane et al. 
2004). Second we calculated the interventricular mechanical delay (IVMD) as the 
delay between RV ejection and LV ejection using pulsed wave Doppler across the 
LVOT and RVOT respectively. Eight beats were acquired at each VV delay. All 
acquisitions were made at end-expiration to minimise respiratory variation.  For both 
APET and IVMD methods, the optimum VV setting was defined as that which made 
the delay the smallest. 
5.5.1.3 Tissue Doppler imaging 
Colour coded tissue Doppler imaging was used for acquisition and analysis, using the 
2 segment model from the onset of QRS complex to the peak of the systolic wave 
form (Bax et al. 2003a; van Bommel et al. 2010b). Apical images of the left ventricle 
including the level of the mitral annulus were acquired with a minimum frame rate of 
90 Hz (Gorcsan et al. 2004b). Images were acquired with LV cavity positioned in the 
centre of the sector showing clear myocardial definition with the patient holding their 
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breath at end-expiration. A minimum of 4 cycles were acquired, allowing 4 separate 
analyses. Time–velocity curves were obtained using a sample volume placed within 
the segments at the region of interest at the basal lateral and septal (Bax et al. 2003a; 
Chung et al. 2008a) segments. Analysis was performed offline using Philips Qlab 8.1 
with cardiac motion analysis (CMQ) software.   
The time-to-peak systolic velocity was measured for each wall from the onset of the 
QRS to the highest peak on the velocity curve within the aortic ejection period. If two 
peaks were seen, we used the timing of the highest peak, and if two peaks of equal 
velocity were seen, the timing of the earliest peak was used. The optimal VV setting 
was that at which the delay between septal and lateral peak S’ velocities was smallest. 
5.5.1.4 3D Echocardiography: Systolic dyssynchrony index 
3D echocardiography was performed using a X3-1 transducer. Four-chamber apical 
views of the heart were acquired with the left ventricle clearly identified. Full-volume 
datasets were acquired; each recorded over 4 consecutive beats. Acquisitions had a 
minimum frame rate of 20 frame/s in keeping with ASE guidelines, with the patient 
breath holding at end expiration. For each VV, delay four replicate measurements 
were taken.  
Offline analysis was performed using Tomtec analysis software, version 2.0 (Tomtec 
GmBH, Germany). The three views used for primary analysis are the 4 chamber view, 
3 chamber and 2 chamber simultaneously at 60 degree views.  End-systolic and end-
diastolic frames were identified, once the ventricle was aligned to eliminate 
foreshortening. Automatic border detection was then carried out and corrected as 
appropriate. A segmented shell is created (Figure 5-1) and time-volume curves and 
the systolic dyssynchrony index were calculated (Gimenes et al. 2008), with the 
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analysis performed by myself. The optimal VV setting was that at which the systolic 
dyssynchrony index was smallest. 
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Figure 5-1  A shell is created with all segments numbered.  
We can see segments 4,5,10 and 11 in the example above. Each of the 16 segments 
have the time to minimal volume measured. 
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5.5.2 Calculating the agreement of selecting the optimal VV delay 
setting within the same modality 
For each of the dyssynchrony markers, I made multiple replicate acquisitions at each 
of the tested VV delays thus mimicking multiple optimisations and allowing me to 
measure the extent to which variation between measurements at different VV delays 
were genuinely due to changes in VV delay, versus simply natural biological 
variation. For aortic pre-ejection time, interventricular mechanical delay and LVOT 
VTI I made 8 replicate measurements. For 3D SDI and TDI, which are more time 
consuming, I made 4 replicate measurements.  
The agreement is quantified as the number of pairwise comparisons between replicate 
optimisations, by the same method, that yield the same optima, Figure 5-2. I 
calculated the number of times the same optima was obtained when repeat 
optimisation processes were performed within the same modality, and displayed this 
as a percentage of the number of pairwise comparisons made. 
 164 
5.5.3 Calculating Kappa within the same modality 
The Kappa statistic gives the excess proportion of agreement. above the agreement 
that would arise by chance alone, for each individual modality studied.  I initially 
calculated the distribution of ‘optimal’ settings across the replicate measurements for 
each modality, Psetting.  Using this value, I then calculated the expected level of 
agreement by chance, Pchance, for that modality, as follows: 
Equation 5-1 
 
( )∑= 2settingchance PP
 
 
I then calculated the raw agreement for that modality, defined as the number of 
occasions when two replicates gave the same optimum in the same patient, divided by 
the number of comparisons made. Expressed formally, this is:  
Equation 5-2 
 
Number of agreements within patients
1
2
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replicates
patients replicates
P N
N N
=
−
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Finally I obtained Fleiss’ Kappa in the usual way: 
Equation 5-3 
 
1
raw chance
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P P
P
κ
−
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5.6 Calculating the scatter of detected optima between repeated 
optimisations for each separate modality 
Using the individual ‘optimum’ VV delay settings for each of the replicate 
optimisations for a specific modality, we calculated their scatter, i.e. the standard 
deviation between the replicate optima, and compared these values of ‘scatter’ 
between the 6 separate modalities. 
 
5.7 Quantification of the genuine effect of interventricular delay 
versus random variability 
The intraclass correlation coefficient (ICC) was used to quantify how well changes in 
synchrony were detected in amongst background noise and spontaneous variability. 
This was calculated for each modality across all patients. As previously described, an 
ICC close to 1 indicates that changes in settings make a relatively big change in the 
measurement parameter in comparison to the random beat-to-beat variability. An ICC 
close to 0 indicates that the random beat-to-beat differences are relatively big in 
comparison to the genuine effect of changing settings.  ICC was defined as the 
variance of the means of the values from each of the tested VV delays, divided by the 
variance of all the values within that patient for that particular modality. 
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5.8 Results 
5.8.1 Assessment of each of the 6 dyssynchrony markers as 
candidates for VV optimisation using single measurements 
First I present the distributions of optimisation measures for single measurements. 
This mimics a simple, rapid clinical optimisation process in which each VV setting is 
applied in turn with a single measurement made for each.  
As described, for each of the dyssynchrony markers, I made not one but multiple 
replicate acquisitions at each of the tested VV with 8 replicate measurements for 
aortic pre-ejection time, interventricular mechanical delay and LVOT VTI, and 4 
replicate measurements for 3D SDI and TDI. 
5.8.1.1 Probability of selecting the same optimum on replicate optimisations 
Within method agreement of optima could not be described as good for any of the 
modalities. 3D systolic dyssynchrony index had 38% agreement (Figure 5-2), tissue 
Doppler imaging 21%, aortic pre-ejection time 49%, interventicular mechanical delay 
31%, LVOT VTI 54% and QRS width 58%. 
The kappa values for the within modality agreement are 0.24 for 3D systolic 
dyssynchrony index, 0.02 for tissue Doppler imaging, 0.36 for aortic pre-ejection 
time, 0.14 for interventricular mechanical delay, 0.40 for LVOT VTI and 0.47 for 
QRS duration. These low values indicate the poor agreement within each 
dyssynchrony marker and itself on successive beats. 
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Figure 5-2 Agreement between replicate VV optimisations by the same method. Inset shows method of calculating this value for 3D SDI.  
Similar calculations were done for the other methods. The agreement is quantified as the number of pairwise comparisons between replicate 
optimisations, by the same method, that yield the same optima.  
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5.8.1.2 Probability of two different optimisation methods agreeing on an 
optimum 
I then examined the agreement, between one method and another, on what the 
optimum VV setting was. I used each of the single replicates in turn. The agreement 
between methods was poor, within many cases the level of agreement being not much 
different from pure chance. 
Figure 5-3 demonstrates how the agreement was calculated and shows both the raw 
agreements and kappa valued between methods. 
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Figure 5-3  Example of how agreement between methods was calculated (3D Systolic dyssynchrony index versus Aortic pre ejection time) 
The top panel shows an example of how the percentage agreement between 3D systolic dyssynchrony index measurements and APET 
measurements was calculated with data shown for 3 of the 13 patients. The lower panel shows the percentage agreement and kappa values 
between each combination of the 6 dyssynchrony markers. 
Patient 1
Optimisation A Optimisation B Optimisation C Optimisation D
-20 -20 -20 -40
Optimisation A 60 X X X X
Optimisation B 60 X X X X
Optimisation C 60 X X X X
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20 20 20 20
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Aortic pre ejection time
Aortic pre ejection time
Aortic pre ejection time
Agreement between modaities for selecting VV optima.
Pair of dyssynchrony markers
Raw agreement 
on optimum
Kappa
TDI vs APET 13% 0.15
TDI vs IVMD 11% 0.17
TDI vs LVOT VTI 11% 0.14
TDI vs QRS duration 21% 0.16
TDI vs SDI 16% 0.17
APET vs IVMD 25% 0.18
APET vs LVOT VTI 28% 0.19
APET vs QRS duration 21% 0.18
APET vs SDI 14% 0.16
IVMD vs LVOT VTI 13% 0.17
IVMD vs QRS duration 15% 0.19
IVMD vs SDI 31% 0.16
LVOT VTI vs QRS duration 16% 0.15
LVOT VTI vs SDI 7% 0.15
QRS duration vs SDI 11% 0.16
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5.8.1.3 The Scatter of VV optima obtained at repeated optimisations 
I calculated the scatter (standard deviation) between the optimal VV delay settings on 
replicate optimisations for each method, as shown in a representative patient in Figure 
5-4 below.  The smaller the scatter for a method, the more consistent the VV optima 
within individual patients will be using that method. 
For 3D SDI the scatter of optima was 23 ms, TDI 26 ms, aortic pre-ejection time 14 
ms, IVMD 28ms, LVOT VTI 21 ms and QRS duration 14 ms. 
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Figure 5-4  Calculation of scatter of optimum VV delays in a representative patient using repeat measurements of aortic pre-ejection 
time as the marker of dyssynchrony.  
There were 6 separate optimisation sequences performed using APET, generating 6 optimal VV delay settings.  We quantified the scatter of 
optima by calculating the standard deviation or scatter of the individual optima identified, each marked by  , 
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5.8.1.4 Quantification of genuine change versus biological variation: 
Intraclass correlation coefficient 
I calculated the intraclass correlation coefficient (ICC), which indicates the extent to 
which difference between single measurements at different VV delays is due to true 
differences between the VV delays rather than random beat-to-beat variation.  
The data from a representative patient, using aortic pre-ejection time as the 
dyssynchrony marker, is shown in Figure 5-5. As can be seen, the scatter between 
replicate measurements was small in comparison to the between-setting differences, 
hence a high ICC was obtained in this example patient using aortic pre-ejection time 
as the modality. 
The ICC for single replicates across all patients was 0.34 for 3D systolic 
dyssynchrony index, 0.32 for tissue Doppler measurements, 0.57 for aortic pre-
ejection time, 0.47 for interventricular mechanical delay, 0.54 for LVOT VTI and 
0.63 for QRS duration. 
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Figure 5-5  Six replicate measures at each VV delay using aortic pre-ejection time as the dyssynchrony marker.  
The replicate measures at each setting are not exactly the same. The ICC is defined as the ratio between the variance of the means at each setting, 
and the variance of all the raw data points. In this example the ICC is 0.74. 
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5.9 Multiple Replicate Measurements  
I then examined the effect of using averages of multiple replicate measurements of the 
variable being optimised, instead of single measurements. 
For those modalities where 8 replicates were possible, namely aortic pre-ejection 
time, IVMD and LVOT VTI, I grouped the raw replicate measurements into 4 groups 
of 2 “averaged measurements”. For TDI and 3D SDI where 4 replicates were 
possible, I grouped the raw replicate measurements into 2 groups of 2 “averaged 
measurements”. 
5.9.1 The effect of multiple measurements on the scatter of VV 
optima obtained 
The scatter of optima obtained fell, when averages of pairs of measurements are 
taken, instead of single measurements. The scatter of optima fell from 23 ms to 18 ms 
for 3D SDI, from 28 ms to 15 ms for TDI, from 14 ms to 10 ms for aortic pre-ejection 
time, 28 ms to 22 ms for IVMD, 21 ms to 16 ms for LVOT VTI and 14 ms to 10 ms 
for QRS duration (p = 0.00047, Figure 5-6). 
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Figure 5-6 The scatter of VV optima obtained using each dyssynchrony parameter at 
rest with single measurements and averaging paired replicate measurements.   
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5.9.2 The effect of multiple measurements on the intraclass 
correlation coefficient 
The intraclass correlation coefficient were systematically higher for the averaged 
measurements than single measurements across all modalities. Using single 
measurements compared to using averaged paired measurements increased the ICC 
from 0.34 to 0.59 for 3D SDI, from 0.32 to 0.51 for TDI, from 0.57 to 0.72 for aortic 
pre-ejection time, 0.47 to 0.59 for IVMD, 0.54 to 0.67 for LVOT VTI 0.63 to 0.74 for 
QRS duration (p = 0.00084, Figure 5-7). 
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Figure 5-7 The Intraclass correlation coefficient of each modality for single and 
averaged paired measurements.  
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5.9.3 Responders and Non-responders 
69% of patients (9/13) were clinical responders following CRT implantation and the 
other 31% patients (4/13) did not clinically improve.  
There was no significant difference between the ICC for responders vs. non 
responders (p = 0.44) across all modalities tested. Nor was there a significant 
difference in the scatter of optimal VV delay obtained (p = 0.53).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-8: The intra class correlation coefficient between responders and non-
responders showed no significant difference across all modalities (p=0.44). 
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Figure 5-9: The scatter of VV optima obtained when replicate optimisations are 
performed showed no significant differences between responders and non-responders 
across all modalities tested (p=0.53). 
The scatter of VV optima obtained on replicate optimisations between 
Responders and Non-responders (p = 0.53)
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5.10 Discussion 
My study shows that each of these dyssynchrony markers has a very high beat-to-beat 
variability. Specifically this variability is large compared to the genuine changes in 
dyssynchrony elicited by changes in pacemaker timings. Together this means that 
single measures of any of these markers cannot realistically be used to optimise 
interventricular delay of a CRT device. Moreover, since such beat-to-beat variability 
swamps the effect of changing VV timings within an individual they are likely to even 
more powerfully swamp the effect of differences in dyssynchrony between 
individuals making it unlikely that single measurements of any of these could be a 
reasonable prospect for a selection criterion for implant of CRT device.  
The methodology of this study permitted me to determine the absolute lower limit of 
measurement variability possible for each of these echocardiographic parameters, 
because I have eliminated any sonographer, observer or temporal influence.  
5.10.1 Why this study design, rather than any other, to assess a 
dyssynchrony marker? 
I developed this study design because it would allow the study findings to be 
reconfirmed (or refuted) by others without undue burden, and because it efficiently 
places a lower limit on the measurement variability. Even though patients, operators, 
and equipment may differ, when all of these are kept constant, and interventricular 
delay changed dramatically, markers of dyssynchrony should vary correspondingly. I 
had hoped that for each patient, each marker would show its own clear optimum, and 
that different markers might mutually agree regarding the optimum. 
In fact I found that not only did markers not agree with each other, but they did not 
even agree with themselves: test-retest reproducibility of the optimum was poor.  
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The greatest problem with all of the echocardiographic modalities used for VV 
optimisation is the large beat-to-beat variability in relation to the genuine effect of 
changes in VV delay, meaning that replicate optimisation sequences (even performed 
a few minutes apart) produce different optima.  Any technique for VV delay 
optimisation should reliably detect the same optimum every time it is carried out. To 
achieve this, the measurement must reliably discriminate genuine changes in 
underlying value from spontaneous beat-to-beat fluctuations (i.e. have a high ICC).   
In this head-to-head comparison of these 6 modalities I found that all performed 
poorly: high beat-to-beat variability, high scatter between optima and low ICC.  There 
is therefore an inevitable poor agreement of optima between different modalities.  
One might expect the advanced echocardiographic modalities (3D echocardiography 
SDI and tissue Doppler) - which directly measure the dyssynchrony between the 
different myocardial segments - to perform better than the other modalities that 
measure either upstream (e.g. QRS duration) or downstream (e.g. APET, IVMD and 
LVOT VTI) effects of this dyssynchrony.   But they consistently performed no better, 
and often worse, than the other modalities.  
While there have reports of tight reproducibility for these markers (Liodakis et al. 
2009; Yu et al. 2004a), in other reports conducted under stringent blinded conditions 
test-retest reproducibility was underwhelming agreement is noted to be much less 
than perfect (Chung et al. 2008a; De Boeck et al. 2008; Turcott et al. 2010; Vesely et 
al. 2008) which is an inevitable consequence of unsatisfactory test-retest 
reproducibility in one or both markers.  Such comparison of an optimisation technique 
with itself is rarely reported on, except where either the same or another operator 
reassesses the same data again, rather than reacquiring an entirely new dataset at a 
later time point.  Because of this variability, there is mathematically little hope of 
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good agreement between modalities for detecting a consistent optimum (Thomas et al. 
2009), and consequently even less chance of VV optimisation resulting in 
improvements in clinical endpoints. Any measurement that incorporates less separate 
constituent measures may perform better because it has less sources of beat-to-beat 
variability and hence potential for error.  This may explain why LVOT VTI and 
APET (which both only a single measurement per VV delay setting) have, both in this 
study and others (Thomas et al. 2009), been shown to have a higher probability of 
detecting the same optimum on different optimisations, less scatter of optima and a 
higher ICC than techniques such as TDI and 3D SDI (which require measures of 
several different myocardial walls/ segments for each VV delay setting). 
5.10.2 Can anything be done to improve the situation? 
Averaging of replicate optimisation sequences reduces the impact of the beat-to-beat 
variability, and therefore reduces the scatter and improves the ICC of replicate 
optimisations. Although planners should incorporate this process into all optimisation 
protocols (and in particular into any study protocol hoping to have a chance of 
demonstrating any clinical benefit from VV optimisation), this is rarely performed 
because of the extra time needed for acquisition and data analysis per patient.  The 
resulting trial, although possessing a high patient throughput, may have no hope of 
efficacy. 
5.11 What do these results mean for clinical VV delay optimisation? 
To be practical for clinical purposes, an optimisation process needs to consume only a 
reasonable amount of time, while achieving an acceptable degree of reproducibility. 
This study shows that for all the modalities tested, averaging replicate measurements 
is essential to have a reasonable reproducibility. Even with averages of 4 or 8 
replicates, this study showed that reproducibility was still not at such a level that is 
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likely to be considered acceptable to most clinicians. More replicates and hence more 
time would be required.  
I can estimate easily how long it would take to measure enough replicates to achieve 
an optimisation to a level that a clinician might find acceptable.  If a raw optimisation 
technique had a scatter of optima (SD) of 28ms, to reduce the SD to 5ms, so that the 
95% confidence interval could be ±10ms, would require (28/5)2 replicates, i.e. 31 
replicates. In Table 5-1 we show how many replicates would be needed for each of 
the methods tested. Even in experienced hands, it can take up to 5 minutes to acquire 
and analyse a 3D image, therefore 30 minutes for a single-replicate optimisation 
between 6 settings using 3D dyssynchrony. To narrow the uncertainty of the optimum 
to ±10ms would require 22-fold replication: this would consume 11 hours, a time so 
long that it would be unlikely to be clinically acceptable. Yet to carry out fewer 
replicates means accepting an uncertainty in the optimum that is correspondingly 
wider and therefore itself may be clinically unacceptable. If these dyssynchrony 
markers cannot consistently distinguish between dramatically different paced 
interventricular delays within an individual, then whether they could ever be used for 
CRT selection criteria is questionable?  
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Scatter (ms) for single replicate 
optimisation across all patients
The number of replicates required to 
confidently provide optima ± 10ms
3D SDI 23 22
Tissue Doppler imaging - 2 seg 26 26
Aortic Pre Ejection time 14 8
Interventricular mechanical delay 29 33
LVOT VTI 21 18
QRS duration 14 7
 
 
Table 5-1 Calculation of the number of replicates required to provide reliable optima with a 95% confidence internal of ± 10ms, for each 
method. 
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I recommend that research and clinical practice with dyssynchrony markers should 
specify explicitly the number of replicates that should be measured and averaged, 
based on (blinded) measurements of beat-to-beat variability.  
5.11.1 Why are our results “worse” than commonly supposed  
I have not excluded any patients and hence those who had difficult images to acquire 
and analyse were included. This was not a study where I picked the best images, but 
instead those which were representative of the CRT device population who have, in 
some cases, more challenging image quality.   
I have included successive beats without any exclusions except for ectopic beats and 
the subsequent beat which would be altered as a result of the ectopic. 
I used no more sophistication in our analysis than we have reported. Other groups and 
studies may have used more subtleties, exclusions, re-analysis, unblinding collateral 
information but these may not been published or fully explained. This may have 
meant that subsequent externally-monitored, prospectively-recruited trials which were 
required to use openly declared methods, were doomed to failure (Chung et al. 
2008a).  I have used published protocols at face value. 
Although no multi-centre trials have been performed for VV delay optimisation, 
similar factors may explain the discrepancy between the clinical results of small 
single-centre trials of echocardiographic measurement of dyssynchrony to guide CRT 
device implantation (Bax et al. 2003a; Bleeker et al. 2007c) and those of the large 
multicentre clinical trials such as PROSPECT, which surprised some experts by 
failing to identify a single echocardiographic modality that could predict CRT 
response (Chung et al. 2008a). 
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5.11.2 Would more training help?  
This centre does not have below-average standards of skill, but a track record of 
research in echocardiography and our practice standards are not below real-world 
clinical practice. 
I do not believe that my blinded test-retest reproducibility data are necessarily poorer 
than that reported by others (De Boeck et al. 2008; Turcott et al. 2010). Quite often 
what is reported as reproducibility turns out to be the variation between one viewing 
and another, of the same recorded heart beat (Zhang et al. 2011). 
I have applied the published protocols for these measurements, in the way that routine 
clinical users are expected to implement them. The only modification I have made is 
blinding, i.e. withholding during analysis-time the value of the VV delay, a normal 
scientific precaution to prevent unintentional bias in the result. 
I performed the studies, conducted the scans and made the measurements, after 
training within the field. While it is possible that additional training may have helped, 
it is not clear from the literature what further duration of training would be required, 
and what its specific content might be.  
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5.12 Limitations 
In this study I have not studied every echocardiographic marker that has been 
proposed but rather conducted a detailed analysis of the beat-to-beat variability versus 
ability to detect things in VV synchrony for a wide spectrum of echocardiographic 
markers. I was mindful of the acquisition time I was asking these patients to undergo. 
Analysis time was also not inconsequential. I believe a principal finding of my study 
is not that any particular echo marker is inadequate as a single measurement, but 
rather that one cannot assume that markers will be adequate without specific 
assessment. For a single echocardiographic marker, a study such as this is not difficult 
to do, and I believe that any centre about to embark on such a marker for clinical 
purposes in optimisation (or even selection) might consider conducting such a brief 
study with their chosen marker, to gain reassurance that the marker behaves as they 
expect, or to modify their plans accordingly.  
This study focussed on short-term variability, and may be criticised for not including 
a re-assessment some months or years later. However, long periods of time permit 
substantial biological changes to become established, to the extent that any 
discrepancy between initial and final echocardiographic measurements might easily 
be evolution of disease. Echocardiographic optimisation cannot therefore be faulted 
for evolving over such periods of time. Instead, my study focussed on short-term 
variability where there was no real possibility that changes were due to evolution of 
disease. In normal clinical practice, one presumably hopes that ones decision remains 
valid at least between one consultation and the next, which is substantially longer than 
the few heartbeats over which we have tested and retested optimisations and found 
them wanting.  
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I believe that this study shows that so great is the biological beat-to-beat variability of 
many of the echocardiographic indices proposed for use in optimisation (and also for 
selection) that the prime attention should be on either identifying markers not subject 
to such variability, or performing high numbers of replicate measurements of existing 
markers. 
5.13 Conclusions 
This study shows that all of the modalities tested for guiding VV optimisation 
performed poorly on an early test of validity, namely the ability to detect that VV 
delay has been changed across a wide range of settings. Beat-to-beat test-retest 
reproducibility is poor.  Protocols using these measurements to assess dyssynchrony 
either in the context of VV delay optimisation or assessment for suitability for CRT 
implantation, should state beat-to-beat reproducibility and the number of replicate 
measurements that should be made and averaged to make the reproducibility of the 
average acceptable.  
The complete disagreement between the candidate dyssynchrony markers within 
individual patients undergoing changes in synchrony means that the number of these 
which are a candidate for quantifying dyssynchrony is at most 1, and perhaps zero.  
High beat-to-beat biological variability may explain why some echocardiographic 
markers, even when physiologically extremely plausible, have as single 
measurements been disappointing in selecting patients for CRT implantation. This 
study design can be applied to assess the plausibility of any proposed dyssynchrony 
marker, before investigators embark on clinical trials attempting to demonstrate the 
marker’s ability to either predict CRT response or guide VV optimisation. 
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6 Rapid method for evaluating and 
improving plausibility of tissue Doppler 
protocols for assessment of 
dyssynchrony in patients being 
considered for cardiac 
resynchronisation therapy  
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6.1 Abstract  
6.1.1 Background  
Conventionally tissue Doppler imaging (TDI) protocols for quantification of 
dyssynchrony do not undergo early screening for relative sensitivity to genuine 
changes in synchrony versus spontaneous beat-to-beat variability. I show how this can 
be done and precision improved. I demonstrate application to the questions of whether 
to measure (a) onset or peak of velocity; (b) 2, 6 or 12 segments; (c) “earliest-to-
latest” or standard deviation of timing; and (d) single or multiple replicates. 
6.1.2 Methods and Results 
Patients with CRT in situ, underwent a detailed protocol of replicate measurements 
and blinded analysis, at VV delays from RV-first 40ms to LV-first 60ms. I quantified 
ability to detect genuine changes in synchrony using intraclass correlation coefficient, 
ICC, (0 = completely overwhelmed by noise, 1 = perfectly consistent). Tissue 
Doppler velocity traces were obtained and timing was defined in each of the 
2×3×2×2=24 potential combinations as listed above from (a) to (d). 
Single measures of dyssynchrony had low ICC, ranging from 0.32 to 0.54. Averages 
of pairs of measurements improved ICC significantly from 0.50 to 0.72 (ANOVA p< 
0.001). ICC was not significantly affected by measuring to onset or peak (p = 0.31), 
the number of segments measures 2 vs. 6 vs. 12 (p = 0.38) or measuring absolute 
differences in wall timings or standard deviation (p = 0.86). 
Scatter between replicate optima showed broadly a similar pattern being significantly 
narrower with averages of two than singles (ANOVA p<0.001). 
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6.1.3 Conclusions   
Despite physiological plausibility, tissue dyssynchrony assessment will never reliably 
categorise patients if it is unreproducible within a few seconds. Manipulating 
interventricular delay experimentally allows single centres to test (and improve) the 
ability of protocols to detect mechanical dyssynchrony. Averaging at least 2 
measurements appears essential, but alone may not be enough, since ICC remains low 
and the width  of the 95% confidence limit of optima (4 x standard error) very wide. 
Reliable long term prediction is unrealistic while sensitivity to dyssynchrony remains 
low.  
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6.2 Background 
As shown in many studies, tissue Doppler imaging (TDI) is a potential choice for 
selection of patients suitable for Cardiac resynchronisation therapy. This analysis 
demonstrates that there is inherent beat-by-beat variability and the TDI 2-segment 
analysis was disappointing as demonstrated in Chapter 5. 
This chapter focuses in more depth to the alternatives available with tissue Doppler 
imaging, namely the analysis of multiple segments, which some perceive to give a 
better, more comprehensive and fuller assessment of the dyssynchronous heart. 
PROSPECT, the largest, prospective, externally-monitored multicentre trial of 
predictability of response to CRT from dyssynchrony markers, showed no significant 
predictability (Chung et al. 2008a). This at first seemed a surprising contrast to 
numerous unblinded studies which had consistently shown strong predictability of 
response from baseline tissue Doppler measurements (Bax et al. 2003a; Bleeker et al. 
2007c; Gorcsan et al. 2004a; van Bommel et al. 2010b; Yu et al. 2003; Yu et al. 
2004a; Yu et al. 2005). 
It is not clear whether the error lies in one single study, or simultaneously in 
numerous others, but the lack of a gold standard for tissue Doppler mechanical 
dyssynchrony has limited scope for a convincing conclusion. It is not even clear of 
how to establish a gold standard for dyssynchrony, so that we can determine how 
precisely each proposed Tissue Doppler index is measuring it, before embarking on 
an expensive trial. 
Blinded test-retest reproducibility is crucial for any technique to have any hope of 
precise predictive power. This is rarely reported for tissue Doppler measurements: 
instead, authors often report two analyses of the same digital data, i.e. the same 
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heartbeat (Zhang et al. 2011). Predictive methods with poor test-retest reproducibility 
cannot reliably predict the future, because a patient with many very different values in 
the present will only have one future. There may be methods to improve 
reproducibility but unless it is recognised to be poor in the first place, clinical 
researchers may not think to implement them. 
But how reproducible is reproducible enough? The level of irreproducibility that is 
acceptable depends on the size of the genuine differences that the test is designed to 
measure. While the current confusion prevents us from knowing the true degree of 
dyssynchrony in any individual patient, we do know that it must change when the VV 
delay of a CRT pacemaker is changed especially if systematically varied over a wide 
range from one extreme to another (De Boeck et al. 2008; Pabari et al. 2011; Turcott 
et al. 2010).  
In this study I present a method for quantifying the plausibility of clinical tissue 
Doppler protocols for assessing mechanical dyssynchrony.  I used this method to 
address several open questions of how dyssynchrony should be quantified and show 
how this method could be used in the future to improve dyssynchrony assessment 
protocols efficiently, so that future trials might have prospect for success.   
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6.2.1 Which tissue Doppler model is correct for assessing 
dyssynchrony? 
This question is still under active debate (Chung et al. 2008a; De Boeck et al. 2008; 
Palmieri et al. 2010; Zhang et al. 2011). Individual centres tend to champion design 
choices adopted locally without much evidence that those choices are advantageous 
over the alternatives and little appetite to carry out small, simple and relatively 
inexpensive blinded experiments on these questions.  
In this study I experimentally manipulate synchrony in patients who already have 
CRT and quantify the sensitivity of detection of these changes in synchrony (as 
opposed to random beat-to-beat variability) of various proposed methods for tissue 
Doppler assessment of dyssynchrony. Using a prolonged protocol of many hours of 
detailed acquisition, followed by blinded measurement, I simultaneously address, in 
factorial form, 4 choices in design of tissue Doppler assessment protocols: 
• Single measurements or averaging multiple measurements per VV delay? 
• Measuring to onset, or peak, of S wave? 
• 2, 6 or 12 segmental analysis? 
• Earliest-to-latest interval or standard deviation of timings?  
 
 
 195 
6.3 Methods 
6.3.1 Tissue Doppler dyssynchrony assessment 
There are many ways of using tissue Doppler imaging to assess dyssynchrony. While 
there are numerous aspects to tissue Doppler, even with the most routine of 
approaches, namely heterogeneity colour-coded tissue Doppler timings, there remain 
many choices that a protocol designer can make. These choices include (a) how many 
wall segments to consider, (b) whether to measure timing from QRS to onset of 
systolic velocity or to peak, (c) whether to calculate the difference in timing from 
earliest to latest or as a standard deviation of wall timings, and finally (d) whether it is 
worth making the effort to measure more than one heart beat at each wall and take the 
average. 
6.3.1.1 2, 6 or 12-segment model  
The simplest subdivision of the ventricle is into two walls, septal and lateral, with 
measurements made at basal levels which has been reported to be diagnostic for 
mechanical dyssynchrony when it exceeds 60ms (Bax et al. 2003a; Bax et al. 2003b). 
A 6-segment approach can also be used (Chung et al. 2008a), by adding the basal 
segments of the anterior, inferior, posterior and anteroseptal walls to the 2-segment 
model.  
A 12-segment model, which extends the 6-segment model by additionally including 
measurements at mid-wall level is also widely recommended (Yu et al. 2002; Zhang 
et al. 2011). 
6.3.1.2 Earliest to latest or standard deviation of wall timings 
Earliest to latest timings is the difference between the wall which contracts earliest 
and the wall which contracts last (Bax et al. 2003b) 
 196 
A standard deviation of timings is also used as a marker of dyssynchrony, which 
calculates the standard deviation of multiple walls i.e. 6 or 12 (Yu et al. 2002; Zhang 
et al. 2011). 
6.4 Study population 
11 outpatients with biventricular pacemakers or biventricular defibrillators previously 
implanted for clinical indications (Barnett et al. 2007) were invited to enter this 
detailed study of tissue Doppler imaging. All patients were free from decompensation 
for greater than 3 months and no changes to medication were made 4 weeks prior to 
entering the study and until all data had been collected. All patients had intrinsic sinus 
rhythm, with 100% biventricular pacing (AsVp) and a fixed AV delay programmed to 
the standard nominal setting of 120ms. 2 patients had only septal and lateral walls 
imaged due to poor visualisation of the other walls. This is in keeping with feasibility 
reported in other studies (Bax & Gorcsan 2009). They were included in the 
appropriate analysis i.e. 2 segment analysis. 
At the time of the study, 1 patient was NYHA class I, 4 were NYHA II and 6 were 
NYHA III. Time between implantation and enrolment was 31 months (range 8 
months to 63 months. 4 subjects were male and 7 female, age 67 years ± 8 years. The 
cause of heart failure was ischemic in 4 subjects and idiopathic dilated in 7 subjects. 
10 patients were taking angiotensin-converting enzyme inhibitors or angiotensin-II 
receptor antagonists, 8 were taking beta-blockers, 7 were taking spironolactone and 4 
were taking a diuretic (loop or thiazide). Patients gave informed consent for this study 
which was approved by the local ethical committee. 
Each underwent a detailed protocol of replicate measurements and analysis under 
blinded conditions, at a series of VV delays from RV-first 40ms to LV-first 60ms.  
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6.5 Measurements 
6.5.1 Image Acquisition 
Tissue Doppler imaging was performed with a 2.5 MHz phase array transducer. The 
gain settings, filters and pulse repetition frequency were optimised. Apical images of 
the left were acquired with the sector size and depth optimised for the best frame rate, 
with a minimum frame rate of 90 Hz (Gorcsan et al. 2008) . Images were acquired 
with the areas of interest i.e. the mitral valve annulus, in the centre of the sector 
showing clear myocardial definition. Tissue Doppler velocity traces were obtained at 
the standard 12 sites by acquiring 4 chamber, 3 chamber and 2 chamber views of the 
left ventricle with the patient holding their breath at end-expiration.  
Pacemaker settings were changed in the usual way to program a range of VV delays: 
RV first at 40ms, 20ms, VV 0ms, LV first 20ms, 40ms and 60ms. I acquired 4 sets of 
replicate measurements (from separate beats) of colour tissue Doppler images. For 
each of the 4 replicate optimisations a separate optimum VV delay was identified as 
the VV delay giving the least dispersion in timing of segmental contraction. This 
yielded 4 replicate assessments of VV optimisation. 
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6.5.2 Image Analysis 
Images were digitised and analysed offline using Philips Qlab 7.0 3DQ and 3DQ 
advanced software. Several questions were to be answered in my analysis:  
1. I used either (1) the first and (2) the average of 2 replicate measurements  per 
VV delay setting to identify the optimum VV delay setting 
2. Timing was defined as either (a) the time from onset of QRS to onset of S 
wave and (b) the time from onset of QRS to the peak of S wave  (Figure 6-1). 
 
Figure 6-1 Demonstration of measuring from onset of QRS to onset of S wave (left 
panel) and from onset of QRS  to peak of S wave (right panel) 
 
 
3. Multiple segmental analysis was performed. I used 2, 6 and 12 segment tissue 
Doppler analysis. To obtain time–velocity curves, a sample volume was 
placed within the segments at the region of interest i.e. for the septal wall as 
shown below in Figure 6-2. 
4. Dyssynchrony was defined as either (i) absolute difference between the 
earliest and latest segments or (ii) standard deviation of the segments. 
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Figure 6-2 showing a tissue Doppler image of the 4 chamber view, with the basal 
septal wall highlighted. Below is the time-velocity curve which is produced. 
 
2 segments involved the basal septum and basal lateral walls; 6 segments involved the 
basal segments of the septum, lateral, anterior, inferior, posterior and anteroseptal 
walls; and 12 segments involved the basal and mid segments of the septum, lateral, 
anterior, inferior, posterior and anteroseptal walls. All measurements were taken by 
me. 
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6.6 Results 
6.7 Using single measurements versus averages of paired 
measurements 
Using averages of paired measurements compared to single measurements when 
performing optimisation of VV delay for all models of tissue Doppler imaging 
analysis showed a higher ICC as shown in Table 6-1 and Figure 6-3, ANOVA 
repeated measures p<0.001, F=361. 
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Table 6-1  Across all patients there was a statistically significant improvement in the intraclass correlation coefficient when averages of paired 
measurements were used compared to single measurements. 
 
 
Intraclass correlation coefficient
Using single 
measurements
Using averaged paired 
measurements
Measuring to Onset of S wave
2 segment 0.32 0.57
6 segment (earliest to latest) 0.49 0.67
12 segment (earliest to latest) 0.47 0.69
6 segment (standard deviation) 0.48 0.63
12 segment (standard deviation) 0.54 0.72
Measuring to Peak of S wave
2 segment 0.32 0.50
6 segment (earliest to latest) 0.42 0.64
12 segment (earliest to latest) 0.43 0.66
6 segment (standard deviation) 0.39 0.61
12 segment (standard deviation) 0.44 0.63
ANOVA p<0.001 (F=361)
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Figure 6-3  The ICC increases significantly across all patients and all measurement 
methods, when averages of paired measurements are used in comparison to single 
measurements.  
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Scatter of optimum
Using single 
measurements (ms)
Using averaged paired 
measurements (ms)
Measuring to Onset of S wave
2 segment 28 15
6 segment (absolute difference) 18 9
12 segment (absolute difference) 23 12
6 segment (standard deviation) 16 8
12 segment (standard deviation) 21 6
Measuring to Peak of S wave
2 segment 26 24
6 segment (absolute difference) 19 11
12 segment (absolute difference) 13 4
6 segment (standard deviation) 22 14
12 segment (standard deviation) 12 8
ANOVA p=0.001 (F=25.8)
 
 
 
 
Table 6-2 The scatter of the optima obtained across all patients decreases 
significantly when averages of paired measurements are used compared to single 
measures. 
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Figure 6-4 The scatter of optima is significantly narrower when averages of pairs of 
measurements are used compared to single measurements. 
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6.7.1 Measuring to onset of S wave or to peak of S wave. 
The intraclass correlation coefficient (ICC), which indicates the extent to which 
difference between single measurements of TDI at different VV delays is due to true 
differences between the VV delays was calculated. The ICC averaged across all 
patients for 2, 6 and 12 segment tissue Doppler imaging is shown in Table 6-3. There 
was no significant difference when measuring either from the onset of QRS to the 
onset of S wave or from onset of QRS to the peak of QRS.  
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Table 6-3 Intra class correlation coefficients of measuring to the onset of systolic wave and to the peak of systolic wave.  There is no 
significant difference in the intra class correlation whether you measure to the onset of systolic wave or to the peak. 
 
Intraclass correlation coefficient
Measuring to Onset of 
S wave
Measuring to Peak of 
S wave
Using single measurements
2 segment 0.32 0.32
6 segment (earliest to latest) 0.49 0.42
12 segment (earliest to latest) 0.47 0.43
6 segment (standard deviation) 0.48 0.39
12 segment (standard deviation) 0.54 0.44
Using averages of paired measurements
2 segment 0.57 0.50
6 segment (earliest to latest) 0.67 0.64
12 segment (earliest to latest) 0.69 0.66
6 segment (standard deviation) 0.63 0.61
12 segment (standard deviation) 0.72 0.63
ANOVA p=ns (0.31)
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The scatter of the optimum obtained when measurement of tissue Doppler were take 
at a series of VV delays are shown in Table 6-4. Across all methods of analysis of 2,6 
and 12 segment analysis showed no significant difference between measuring to the 
onset of the S wave or measuring to the peak of the S wave, ANOVA p= 0.90. 
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Table 6-4 Scatter of optimum measuring to the onset of systolic wave and to the peak of systolic wave.   
There is no significant difference in the scatter of optima obtained whether you measure to the onset of systolic wave or to the peak. 
 
Scatter of optimum
Measuring to Onset of 
S wave
Measuring to Peak of 
S wave
Using single measurements
2 segment 28 26
6 segment (earliest to latest) 18 19
12 segment (earliest to latest) 23 13
6 segment (standard deviation) 16 22
12 segment (standard deviation) 21 12
Using averages of paired measurements
2 segment 15 24
6 segment (earliest to latest) 9 11
12 segment (earliest to latest) 12 4
6 segment (standard deviation) 8 14
12 segment (standard deviation) 6 8
ANOVA p=ns (0.90)
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6.7.2 Comparison between differences of absolute values and 
standard deviation calculations of the timings of 6 and 12 
segment models of tissue Doppler analysis 
Measuring the absolute difference between the walls of the segments measured 
compared to the standard deviation of the timings of the walls made no difference to 
the ICC or to the scatter of optima obtained across 6 or 12 segmental analysis. This is 
shown in Table 6-5. 
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Table 6-5 Measuring earliest to latest versus standard deviation between wall timings. The Intraclass correlation coefficient and the scatter of the 
optima are not significantly different when the earliest to latest timings are used, or whenever the standard deviation of timings are used for 6 or 
12 segment TDI models. 
 
Intraclass correlation coefficient Scatter of optimum (ms)
Earliest to latest 
between walls
Standard deviation 
between wall timings
Earliest to latest 
between walls
Standard deviation 
between wall timings
Using single measurements
6 segment (onset) 0.49 0.48 18 16
12 segment (onset) 0.47 0.54 23 21
6 segment (peak) 0.42 0.39 19 22
12 segment (peak) 0.43 0.44 13 12
Using averages of paired measurements
6 segment (onset) 0.67 0.63 9 8
12 segment (onset) 0.69 0.72 12 6
6 segment (peak) 0.64 0.61 11 14
12 segment (peak) 0.66 0.63 4 8
ANOVA p=ns (0.86) ANOVA p=ns (0.68)
 
 211 
6.7.3 2 versus 6 versus 12 segments 
There is no effect on the intra class correlation coefficient whether 2, 6 or 12 
segments were used. There is weak evidence on the scatter of the optimum identified 
(ANOVA p=0.035) with a trend to a wider scatter with a 2-segment model (Table 
6-6). 
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Table 6-6 The effect of measuring 2, 6 or 12 segments for TDI analysis.  
The top panel shows the effect on the intra class correlation coefficient and the lower panel shows the effect of the scatter of the optimum 
identified when repeated optimisations have been performed. 
 
Intraclass correlation coefficient
Using single measurements (ms) Using averages of paired measurements (ms)
Measuring to Onset of 
S wave
Measuring to Peak of S 
wave
Measuring to Onset of 
S wave
Measuring to Peak of S 
wave
2 segment 0.32 0.32 0.57 0.50 comparing 2, 6 and 12-segments
6 segment 0.49 0.42 0.67 0.64 ANOVA p=ns (0.38)
12 segment 0.47 0.43 0.69 0.66
 
 
Scatter of optimum
Using single measurements (ms) Using averages of paired measurements (ms)
Measuring to Onset of 
S wave
Measuring to Peak of S 
wave
Measuring to Onset of 
S wave
Measuring to Peak of S 
wave
2 segment 28 26 15 24 comparing 2, 6 and 12-segments
6 segment 18 19 9 11 ANOVA p=0.035
12 segment 23 13 12 4
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6.8 Discussion 
This study shows that for all methods of analysing colour coded tissue Doppler 
imaging measurements there is high spontaneous beat-to-beat variability and a 
correspondingly low intra class correlation coefficient i.e. poor signal-to-noise ratio. 
Single measures of any of the approaches here cannot realistically claim to be reliable 
predictors of the future because they do not even predict themselves a few seconds 
later. 
6.8.1 Beat-to-beat variability taboo 
Blinded beat-to-beat variability is rarely discussed in unblinded studies that report 
marked predictor values of dyssynchrony for clinical outcomes. 
Sometimes reanalysis of the same heart beat (by the same or different operator) is 
reported (Zhang et al. 2011) but this is not test-retest reproducibility because it omits 
biological variability between beats. Reanalysis of the same beat yields correlation 
coefficients in the range of 0.95 to 0.99 (Palmieri et al. 2010) which can therefore be 
seen to be only a very small minority of the clinically relevant total variability.  
It is possible that some centres have developed special positioning of the patient and / 
or probe, or have special protocols for selecting beats that have unusual consistencies 
but, if so, these appear not to have been disclosed and put readers at a disadvantage 
when reproducing the work locally. 
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6.8.2 Inability to detect resynchronisation when it occurs 
Difficulties in detecting resynchronisation arise from the lack of certainty in the 
results obtained. This is particularly concerning, when a measurement is performed on 
2 consecutive occasions and grossly different results are obtained. The method used, 
whether it be tissue Doppler imaging, as in this study, or an alternative is then brought 
into question. To ensure that we are reliably detecting resynchronisation, we need to 
have narrow confidence intervals, within which is an acceptable range.  
In this study I have shown the scatter of optimum that have arisen when tissue 
Doppler imaging has been used in various models. I had tested a wide range of tissue 
Doppler definitions of dyssynchrony including testing the definitions of timings based 
on the onset of S-wave, and the peak of S-wave to allow a comprehensive analysis of 
the various possibilities. I tried hard not to favour on criterion over another. 
 The 95% confidence interval of these values equips us with the knowledge of the 
range of values we may obtain whether we need to use: 
• single measurements or averaging multiple measurements per VV delay? 
• measure to onset, or peak, of S wave? 
• 2, 6 or 12 segmental analysis? 
• earliest-to-latest interval or standard deviation of timings? 
Figure 6-5 shows the confidence intervals of each tissue Doppler parameter and the 
reduction in width of confidence intervals when paired measurements are averaged. 
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Figure 6-5 The width of 95% confidence intervals which will surround the optimum 
detected are shown above for each possibility of tissue Doppler measurements used. 
The graphical representation shows the dramatic decline in this width when averages 
of pairs are used. Numerically we can see the smallest width with 12 segment earliest 
to latest using paired measurements. 
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6.8.3 Implications for protocol designs and reproducibility  
To ensure that a design protocol will reliably test what it is meant to i.e. identify the 
optimal setting with the method used, then it is important to establish the test retest 
reproducibility to ensure we are happy with the results, and that this will then give a 
result which has an acceptable confidence interval. To date, the highly transparent 
studies looking at test-retest reproducibility have failed to confidently point towards 
tissue Doppler imaging as a method which can be used for this purpose (De Boeck et 
al. 2008; Vesely et al. 2008). 
However, every method can be improved upon and hence use averages of multiple 
settings to improve the sensitivity and reduce the confidence interval of the optimum 
obtained (Pabari et al. 2011).  
Some groups have repeatedly demonstrated that colour coded TDI is suitable and able 
to identify patients for CRT implantation. Other groups have found that this modality 
is limited in its test-retest reliability (Vesely et al. 2008) and in a multicentre trial the 
results for all criteria of TDI analysis were modest (Chung et al. 2008a). These 
differences could be clarified if protocols were designed using the suggestions arising 
from this study 
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6.9 Limitations 
This study may be criticised for having too few patients, but this was a detailed 
meticulous protocol which was time consuming for the patients and not ethical to 
apply to even more patients until methods are improved – which could then be tested 
by this new method, on even a single pilot patient, to establish at least one adequate 
ICC before formally designing a future study. 
We did not follow up the patients for a period of time afterwards and rescan them, 
with good reason. Because each patient (at each setting) had a wide variety of 
possible optimal values, any setting could be claimed to be optimal by one criterion or 
another. Without establishing a specified protocol for selecting an optimal value, 
looking back from the future to find a fit would risk confirmation bias which would 
artificially enhance correlation coefficients. 
TDI has many limitations however it is still one of the most extensively studied 
echocardiographic methods for assessment of LV dyssynchrony. Limitations include 
(1) angle dependency which can alter velocities significantly, (2) measurements of 
wall motion does not indicate whether it is active contraction or passive motion, with 
even akinetic walls being dragged across, and (3) the fact that several views are 
required for all walls to be evaluated because all walls cannot be captured in a single 
apical plane. Multiple acquisitions mean that different beats are being used for 
different walls (Agarwal et al. 2009).  
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6.10 Conclusions 
Tissue Doppler imaging as a marker for optimising CRT is disappointing. It has a low 
sensitivity even for detecting large changes applied exponentially with everything else 
held constant. With all the potential combinations of measurements available to us 
namely measuring (a) onset or peak of velocity; (b) 2, 6 or 12 segments and  (c) 
“earliest-to-latest” or standard deviation of timing, none convincingly improved the 
sensitivity of this marker to a level that might be reasonable to apply in day-to-day 
clinical practice. Averaging multiple replicates is currently the only plausible 
approach to reducing the wide confidence intervals and improving ICC in order to 
make tissue Doppler imaging a reliable predictor and marker for optimising CRT. 
However the number of replicates needed may not be palatable. 
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7 Comparison of the reproducibility of 
left ventricular outflow tract velocity time 
integral (LVOT VTI) versus peak velocity 
(Vmax) as targets for optimisation of VV 
delay in cardiac resynchronisation 
therapy. 
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7.1 Abstract 
7.1.1 Background 
Clinically practised echocardiographic optimisation of VV delay in Cardiac 
Resynchronisation therapy (CRT) typically seeks to maximise flow through the left 
ventricular outflow tract (LVOT), conventionally assessed using the velocity–time 
integral (VTI). In this study I compare VTI maximisation against maximisation of 
peak velocity (Vmax), to determine which provides a more reproducible optimum.  
7.1.2 Methods 
I measured LVOT VTI and Vmax at 6 different settings of VV delay in 40 subjects and 
determined the optimal VV delay settings using each Doppler measure. We compared 
the scatter of the identified optima and the intra-class correlation coefficient (ICC, a 
measure of signal-to-noise ratio) between the two techniques. 
7.1.3 Results  
Optimisation by Vmax showed a smaller scatter between repeat optimisations (SD 4ms 
narrower, p=0.001) than optimisation by VTI. Using averages of triplicate measures 
for optimisation showed a smaller scatter than single measures (SD 5ms narrower, 
p<0.0001).  
ICC was significantly stronger for Vmax than VTI (by 0.13, p<0.0001). It was higher 
for averages of triplicate measures (by 0.05, p=0.001).   
Despite the greater precision, time taken to analyse a 6-setting optimisation was 
shorter using Vmax than VTI (17.5 versus 59.1 seconds, p<0.0001). 
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7.1.4 Conclusions 
For optimisation purposes, it is critical to be able to detect small differences in signal 
reliably, and time is at a premium. Measuring peak velocities takes one-third of the 
time to analyse and delivers significantly more precise localisation of the optimum 
than measuring VTI. Clinicians choosing to optimise VV delay by LVOT Doppler 
might therefore be advised to use peak velocity and average multiple replicates if 
economy and precision are desired. 
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7.2 Background 
There remains controversy regarding whether programming different ventriculo-
ventricular delay (VV delay) settings makes any difference to patients with cardiac 
resynchronisation therapy (CRT) devices. If CRT is truly about resynchronisation, 
intuitively the programmed VV delay must be important. However, the question of 
the reproducibility of the standard methods for optimisation is rarely addressed on a 
formal blinded basis. If VV delay optimisation is to be rejected as worthless because 
of apparent lack of differences in haemodynamic effects between different VV delay 
settings, then the term resynchronisation might also be called into question.  Although 
the range of VV delay settings tested during optimisation may not have included one 
that achieves perfect resynchronisation, it must have surely included some highly 
undesirable ones. If it does not matter which setting is selected then the marked 
benefit proven for biventricular pacing might be arising from mechanisms other than 
resynchronisation of the LV walls (Kyriacou et al. 2011).  
Cardiac resynchronisation therapy provides clinical and prognostic benefit to patients 
with heart failure (Abraham et al. 2002; Boriani et al. 2006; Cazeau et al. 2001) 
therefore it is rational to attempt to maximise the hemodynamic improvement derived 
from the devices, by optimising the programmed settings. Clinically however, 
echocardiographic VV delay optimisation is not routinely performed for two main 
reasons; because of the time involved to perform optimisation algorithms and because 
the endpoint studies so far have not consistently demonstrated clinical improvement 
(Boriani et al. 2006; Vanderheyden et al. 2005).  
It is difficult however to find in the literature the early simple studies demonstrating 
that, in an objective environment, VV optimisation can actually be carried out (i.e. 
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yields the same results a few minutes later). Without this confirmation, it is not 
possible to be certain that the VV optimisation procedures now being carried out are 
reliably identifying a consistent value for each individual, or just yielding a random 
value. If current VV optimisation protocols are unreliable, then failure of VV 
optimisation to yield consistent clinical improvements might reflect on the protocols 
rather than on the concept of resynchronisation itself. 
To be of practical value, a protocol must yield the same VV delay optimum on 
successive optimisations, especially over the short term. If it does not then either the 
true optimum is varying over such short time intervals (in which case optimisation 
can never realistically keep up with it to allow consistent resynchronisation), or the 
protocol is unreliable at detecting the true optimum (in which case the protocol should 
be improved).  A likely strong driver of the relative precision or variability of a VV 
delay optimisation protocol is the signal-to-noise ratio of the variable being measured 
during optimisation (Pabari et al. 2011; Whinnett et al. 2008).  
Currently there is no gold standard echocardiographic measure used to guide the non-
invasive optimisation of VV delay in CRT devices, although left ventricular outflow 
tract – velocity time integral (Geibel et al. 1991; Sawhney et al. 2004; Sogaard et al. 
2002) (LVOT VTI, also called ‘stroke distance’), as a practical surrogate for stroke 
volume is widely used, especially in the research setting (Bertini et al. 2010; Bleeker 
et al. 2007c; Boriani et al. 2006; Duvall et al. 2010; Geibel et al. 1991; Sawhney et al. 
2004; Sogaard et al. 2002; van Gelder et al. 2004; Vanderheyden et al. 2005; Zuber et 
al. 2008). However if LVOT VTI is insufficiently reproducible (Jansen et al. 2006a), 
then using it to guide optimisation will yield variable “optima”, and conclusions 
drawn from studies using this method may underestimate the benefit of optimisation. 
Even if it takes more time to deliver a more reproducible technique for optimisation, 
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such investment is a sine qua non before expecting clinical benefits. If we had a better 
way of detecting the optimum, that had been rigorously evaluated, the clinical 
improvement and endpoints may be stronger and more convincing therefore 
encourage clinicians to do more routinely. 
An inherent property of Doppler echocardiographic assessment of LVOT flow is the 
physiological variability between beats. Optimisation of VV delay requires detection 
of genuine persistent changes in cardiac function between VV settings (“signal”), 
which may be small in comparison to the beat-to-beat variability (noise) of the 
Doppler trace. A likely strong driver of precision of VV optimisation is the signal-to-
noise ratio of the variable being measured (Pabari et al. 2011). 
In this study I conduct head-to-head comparison of LVOT VTI and peak velocity 
(Vmax) for optimisation of VV delay in patients with CRT devices. First, I quantify the 
relative immunity of each method to noise, using the intra class correlation (ICC) 
(Muller & Buttner 1994). This is a number between 0 (indicating a method for which 
a biological variability completely overwhelms any meaningful signal) and 1 
(indicating a measure in which differences between settings are perfectly identical on 
each evaluation with no disruption by biological variability). 
Second I describe the reproducibility of the two optimisation techniques by 
determining the scatter of the VV optima obtained on repeat optimisations. I 
calculated the standard deviation (SD) of VV optima from serial repeat optimisations 
within the same individuals on the same day. Ideally successive optimisations should 
derive the same optima, hence the standard deviation (SD) or scatter would be zero. In 
reality there may be slight differences in the optima when successive optimisations 
are performed therefore if 6 optimisations are performed, 6 optima will be obtained. 
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The standard deviation (SD), or scatter, is the spread of these results.  To measure the 
change in signal when VV delays are changed, we need to choose a measure with the 
greatest reproducibility and signal-to-noise ratio (Pabari et al. 2011; Whinnett et al. 
2008). 
Third, I evaluate the impact of conducting and averaging multiple replicates of each 
measure (instead of a single measure) on the noise immunity (ICC) and scatter (SD) 
between replicate optimisations. This will minimise the scatter between optima on 
repeat optimisation (Pabari et al. 2011). I would predict that in order to further 
improve the reproducibility of the algorithm, averaging repeat optimisations would be 
necessary, further increasing the time taken for acquisition and analysis of data during 
an optimisation procedure. 
Finally I determine whether using LVOT Vmax instead of LVOT VTI reduces the 
acquisition and analysis time, hence enhancing the feasibility of clinical VV 
optimisation of CRT devices. 
 226 
7.3 Methods 
7.3.1 Study Population 
40 consecutive outpatients with biventricular pacemakers or biventricular 
defibrillators previously implanted for standard clinical indications (Barnett et al. 
2007) were enrolled into this study. 28 subjects were male and 12 female, age 73 ± 
7.7 years (mean ± sd).   
The cause of heart failure was ischemic in 15 subjects and idiopathic dilated in 25 
subjects.  At the time of the study, 1 patient was NYHA class I, 17 were NYHA II and 
22 were NYHA III.  34 patients were taking angiotensin-converting enzyme inhibitors 
or angiotensin-II receptor antagonists, 32 were taking beta-blockers, 18 were taking 
spironolactone and 27 were taking a diuretic (loop or thiazide).   
All patients were 100% biventricularly paced and free from decompensation for 
greater than 3 months. 
The time between CRT device implantation and enrolment into the study was 
32.3months (range 3 months to 75 months).  The LV lead was placed in the optimal 
position that was possible during implantation.  All patients were 100% 
biventricularly paced during the study and AV delay was programmed to the nominal 
setting of AV 120ms. 
Patients gave prior written informed consent for this study which was approved by the 
local ethical committee. 
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7.3.2 Protocol 
Patients lay awake, recumbent in the left lateral position on a couch having rested 
supine for at least 10 minutes.  2 operators were present – one to reprogram the CRT 
devices via a telemetry head, and the second to acquire the Doppler 
echocardiographic images. The echocardiographer was blinded as to the pacemaker 
settings programmed by the other operator. 
The programmed VV delay was changed in a random order, and the VV delay 
settings that were tested were left ventricular activation first by 60ms, 40ms, 20ms 
and 0ms and right ventricular activation first by 20ms and 40 ms.  
7.3.3 Measurements 
Echocardiography was performed on a single visit to the hospital with the same 
experienced operator conducting all echocardiographic measurements using a Philips 
IE33 machine with a S5-1 transducer. Measurements were taken from the apical 5-
chamber view with pulse wave Doppler sampled at the left ventricular outflow tract 
approximately 1 cm below the aortic annulus as per published guidelines (Gorcsan et 
al. 2008). Six beats were acquired at each VV delay, at end expiration.   
7.4 Analysis 
Measurements of peak velocity and VTI were conducted offline, under timed 
conditions, in a random order, with the operator blinded to the programmed VV delay. 
VTI measurements were made by tracing around the flow envelope manually as per 
usual practice. The peak measurement was made from the same captured images but 
independently of, and blinded to, the VTI tracing. 
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7.4.1 Determination of Optimal VV delay 
The VV delay at which the Doppler signal was maximal was identified for both the 
Vmax and VTI measurements, producing an optimal VV delay for each of the 2 
parameters for each patient.  This was conducted 6 times so that six replicate 
optimisation sequences were performed in each patient. 
7.4.2 Calculation of the effect of averaging replicate optimisation 
sequences on the scatter of identified optima 
I determined the effect of averaging replicate optimisation data, ensuring that no raw 
measurement that was used to determine one optimum, contributed to the 
determination of another optimum.  This ensured that the optimum VV delay 
identified from each replicate optimisation sequence was independent. 
In each patient, I averaged the raw VTI and Vmax measurements at each setting for 
each of the 6 replicate optimisation sequences, in pairs (averages of two 
measurements) or triplets (average of 3 measurements). The 6 raw data measurements 
provided three sets of “averages of two” values for each VV delay.  From this data, I 
then identified the three optima arising, for both VTI and peak velocity. When I 
averaged the triplicate sets of raw data, this provided two sets of “averages of three”, 
and from this we were then able to identify two optima for each of VTI and Vmax, 
Table 7-1. 
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Table 7-1: Data from one patient showing all raw measurements of VTI from 6 
separate optimisation sequences.  This demonstrates how we averaged raw data as 
pairs and triplets, and calculated the between optima scatter (SD) 
VV delay setting (ms)
-40 -20 0 20 40 60
Analyzed as Singles LVOT VTI (cm)
#1 13.3 15.9 15.1 15.6 15.8 15.6 -20
#2 13.0 15.0 13.9 15.4 16.2 15.3 40
#3 13.7 14.1 15.4 15.3 15.2 14.1 0
#4 13.7 15.0 15.3 15.9 15.1 14.9 20
#5 13.0 14.8 15.3 15.2 15.9 15.0 40
#6 13.2 14.4 15.6 15.2 16.8 15.2 40
Analyzed as averages 
of Pairs of data
#1
#2
#3
#4
#5
#6
Analyzed as averages 
of Triplets of data
#1
#2 15.7
#3
#4
#5 15.9
#6
Scatter of 
optimum (SD)
23.1 ms
9.4 ms
40
40
20
40
40
0 ms
Optimum VV 
delay (ms)
14.8 15.4 15.4 15.1
15.2 16.3 15.1
13.3 15.0 14.8 15.4 15.0
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Using the optimal VV delay settings identified from each of the 6 replicate sequences, 
we then calculated the scatter of optima using standard deviation, for both LVOT VTI 
and Vmax. An example patient is shown in Figure 7-1 demonstrating the scatter of 
optimal VV delay obtained by VTI and Vmax. 
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Figure 7-1: An example patient comparing the scatter of the values for optimal 
VV delay between velocity time integral and peak velocity. 
The top panel shows the optima obtained when 6 replicate optimisations were 
performed using VTI and the bottom panel shows the optima obtained when 6 
replicate optimisations were performed using Vmax.  The scatter (SD) of the values  of 
optima was calculated from this data to be 7.5ms for VTI and 0ms for Vmax.   
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I then assessed the effect of averaging replicate optimisations on the scatter of optima, 
using the 6 individual values, the 3 pairs of replicate averages and the 2 groups of 
triplicate averages. While a narrow scatter (good reproducibility) does not guarantee 
that the method is good, a wide scatter (poor reproducibility) does guarantee that it is 
poor. 
7.4.3 Calculation of Intraclass Correlation Coefficient  
The intraclass correlation coefficient (ICC) quantifies the extent to which 
measurements differ between settings because of genuine difference between settings 
versus random biological variation.  As described in the methodology section, the ICC 
quantifies how well each modality could detect a genuine improvement arising from a 
change in VV delay, as distinct from background spontaneous beat-to-beat variability. 
ICC close to 1 indicates that the changes are detected when settings are altered, 
whereas ICC close to 0 indicates that spontaneous variability is large in comparison to 
changes which occur hence true detection of change is unlikely.  
7.4.4 Calculation of within-patient agreement of replicate 
optimisations 
I calculated the within-patient agreement of optima obtained using repeated data 
acquisition, using Fleiss’s Kappa, for VTI and for Vmax  separately. If each time an 
optimisation was performed the same optimum was obtained, then Kappa = 1. If the 
optima obtained on replicate optimisations agree only as often as expected by chance, 
then Kappa would be zero. 
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7.4.5 Calculation of between method agreement of VV optimisation 
I calculated the agreement between VTI and Vmax derived VV optimum using the 
absolute percentage agreement between the two methods, and using Fleiss kappa as 
described above. 
7.4.6 Calculation of time taken to perform analysis of VTI and Vmax. 
I timed how long it took to analyse a full optimisation process. We measured the time 
taken to trace the LVOT velocity time integral at each VV delay setting in each 
patient. This was then repeated for measurements of Vmax. 
7.4.7 Statistical Analysis 
Stata version 11.0 for Windows (StataCorp LP, College Station, Texas) was used for 
statistical analysis. A 2 x 3 mixed linear model was used to quantify the effects of 
using VTI versus Vmax to guide optimisation, and of using single measurements 
versus averages of pairs or triplicate measurements for analysis. Fleiss kappa values 
were calculated for within and between patient results. Comparison of time taken 
using Vmax versus VTI for analysis was performed using a paired t-test. A p value 
<0.05 was considered significant.  
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7.5 Results 
In all enrolled patients, acquisition of images and measurements of  LVOT Vmax and 
LVOT VTI were possible for all VV delay settings. 
7.5.1 Relative characteristics of VTI based optimum versus Vmax 
based optimum 
The scatter between repeated optima obtained was better (smaller) for Vmax-based 
optimisation than for VTI-based optimisation (expressed as standard deviation, p = 
0.001, Table 7-2, top panel).  
Vmax measurements were more immune to spontaneous variability than VTI 
measurements. The ICC, was significantly higher for Vmax than for VTI 
(p<0.0001),Table 7-2 bottom panel.  
7.5.2 Consequences of averaging replicate measurements 
The scatter of replicate optimisations was improved (narrower) by moving from 
single measurements to averages of pairs or triplets of the raw VTI and Vmax 
measurements (p<0.0001), as shown in Table 7-2.  
For both Vmax and VTI, spontaneous variability was smaller using averages of pairs or 
triplets of measurements rather than single measurements, as shown by a higher ICC 
(p<0.0001), Table 7-2.  
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Table 7-2 The scatter and intraclass correlation coefficient for both Vmax and 
VTI 
The scatter (or standard deviation) for single measures, average-of-two and average-
of-three measures (across all patients) is shown for both VTI and Vmax in the top 
panel.  Intraclass correlation coefficient is similarly compared in the bottom panel.  
 
Scatter (Standard Deviation, ms)
VTI Vmax
Singles 18.1 15.3
Pairs 14.9 8.2 p<0.0001
Triplicates 7.8 5.4
p= 0.001
 
Intraclass Correlation Coefficient (ICC)
VTI Vmax
Singles 0.48 0.59
Pairs 0.55 0.68 p<0.0001
Triplicates 0.57 0.72
p< 0.0001
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7.5.3 Within-patient agreement of VV optima obtained on replicate 
optimisations  
The within-patient agreement of VV optima selected with repeat optimisations was 
better  (higher) using Vmax than using VTI when assessed using both percentage 
absolute agreement and Fleiss kappa methods (absolute percentage agreement Vmax 
59.8% versus VTI 47.3%, p=0.015, Fleiss kappa Vmax 0.51 versus VTI 0.36).  
Averaging triplicate measures further improved within-patient agreement (VTI from 
47.3 to 62.5%, p=0.023, Vmax from 59.8 to 72.5%, p=0.035). 
7.5.4 Between method agreement of VV optimisation 
The VV optimum obtained by VTI and Vmax agreed in 23 out the 40 subjects 
(absolute percentage agreement 58%, Fleiss kappa 0.52). In 76% of cases the 
optimum by one method was within ±20ms of the optimum by the second method, 
when using single optimisations, Figure 7-2.   
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Figure 7-2 The difference in the VV optimum obtained between VTI and Vmax across 
all patients. In 58% of cases the optimum was the same for both VTI and Vmax. For 
76% of cases the optimum by VTI and Vmax were within 20ms of each other. It 
should be noted that "± 20 ms" permits, in most cases, the second optimum to be any 
of 3 of the 6 tested settings.  
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7.5.5 Responders and non-responders 
Of the 40 subjects, 28/ 40 (70%) were clinical responders. In the responder group the 
ICC was greater when measured using Vmax compared to VTI, 0.65 vs 0.55, p=0.021 
across 28 patients. In the non-responder group of 12 patients, there was no significant 
difference although a trend to a greater ICC in the Vmax measurements vs. VTI 
measurements, 0.65 vs 0.51 respectively, p=0.20.  
The scatter of the VV optimum obtained showed a similar pattern. The scatter was 
smaller using Vmax compared to using VTI in the responder group, 14.0 ms vs. 18.8 
ms (p=0.028). In the non-responder group, there was no significant difference 
between Vmax and VTI in the scatter of VV optima obtained 17.6ms vs 16.4ms 
(p=0.72). 
The smaller number of patients who were clinical non-responders (12 rather than 28) 
is the likely reason for the lack of evidence of a statistically significant difference 
between responders and non responder groups. 
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Time taken to perform optimisation analysis 
It was more than 3 times faster to perform the analysis of a full optimisation protocol 
using Vmax than VTI, (17.5 vs. 59.1 seconds, p<0.0001), Figure 7-3. 
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Figure 7-3 Time taken to analyse single measures, 2’s and 3’s as used for the single, 
averages-of-two and averages-of-three calculations.  
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7.6 Discussion 
These data highlight the characteristics, both favourable and challenging, of using 
Doppler echocardiography to guide the optimisation of VV delay in CRT devices. 
The inherent variability in Doppler measurements between beats must be taken into 
consideration when assessing its suitability for use in optimisation protocols.  If 
assumed to be negligible, this variability (“noise”) can easily swamp the “signal”, 
which often changes only subtly between different settings, making consistent 
identification of the optimal VV delay problematic (Pabari et al. 2011)  
This study shows that any attempt at optimising VV delay using LVOT Doppler must 
be accompanied by verification that the scatter between replicate measurements is 
either small (which is unlikely) or quenched by sufficient replication and averaging, 
to make the optimisation process credible. 
The head-to-head comparative data indicate that using Vmax to guide VV optimisation 
takes less time and gives a more reproducible optimum, and therefore would seem to 
be unambiguously preferable to using VTI. 
These findings have implications for the interpretation of studies where an 
optimisation protocol was trialled for effects on clinical endpoints (Ellenbogen et al. 
2010) but for which  precision of the optimisation procedure has not been evaluated 
(or has not been published). The necessary evaluation is test and retest (i.e. separate 
data, not re-evaluation of the same JPEGs) reproducibility, with observers blinded on 
the second occasion to the results obtained from the first.  
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7.6.1 How can an incomplete picture be better? 
Recommending measurement of peak velocity rather than VTI for the purpose of 
optimisation seems to run counter to many axioms in echocardiography, and I do not 
do this lightly. 
First, VTI gives a more complete picture, because it captures the profile of flow 
throughout ejection, whereas peak velocity only assesses a single instant. Second, VTI 
allows calculation of stroke distance (Colocousis et al. 1977), and therefore stroke 
volume and cardiac output, which are physiologically and clinically valuable to know.  
I do not consider these considerations incorrect, nor unimportant, but rather that they 
are less important than delivering the fundamental requirement without which 
optimisation is doomed to fail before it begins: that is, to be reliable in detecting the 
very small changes in cardiac function occurring with alterations in VV delay. For 
this very specific requirement, capturing a more complete picture does not help if that 
bigger picture contains more additional noise than it does additional signal. Nor is it 
clinically essential to establish estimates of the stroke distance, stroke volume or 
cardiac output for each tested setting unless those measures have the best signal-to-
noise ratio. If knowledge of these variables is desired, they can be assessed at the 
optimised setting, i.e. after (rather than as part of) the optimisation process. I would 
argue that a less comprehensive picture can be better for the purpose of optimisation, 
provided it has a higher signal to noise ratio.  
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7.7 The importance of assessing signal-to-noise ratio 
when planning optimisation algorithms 
Echocardiography is attractive to use as a tool to guide optimisation because it is non-
invasive and widely available with no additional operator training needed. 
Nevertheless the choice of what technology to use, or which variable within that 
technology is most suited should not be based on such superficial concerns but rather 
on a sound basis. 
In principle, the first step in assessing the suitability of a proposed variable for 
guiding optimisation would be to establish its intraclass correlation coefficient while 
VV delay is adjusted. If the ICC is close to 1, it is a plausible candidate variable to 
take forward for further testing (for example, of the reproducibility of the optimum 
obtained at separate visits). If the ICC is ~0.5 or lower, it is not a plausible candidate 
(Pabari et al. 2011). This initial screening test would just need a few (for example 6) 
replicate measurements at each of the range of settings intended to be used clinically 
(for example 6 settings). These 36 measurements need not take more than half an hour 
to conduct per patient, unless the method is unusually complex (in which case it is 
unlikely to be ready for routine use) and need only be done for a dozen or so patients.  
This elementary step is a prerequisite before issuing a recommendation of how to 
conduct clinical optimisation.  
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7.7.1 Averaging multiple measurements 
Conducting multiple replicates is an important step for reducing the impact of 
unwanted noise (Francis et al. 1999) and hence maximising the precision of any 
measurement technique, but it is not always practical to do this under the time 
constraints of clinical practice. Most research protocols involve multiple replicates to 
be made, although many study reports do not state how many replicates have been 
averaged or if simply the best-looking recording of the replicates at each setting has 
been selected as representative.  
If using LVOT Doppler signals to guide optimisation, the present study shows that 
using Vmax allows more than 3 times more optimisations to be analysed within the 
same timeframe as analysing a single optimisation using VTI. In addition, Vmax is 
more reliably sensitive to the genuine changes between settings. 
7.7.2 How to have confidence in the method of optimisation 
The natural variability (or noise) in the Doppler signal is likely to make identification 
of the true underlying VV optimum difficult. The critical information is the test-retest 
reproducibility of the VV optimum (from data acquired in separate visits) of any 
method recommended in a guideline, or carried out in an endpoint trial? The present 
analysis, and previous studies (Turcott et al. 2010; Whinnett et al. 2006a) suggests 
that the reproducibility is poor using guideline-recommended methods, and therefore 
may have been poor in trials (unless those trials used some undisclosed steps to 
reduce noise). Other centres have had greater success with better reproducibility, but 
the conclusion that must be drawn is that reproducibility of this technique varies 
either between operators and / or centres (Thomas et al. 2009; Turcott et al. 2010) .  If 
this is the case, rather than rejecting the concept of VV optimisation altogether if the 
trials do not show endpoint benefits, we might better put efforts into developing 
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methods for optimisation that are confirmed, in independent hands, to be reproducible 
between visits, with appropriately blinded operators.  
Such studies are very much cheaper and quicker to do, and are an essential prelude to 
longer-term outcome studies. That they have not been published is a surprise.  
7.8 Limitations 
This study did not set out to examine, or predict, response to CRT implantation. It did 
not set out to measure long-term outcomes at each optimised setting, because there is 
no point trying to do so until we have a technique that recommends a single optimum 
consistently for one patient (Ellenbogen et al. 2010; Pabari et al. 2011). For measuring 
VTI I took the standard approach which involves tracing around the outer perimeter 
of the VTI envelope (Bertini et al. 2010; Tribouilloy et al. 1994). There are other 
methods using automated algorithms which might potentially improve the precision 
obtainable. These however are not generally available or used in the standard clinical 
practice setting. Since I was addressing the practical question of how the precision of 
optimisation could be improved above guideline-recommended methods, in a real-
world clinical setting without using any new advanced modalities, I adopted the 
method conventionally used during clinical optimisation.  
This study does not consider more modern echocardiographic measurements than 
spectral Doppler, for example tissue Doppler or strain (Bertini et al. 2010) which may 
require additional training for both acquisition and analysis. All echocardiographers 
are familiar with measuring spectral Doppler peak velocity from routine assessment 
especially of valves (Minners et al. 2008). However, the approach taken in this study 
might also be taken for any number of other potential markers, and would allow 
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markers to be screened for plausibility before undertaking prolonged studies (Pabari 
et al. 2011). 
I should highlight again that I am not disputing the important role for VTI 
measurement in clinical practice, as this permits evaluation of stroke volume and 
thereby cardiac output. Rather, I am just addressing the specific question of which 
measurement gives the best reliability to detect the small changes occurring when VV 
delay is changed, which is the key requirement to reliably identify an optimum. 
7.9 Conclusion 
Whether VV optimisation of CRT devices is worthwhile or not has not been settled. If 
it is not, i.e. the programmed VV delay is not important, then the term 
“resynchronisation” is no longer tenable. If, on the other hand, VV delay does matter, 
then it is essential for optimisation methods to give reproducible results.  
Following the guideline protocol, which is to use LVOT VTI to guide VV delay 
optimisation, gives an unreliable optimum. LVOT Vmax, obtained in a similar manner, 
is 3 times quicker to analyse and yields an optimum more reproducible. This 
advantage of using peak velocity for optimisation is seen even more clearly when 
multiple measurements are averaged, making the optimisations more precise.  
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8 Invasive pressure and flow 
measurements during AV delay 
improvement reveal a compensatory 
peripheral vasodilator response which 
attenuates the initial blood pressure 
increment: implications for the design 
of AV optimisation protocols 
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8.1 Abstract  
8.1.1 Introduction 
With synchrony of ventricular contraction already restored by cardiac 
resynchronisation therapy (CRT), optimisation of atrioventricular (AV) delay relies 
on improving filling. Although when AV delay is improved blood pressure 
immediately rises, there is a subsequent partial decline. Is this secondary decline 
because (1) non-invasive measurements are unreliable, (2) cardiac function increment 
is short-lived or (3) peripheral vasodilatation occurs? I conducted invasive 
experiments to answer this. 
8.1.2 Methods and Results 
Nine patients with heart failure, CRT and underlying left bundle branch block, 
underwent changes in AV delay from 40 to 120 ms. I simultaneously measured beat-
by-beat invasive aortic pressure and flow, and non-invasive pressure (Finometer). 
Triplicate experiment runs were performed and averaged to minimise biological 
noise. 
There was an immediate increment in invasively measured blood pressure of 
+14.7±2.0mmHg (p=0.0001), but after the initial 10 beats there was a secondary 
progressive decline to a lower plateau of +8.0±1.8mmHg (p=0.004). The initial 
increment was caused by a prompt rise in flow by +9.1±2.4% (p=0.007) which did not 
drop later. The secondary fall in pressure was caused by a delayed gradual decline in 
total peripheral resistance.  Finometer-derived non-invasive blood pressure tracked 
invasive pressure closely (r=0.97). 
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8.1.3 Conclusion 
When AV delay is made more favourable, only the instant pressure increment is 
caused by increase in stroke volume. The secondary pressure decline is caused by 
systemic vasodilatation. Non-invasive blood pressure changes in parallel with 
invasive pressure when AV delay is altered, therefore may be a convenient, accessible 
target for CRT optimisation. Design of AV optimisation protocols, which face severe 
challenge of signal versus noise, might benefit from recognition that not all beats are 
equally informative: the first few after a transition are most signal-rich. 
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8.2 Background 
Following the work carried out using echocardiography, I was not entirely satisfied 
with the signal-to-noise ratio of the echo parameters. Even Doppler echocardiography 
has a relatively unsatisfactory signal-to-noise ratio, therefore I looked at ways to 
reduce signal further, improve the signal when intra cardiac timings are changed and 
hence eliminate the hindering factors which affect echocardiography as a modality in 
understanding changes that occur after timings are altered.  
This lead to the next study which I performed; measuring invasive flow and pressure 
simultaneously on a beat-by-beat basis when intra cardiac timings are changed from 
one setting to another. To improve the signal-to-noise ratio I used AV delay settings 
of 120ms to 40 ms and this provides greater change in hemodynamic measure hence a 
greater signal is visible (Pabari et al. 2011; Whinnett et al. 2006b), and performed 
replicate measurements as described below to minimise the noise (Pabari et al. 2011). 
Over 100,000 times per year in USA and Europe alone (Cunningham D et al. 2011), a 
CRT device is implanted but after each procedure the clinician is left with an 
undesirable conflict between theory and practice. On one hand, carefully conducted 
randomised controlled clinical trials have demonstrated that qualitative optimisation 
(by visual inspection of transmitral Doppler) does not significantly improve outcomes 
compared with a standard setting of 120 ms AV delay (Ellenbogen et al. 2010). Yet 
on the other hand the sole theoretical reason for implanting these devices is to 
improve intra cardiac timings in order to maximise cardiac function and improve 
symptoms.  It would be inconsistent with the stated purpose of the devices if, in 
patients with appropriate biological targets (LBBB and wide QRS), AV delays 
ranging as widely as 31ms to 300 ms (Cleland et al. 2001; Ellenbogen et al. 2010; 
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Whinnett et al. 2006b)  and VV delays from RV-first 40ms to LV-first 40 ms, made 
no difference to the physiological effect of the device (Inoue et al. 2005b). 
One potential explanation for this apparent discrepancy is that many of these studies 
used the iterative method for AV delay optimisation – a qualitative technique that 
employs visual inspection of Doppler traces to detect the optimum setting. This has 
imperfect reproducibility (Raphael CE. et al. 2011; Turcott et al. 2010)  and may not 
have identified the optimal setting for individual patients with high fidelity.  
Quantitative optimisation is the alternative which should now be explored. It requires 
making measurements at each setting and establishing their uncertainty, so that it can 
be confirmed that the setting which appears to be the optimal is not simply the highest 
by chance (Pabari et al. 2011). Quantitative pressure measurements, made invasively 
at the time of implant, consistently show a clear maximum within individual subjects 
(Auricchio et al. 1999a; Perego et al. 2003) and therefore pass the first hurdle for an 
optimisation process to be considered valid. Historically, AV delay has been 
optimised using assessments in diastole such as transmitral filling pattern, whereas the 
primary target of LV pacing is considered to be systolic mechanical dyssynchrony. 
There are a variety of approaches to develop a non-invasive quantitative process 
suitable for use in an outpatient setting. These include quantitative non-invasive beat-
by-beat pressure monitoring (van Geldorp et al. 2011; Whinnett et al. 2006a), and 
quantitative echocardiographic measurements of velocity time integral (Jansen et al. 
2006b; Thomas et al. 2009) (i.e. stroke volume). However, there are 2 important 
questions. 
First, the immediate primary change in pressure after changing the AV delay is 
followed by a secondary decline after a few seconds (Whinnett et al. 2011). One 
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explanation for this is that the increased duration of filling for a single beat at the time 
of change in AV delay produces a transient increase in LV volume that allows a 
transient increase in stroke volume. If that is the case, the increment seen during such 
protocols may be largely reflecting transient phenomena which are not likely to affect 
long term physiology, and meanwhile any genuine persistent physiological benefits of 
the change in AV delay may be difficult to detect in the presence of this irrelevant 
transient increment. Alternatively, the decline may represent potentially-beneficial 
homeostatic responses i.e. partial relaxation of the vasoconstriction characteristic of 
heart failure.  
Second, although non-invasive blood pressure may well be a practical mode of 
optimisation, it is not clear if non-invasive measurements adequately track invasive 
measurements in the context of pacemaker optimisation with sufficient fidelity. 
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8.3 Methods 
8.3.1 Protocol design elements for reliability of results 
8.3.1.1 Invasive acquisition.  
I examined carefully the temporal pattern of concurrent changes of aortic pressure and 
flow when a pacemaker setting is changed. I used well-established invasive methods 
that deliver beat-to-beat measurements.  Simultaneously I used non-invasive beat-to-
beat blood pressure measurements to assess their fidelity in tracking the invasive 
blood pressure measurements, and therefore their validity for measuring the blood 
pressure response during AV delay optimisation.  
8.3.1.2 Signal and noise.  
Measurement imprecision and physiological variability frequently obscure the 
underlying true, albeit often small, changes during a clinical optimisation procedure 
and therefore we took special steps to maximise the signal (Whinnett et al. 2011) (by 
guaranteeing a large haemodynamic effect) and to minimise noise (Pabari et al. 2011) 
(by performing multiple replicates in each patient which could then be averaged). 
8.3.1.3 Minimising noise: replication and selection of variables.  
The purpose of this experiment was to establish invasively and with temporal 
precision, the time course of the sequence of changes in aortic pressure and flow after 
a change in AV delay of a CRT device. I did not want to study the effect of 
resynchronisation itself, but only that of a change in AV delay, and therefore I 
compared states that were biventricularly paced. The reason no previous study has 
reported on this time course is that the changes are subtle in comparison to 
spontaneous beat-by-beat biological variability. Precision is increased (i.e. standard 
error of the mean is reduced) by using a measure with a small spontaneous biological 
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variability and by averaging multiple replicate experimental runs. I chose to track 
changes in stroke volume using Doppler flow velocity because using standard 
techniques its spontaneous variability is ~5% in comparison to ~11% for 
thermodilution (Lehmann & Platt 1999); and because the Doppler provides beat-by-
beat information which is necessary to examine this time course. 
8.3.2 Maximising signal: only two AV delays.  
I chose two AV delay settings that, despite being predefined, would consistently 
provide contrasting cardiac outputs. One was 40 ms which would cause truncation of 
the A wave and therefore poor cardiac output. The other was 120 ms which was 
designed to be different by enough to provide substantially better physiology and yet 
not so much longer as to risk fusion in any of the patients. I did not make 
measurements in any modes without biventricular pacing because I wanted to lavish 
all the available experimental time on answering as precisely as possible the question 
of AV delay alteration within the range during which full biventricular pacing was 
definitely in place. 
I did not test any further AV delays (and specifically did not explore the “good” 
region closely) because increasing the number of AV delays by N-fold would increase 
the acquisition time for the patient not just N-fold but approximately N 5-fold. The 
reason is that the shape of haemodynamic response is curved approximately 
parabolically (Whinnett et al. 2006b) near the optimum, so an AV delay N times 
closer to the optimum would have haemodynamic effects ~N 2 times closer to the 
optimal, and would therefore by the Central Limit Theorem require ~N 4-fold more 
replicate measurements per AV delay to resolve the difference to the same level of 
certainty. Therefore, for example, doubling of the number of AV delays tested 
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increases the number of measurements required per patient to achieve the same 
resolution between settings by ~25=32-fold.  
8.4 Study population  
Patients eligible for CRT implantation according to published guidelines (Barnett et 
al. 2007) (NYHA III or IV heart failure, QRS> 150ms, EF < 40% and on maximal 
medical therapy) and required coronary angiography as part of their standard clinical 
investigations were recruited from Imperial College NHS trust cardiology outpatients. 
Exclusion criteria were significant coronary stenosis requiring revascularisation, or 
any degree of aortic stenosis or aortic regurgitation assessed as being greater than 
mild, atrial fibrillation or incomplete ventricular capture when pacing. Patients gave 
informed consent for this study which was approved by the local ethical committee.  
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8.5 Measurements  
8.5.1 (a) Invasive measurements 
Aortic pressure and flow were respectively assessed using a fluid filled catheter and 
Doppler flow wire (Volcano FloWire 1400) positioned in the aorta approximately 5 
cm from the aortic valve. The experiment was designed to use standard Doppler flow 
velocity measurements rather than standard thermodilution measurements for two 
reasons. First, the coefficient of variation between measurements was 2-fold smaller 
(5.6% versus 11.0%(Lehmann & Platt 1999) respectively) and therefore the changes 
in flow could be detected with the same precision with 4 times fewer repetitions of the 
protocol. Second, Doppler flow velocity measurements provide data with very high 
temporal precision in comparison with thermodilution, and thereby permit the time 
course of effect to be more precisely evaluated. 
8.5.2 (b) Non-invasive blood pressure measurements 
Beat-to-beat systolic and diastolic blood pressures (SBP and DBP) were also 
measured non-invasively simultaneously using a photoplethysmograph device 
(Finometer, Finometer Medical Systems, Netherlands). This system uses a cuff placed 
around the finger with a built-in photo-electric plethysmograph and volume-clamp 
circuit which dynamically follows arterial pressure, to yield the beat-to-beat arterial 
pressure waveform (Imholz et al. 1998; Penzel et al. 1992; Smith et al. 1985; van et 
al. 1985).  
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8.5.3 Pacing protocol 
During coronary angiography, temporary biventricular pacing was performed in 
eligible subjects. A quadripolar electrode catheter (Josephson Curve, Bard Viking) 
was placed in the right atrium (usually the right atrial appendage) and a pentapole 
electrode catheter was placed at the right ventricular apex. An AL1 and/or a channel 
sheath was used to gain access to the coronary sinus and an ATW wire was positioned 
in a lateral or posterior-lateral coronary sinus branch for LV temporary pacing(Lane et 
al. 2008). LV capture was verified using a 12 lead ECG.   
A CRT pacemaker (Medtronic InSynch III 8042) was connected extracorporally and 
transitions made via a standard pacemaker programmer. DDD pacing mode was used 
with heart rate was fixed at 100bpm in all patients by atrially pacing. Stable pacing 
and sensing for all 3 pacing wires was monitored throughout the protocol in all 
patients. By lengthening the paced AV delay progressively, we checked in each 
patient that the AV delay at which the right ventricular lead began to sense or the 
QRS began to change shape was well beyond 120 ms (range 240 ms to 320 ms). This 
ensured full biventricular pacing at paced AV 120 ms.  
The protocol consisted of a series of transitions from AV delay 40ms to 120 ms.  
Measurements were recorded for at least 100 beats before and 100 beats after the 
change in AV delay. To minimise the effect of random variation, triplicate runs of the 
experimental protocol were conducted so that each patient’s dataset was composed of 
an average of 3 runs, aligned by beat and registered to the time point of transition 
from 40 ms to 120 ms.  
  
257 
8.5.4 Total Peripheral Resistance  
To detect changes in total peripheral resistance (TPR) we used the formula: 






××
=
rateheart area sectional cross LVOT distance Stroke
Pressure ArterialMean 
 Resistance Peripheral Total
 
Because LVOT cross sectional area and heart rate remained constant, fractional 
changes in total peripheral resistance could be calculated as: 






=
 volumeStroke
Pressure ArterialMean in change Fractional  TPRin  change Fractional
 
8.5.5 Data Acquisition and Analysis 
Simultaneous recordings of invasive flow, aortic invasive blood pressure and non-
invasive blood pressure were measured on a beat-by-beat basis throughout the 
protocol.   
Data were acquired using a NIDAQ AI-16E-4 analogue-to-digital card (National 
Instruments, Austin, TX) and Labview (National Instruments, Austin, TX). We 
analysed data using custom software, based on the Matlab platform (MathWorks, 
Natick, MA)(Davies et al. 1999) .  
8.5.6 Statistics 
Values are presented as mean ± sem, unless otherwise stated. Paired comparisons of 
continuous variables were made using Student’s paired t test. A p-value of <0.05 was 
taken as statistically significant. Statview 5.0 (SAS Institute Inc., Cary, NC) was used 
for statistical analysis. 
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8.6 Results 
8.6.1 Patient characteristics 
A total of 9 subjects (8 male, mean age 63 years, range 42 to 80 years underwent this 
study.  At the time of study, 7 were NYHA class III and 2 were NYHA IV. The cause 
of heart failure was ischemic in 3 and idiopathic dilated in 6. All patients had left 
bundle branch block on their native ECG with a QRS duration mean of 175 ms and 
standard deviation of 16 ms. All patients were taking angiotensin-converting enzyme 
inhibitors or angiotensin-II receptor antagonists, 6 were taking beta-blockers, and 8 
were taking a diuretic (loop or thiazide). 8 out of 9 patients had an echocardiogram at 
our institution. Non-invasive assessment of cardiac output by the LVOT integral 
method was 3.8 l/min ± 0.24 l/min at rest pre implantation. 
8.7 Phases of Response to change in AV delay from 40 to 120 ms. 
We observed a multiphasic pattern of response in the invasive measurements acquired 
during the change in AV delay from 40-120 ms, in all subjects.  There were 4 phases 
to the response including 2 plateau phases. First, the initial beat had an unnaturally 
long diastolic period preceding it and therefore had a large stroke volume Figure 8-2.  
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Figure 8-1  Beat-to-beat changes in invasive blood pressure when AV changed from 40 ms to 120 ms across all patients. After the 
transition the four phases are shown: (1) the first beat, (2) the early plateau (beats 2-11), (3) a progressive decline and (4) the late plateau (beats 
20-80). 
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Figure 8-2 Change in invasive flow, shown beat-by-beat, as AV delay is changed from 40 to 120ms across all patients.  
The early plateau (beats 2-11) and late plateau (beats 20-80) are clearly demarcated with a significant increase between AV 40 ms and the early 
plateau and a further increase between the early plateau and late plateau. 
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Second, there was a period of about 10 beats (beats 2 – 11) with a substantially 
elevated blood pressure (Figure 8-1) and somewhat elevated flow (Figure 8-2). Over 
the next approximately 10 beats there were further changes, and then a new plateau 
was evident as a fourth phase from beat 20 onwards.  
The invasive pressure early plateau, defined as beats 2 to 11, was elevated at 14.7 
mmHg ± 2.0 mmHg, (p=0.0001) above baseline. The late plateau (phase 4) (from beat 
20 onwards) was 8.0 mmHg ± 1.8 mmHg above baseline (p=0.003).  This was 
significantly lower than the early plateau (p=0.004), Figure 8-1. 
Invasive flow velocity integral had an early plateau of 9.1% ± 2.4% (p=0.007) above 
baseline. After this it did not show a fall but in fact was maintained at this elevated 
level with a maximum in the late phase of 10.3% ± 1.6% (p=0.004) above baseline. 
8.7.1 Comparison between invasive and non-invasive blood 
pressure measurements following the change in AV delay from 
40-120ms 
Non-invasive blood pressure showed an identical pattern of response to that of 
invasive pressure, as shown in Figure 8-3. The blood pressure early and late plateaus 
from non-invasive measurements were 14.3 mmHg ± 2.3 mmHg and 8.2 mmHg ± 3.2 
mmHg respectively above baseline. These are similar to the invasively measured 
increments, Figure 8-3. The beat-by-beat data for non-invasive and aortic pressure 
showed parallel behaviour (Figure 8-4, r=0.97). 
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Figure 8-3 Beat-to-beat data for invasive and Finometer (non-invasive) systolic blood pressure across all patients during a programmed change 
in AV delay from 40 to120 ms, averaged across all subjects. 
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Figure 8-4 Relationship between change in beat-to-beat invasive SBP and 
Finometer SBP.  
Data is averaged across all subjects between transitions AV 40ms to 120 ms, and AV 
120 ms to 40 ms, from Figure 3 (r=0.97). 
 
 
  
264 
8.7.2 Reverse transitions: 120 ms to 40 ms 
In a post-hoc analysis we examined the data that had been acquired during reverse 
transition, i.e. from 120 ms to 40 ms. There is a drop in invasive blood pressure to 
−14.4 mmHg ±2.3 mmHg below baseline (p=0.0004) in the period from beats 2 to 11 
(Figure 8-5), and a parallel drop in flow VTI to −11.2% ± 1.6 % (p=0.0001), Figure 
8-6. Pressure the rises a little (p=0.0006) so that in the late phase of 20 beats onwards 
it is −7.8mmHg relative to baseline (p=0.002). This partial recovery is not caused by a 
rise in flow VTI, which is not significantly different in the late phase and remains 
clearly lower than before the transition (p=0.00003, Figure 8-7). 
 
  
265 
-25
-20
-15
-10
-5
0
5
-50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80
AV 120msAV 120ms Pacemaker settingsAV 120ms
AV 40ms
Beats since transition 
Change in 
invasive 
SBP 
(mmHg)
Late Plateau
Early 
Plateau
 
 
 
 
 
 
 
 
 
 
Figure 8-5 Beat-to-beat changes in invasive blood pressure when AV changed from 120 to 40 ms across all patients. There is a drop in 
invasive blood pressure to −14.4 mmHg ±2.3 mmHg below baseline (p=0.0004) in the period from beats 2 to 11 
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Figure 8-6 Change in invasive flow, shown beat-by-beat, as AV delay is changed from 120 to 40ms across all patients.  
The early plateau (beats 2-11) and late plateau (beats 20-80) are clearly demarcated with a decrease in flow between AV 40 ms and the early 
plateau. Of note there is a lack of the prominent first beat effect seen when the transition occurs from 40 to 120ms.
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8.7.3 Mechanisms: Delayed change in Total Peripheral Resistance 
From the pre-transition state, total peripheral resistance (TPR) is no different in the 
early plateau phase but then falls during the late plateau. This is shown in Figure 8-7 
demonstrating the effect on TPR with the transition from 40ms to 120 ms, and the 
reverse effect when transition made from AV 120 ms to 40 ms. 
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Figure 8-7 Beat-to-beat changes in Total Peripheral Resistance across all patients 
for change in AV delay from 40ms to 120ms (top panel) and 120ms to 40ms 
(bottom panel).  
There is a delay of a few beats after which there is a progressive change in total 
peripheral resistance between AV delay 40 ms and AV delay 120 ms, and rise in 
resistance between 120ms 40ms which is highlighted by the grey shaded area. It then 
change then stabilises over subsequent beats at that level reached after 20 beats. A 5-
beat moving average line is also shown. 
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8.8 Discussion 
This study employs an experimental methodology with a deliberately high signal-to-
noise ratio to permit temporal resolution of the changes in blood pressure and aortic 
flow following changes in AV delay. It does not address the mechanism of action of 
cardiac resynchronisation itself, since all patients had full CRT pacing throughout, but 
rather focuses only on the effect of changes in AV timing on downstream physiology 
in the systemic arteries. It shows an immediate increase in aortic pressure and flow 
forming an early plateau following transition from AV 40 ms to AV 120 ms. A few 
seconds later there is a further increment in flow accompanied by a fall in pressure, 
which is likely to represent secondary systemic vasodilatation. Beat-by-beat non-
invasive blood pressure closely tracks changes in invasive aortic blood pressure 
during this manipulation confirming the validity of this approach for blood pressure 
monitoring during haemodynamic optimisation of CRT. These observations may be 
helpful in designing CRT optimisation protocols. 
8.8.1 Relevance to quantitative optimisation of CRT 
CRT exerts its benefits by changing intra cardiac timings. Even small improvements 
in cardiac function if sustained can be worthwhile (Cleland et al. 2005), but 
measurement imprecision and spontaneous physiological variability within 
individuals makes optimisation difficult (Francis 2011; Pabari et al. 2011). Averaging 
multiple replicate measurements to improve precision (Le Cam L 1986) is laborious if 
not automated. Protocols are typically not designed and verified to deliver precision 
of optimisation, and so even carefully-conducted endpoint research (Cleland et al. 
2005; Ellenbogen et al. 2010; Pabari et al. 2011) may not be definitively testing the 
clinically important hypothesis that precise AV optimisation is helpful.    
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Non-invasive measuring of blood pressure is not uncomfortable and might be fully 
automated.  Nevertheless, it faces two challenges. First, there are two classes of 
consequences of improving AV delay: sustained improvement of cardiac function, 
and a mere transient “bump” caused by a single cardiac cycle with a longer diastole. 
Only sustained consequences matter. The initial blood pressure increment with 
improvement in AV delay is followed by a partial decline after a few beats (Whinnett 
et al. 2011). If the secondary decline is of both pressure and flow in concert then the 
earlier initial apparent haemodynamic benefit may be just a transient “bump” rather 
than sustained.  
Second, non-invasive measurements might not faithfully reflect invasively defined 
changes. Although beat-by-beat non-invasive blood pressure (Imholz et al. 1998; 
Lansdorp et al. 2011; Schutte et al. 2004) has been validated extensively it has 
generally not been in patients undergoing manipulation of intra cardiac timings and so 
validity in this context is less clear. So far, most pressure-based haemodynamic 
optimisation have therefore used incontrovertible, invasive measurements (Auricchio 
et al. 1999a; Kass et al. 1999; Nelson et al. 2000)  
8.9 Immediate and delayed effects of changes in pacemaker 
settings 
This study is unique in performing beat-by-beat simultaneous invasive measurements 
of aortic pressure and flow, and being explicitly designed to deliver a large “bump” in 
pressure and flow by changing AV delay (Whinnett et al. 2006b). The cardiac cycle at 
the instant of transition has an abnormally long R-R interval for that single beat only, 
because the pacemaker maintains the P-P interval and lengthens the P-R interval 
instantly. One beat therefore has very prolonged filling and a much greater stroke 
volume (Figure 8-2), but in the reverse state i.e. 120 ms to 40 ms, where the PP 
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interval is prolonged and RR interval is unaltered this prominent first beat change 
does not occur. This is shown in the schematic diagram below (Figure 8-8), where the 
changes which occur between the “PP” and “RR” intervals when the AV delay is 
changed from 40ms to 120ms and from 120ms to 40ms are clearly illustrated. 
 From the second beat onwards there is a plateau of limited duration during which 
stroke volume is elevated and aortic systolic pressure are both increased. A similar 
rise of non-invasive systolic pressure was also seen. This early plateau is presumed to 
be an instant, direct cardiac effect of changes in pacemaker setting that increases 
cardiac output. 
The early plateau is followed by a phase of significant fall in pressure caused by a fall 
in total peripheral resistance (Figure 8-7) and not by a fall in flow. The most likely 
explanation is progressive vasodilatation in the circulation, which does not begin 
immediately after the AV delay transition but after a short delay. Its onset (defined by 
the early plateau ending and being replaced by a downward trend in pressure) is 
approximately beat 13, and it is established (onset of the late plateau) by 
approximately beat 18. The R-R interval is 600 ms and therefore we can say that this 
secondary vasodilatation process begins to manifest at ~8 seconds and seems to be 
established by ~11 seconds.  
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Figure 8-8  Asymmetrical impact of AV-lengthening and AV-shortening. In the top panel change occurs from AV 40 to 120 ms. The PP 
intervals are uninterrupted because at the point of transition there is a single prolonged RR interval. This results in a greater diastolic filling 
period and hence a greater stroke volume. The lower panel shows the transition from 120 to 40 ms. In this case, the RR interval is uninterrupted 
and the stroke volume is therefore maintained relatively consistently within the first beat at transition. Instead it is the PP interval that is 
increases. 
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8.9.1 Is AV delay optimisation dead in the wake of SMART AV? 
The SMART AV trial which showed that neither qualitative selection of preferred 
transmitral Doppler flow pattern nor an electrical process designed to mimic this 
process, conferred statistically significant benefit on any of the endpoints measured. 
However, widely-used optimisation methods can disagree in many patients (Turcott et 
al. 2010), has two implications. First, disagreeing methods cannot all be correct: 
almost all must be incorrect. Second, however well-conducted, a trial of one method 
is no guide to the expectation from another. 
A 3-phase process for developing optimisation science may be fruitful. First, list 
methods that have satisfactory test-retest reproducibility under blinded conditions. 
(Transmitral Doppler pattern optimisation may not belong on this list, since its 
between-observer and within-observer agreement from identical data is poor (Raphael 
CE. et al. 2011), so that its test-retest reproducibility must certainly be worse). 
Second, identify those that cluster together, agreeing closely on the optimum under 
blinded conditions, and separating those that (despite being reproducible) disagree 
with the main cluster of methods. Third, of the cluster of reproducible, mutually-
agreeing methods, trial the most clinically-convenient, using the careful rigorous 
approach of SMART-AV. 
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8.10 Limitations 
These experiments were conducted in humans and were designed to elicit information 
with sufficient precision using an experimental protocol of acceptable duration. As a 
result, there are several limitations.  
First, I did not conduct thermodilution cardiac output measurements. As a result, I 
cannot confirm what the beat-by-beat effect of thermodilution cardiac output would 
be. However, thermodilution is not well suited for such sensitive temporal resolution 
and its susceptibility to spontaneous variation (noise) even in expert hands is twice 
that of beat-by-beat Doppler aortic flow VTI, and therefore would require four times 
as many patients to be studied and yield information with the same confidence. 
Second, I only studied a single transition: AV 40ms to 120ms. This study was not an 
optimisation protocol but sought quantitative temporal information about the 
downstream physiology to inform design of optimisation protocols.  I therefore cannot 
state with certainty that the time courses of effects of changes between other pairs of 
settings would be the same. 
Third, this study of the acute invasive haemodynamics cannot confirm whether these 
changes are sustained over days or years. To test whether there are even later phases 
would be possible by this approach in humans.  
Finally, the number of patients studied was not large but the design was able to 
resolve the time course with high fidelity because each patient underwent repeated 
beat-to-beat direct invasive measurements (attenuating noise), and the signal was 
arranged to be large. My patients were not selected for any characteristic other than 
those listed in the enrolment criteria and are representative of patients referred for 
CRT. 
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8.11 Conclusions  
Non-invasive blood pressure has been proposed for optimising AV delay in CRT, but 
the immediate pressure increment partially fades within a few seconds. These 
simultaneous invasive blood pressure and flow measurements show that this 
secondary fall in non-invasive blood pressure is not a failure of non-invasive 
monitoring, nor the end of a short-lived improvement in cardiac output, but rather a 
manifestation of reduction in peripheral resistance that may indeed be desirable. 
Aortic flow, invasive aortic pressure and non-invasive finger blood pressure all rise 
together immediately following a change in AV delay and therefore early 
measurements of these are plausible candidates for optimisation. However, after a few 
seconds pressure delays somewhat. Planners designing optimisation protocols may 
choose to measure pressure for its favourable noise characteristics and potential for 
non-invasive measurements, but they should do so without delay. 
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9 Synthesis 
In this thesis I have identified that beat-to-beat biological variability of all the widely 
recommended markers of dyssynchrony is far too large to be realistically used in 
optimisation. Although making multiple repetitions can alleviate this problem, the 
number of replicates needed is very large and might not be clinically practical unless 
either markers become available that are measurable with higher precision, or 
automated methods become available to make multiple measurements less time-
consuming. 
Since these echocardiographic markers have such large beat-to-beat variability there 
is no chance they will predict response to the level of reliability that is claimed in 
many publications. The response markers also have intrinsic variability which is wide 
compared to the spectrum of changes seen in randomised controlled trials. Moreover, 
from my local data, such variability appears to arise immediately and not be 
particularly dependant on passage of a long time.  This indicates that the variability 
should not be assumed to be genuine variation in clinical status, but rather should be 
suspected to be spontaneous beat-to-beat variability that does not have clinical 
meaning.  
As a result of the above, many highly skilled specialist centres have reported strong 
predictors of response which must either be a coincidence, inadvertent self deception 
or intentional mis-representation, because they exceed the limit of mathematical 
possibility. Studies conducted to normal scientific standards consistently stay within 
these limits. Therefore a large number of these papers need to be abandoned (and 
perhaps retracted). In future, studies of poor design should not be initiated, or if 
initiated and completed, not given credence in the literature. 
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With my colleagues I have identified two key pre requirements, without which it 
makes no sense to embark upon an attempt of reliable prediction: 
·        Reliable measures of response i.e. those which remain stable within individuals 
·        Candidate dyssynchrony markers with good blinded test-retest reproducibility 
 
In parallel with my non-invasive work, I have also conducted an invasive study to 
establish, without fear of contradiction, the relative potential of flow and pressure 
measurements in optimisation of CRT. This study demonstrated that flow 
measurements, which might potentially be measured by echocardiographic measures, 
show a sustained increase following a change to a favourable AV delay, whereas 
pressure initially rises but then partially declines. This shows that measuring flow 
could be used for optimisation purposes provided a high reproducibility was obtained. 
Pressure measurements are a plausible alternative, and can be measured just as 
reliably non-invasively, but are best measured in the early phase after the change in 
the intra-cardiac settings.  
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9.1 The puzzle of dyssynchrony and response 
I have identified that there is substantial difference between centres of dyssynchrony 
markers to determine response. By mathematically calculating the maximal possible 
R2 values of these markers and the maximum R2 values of ejection fraction 
variability, I have calculated the best possible R2 value for prediction: the “contraction 
factor of R2”. Therefore, I am able to confidently state that it is not realistic to expect 
a good correlation between dyssynchrony markers and prediction of ∆EF. 
The ∆EF, when repeated echocardiographic measurements were performed at our 
local hospital, showed that the standard deviation between these repeated values 
ranged between 10 and 20%. This is not dissimilar to published values of EF 
variability of at least 10% (Otterstad et al. 1997). This demonstrates the implausibility 
of definitions of response of 10-15% being reliably predicted by any baseline marker 
or combination of markers.  The real puzzle is not why dyssynchrony does not 
successfully predict response in some studies, but why anyone takes seriously any 
studies that say it does.  
The responsibility may lie more properly with us as an audience for several 
weaknesses in application of normal scientific critique. 
Sound-bite Susceptibility. As a community we accepted uncritically the name “cardiac 
resynchronization therapy”. With repetition it became obvious that quantifying 
mechanical dyssynchrony (which can only refer to ventricular timings, since atrium 
and ventricle should not be synchronous) would quantify degree of benefit. Obvious, 
but not necessarily true. Experimental investigation of the mechanism of action 
remains at an early stage. A neutral term such as “biventricular pacing” might reduce 
cognitive distortion. 
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Authority Awe. Physical science audiences judge a scientific finding by the precise 
nature of the experiment, the attention to detail and the track record of previous 
results being verified by others. Cardiological audiences may not apply the same level 
of scrutiny (e.g. bias-resistance is rarely debated) and may suffer from the availability 
heuristic (judging the credibility of sources from their visibility rather than their track 
record of reliability). Audiences could usefully restore habits from their earlier 
scientific training. 
Amnesia. Hearing of each successive novel predictive marker with progressively more 
excellent predictive capacities, cardiological audiences often forget to ask what 
happened to yesterday’s markers. If two different markers predict excellently, they 
must agree almost perfectly; if the latter is not the case, the former is not credible. 
Audience memory would help resist successive overstatements. 
Paralysis. Physical scientists, hearing of an efficacious new approach, rush back to try 
it out in small experiments. Cardiological audiences may feel unable to do this. Yet 
simple experiments taking only minutes can quickly reject some claims. One example 
is evaluation of blinded test-retest reproducibility, and application of the formulae in 
this thesis. Another is adjustment of interventricular delay in a single biventricular 
pacemaker patient, with blinded measurement of mechanical dyssynchrony. Any 
reliable marker will show a clear, reproducible minimum. If not, it cannot credibly 
classify dyssynchrony status across different patients (Pabari PA et al. 2012). 
Wishful thinking. We all want our specialty of echocardiography to be relevant. 
Reports of successful application are therefore intrinsically popular. But this is failure 
to separate our individual skill as echocardiographers, from the ability of one 
echocardiographic technique to deliver what is claimed. Distinguishing falsity of a 
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hypothesis from personal inadequacy requires courage, but is worthwhile, since it is 
the hallmark of science. 
Cryptic commenting. Even when experts carefully review available methods, and 
tabulate that dyssynchrony markers are intensely vulnerable to noise and sometimes 
choice of measurement location so that there is risk of “dialling in” any clinically 
desired level of dyssynchrony (Abraham et al. 2007), nevertheless the published 
conclusion may not be quantitatively clear on the implication for claims of response 
prediction (MacRoberts MH & MacRoberts BR 1984). 
Bias blindness. We frequently confuse bias (which arises from study design) with 
chance (which is addressed by p values). Large study sizes reduce the impact of 
chance, but increase the false statistical significance of the effects of bias. Even the 
most methodical of clinician audiences – guideline bodies – consistently consider 
observational studies (if large) as the same level of evidence (“B”) as a randomised 
controlled trial. We should become alert to the fact that large study size increases 
susceptibility to bias. 
Test-retest taboo. We confuse re-measurement of identical digital images with 
genuine test-retest reproducibility, entirely ignoring the majority of variability which 
occurs between beats. Test-retest variability can be readily checked by clinicians 
(Finegold et al. 2012).  
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9.2 The puzzle of optimisation 
The concept of optimisation was initially thought to be fairly simple. By changing 
intra-cardiac timings to a more favourable setting in an individualised manner per 
patient, it would surely be possible to give the patient some advantage. This may 
sound plausible, but in reality I have identified some flaws with this concept. In an 
ideal world, if we were measuring a noise-free parameter as settings were changed,  
then we could confidently state that that we were improving patient settings. However 
any real life parameter which is measured has a significant noise component, and this 
noise (when measured as a single beat), is in almost all cases much larger than the 
genuine difference between settings. For this reason, the protocols that are claimed to 
permit optimisation by making a single measurement at each of several settings and 
then choosing the setting with the highest measurement, are almost all incorrect and 
the claimed positive results are almost all the results of wishful thinking on behalf of 
the researchers.  
I have mathematically shown the impact of signal and noise on the effectiveness of 
optimisation. I have demonstrated that the information content (the relative amount of 
useful information versus random variability) has an enormous effect on reliability of 
optimisation. I have identified a series of illusions regarding optimisation of CRT that 
frequently afflict the literature, demonstrating the importance of asking for the 
confidence interval of any observed optimum. This allows us all to evaluate how 
much we should trust an apparent change in optimum after a second optimisation 
process. 
I have shown what steps are important in improving the quality of the process of 
optimisation. These are as follows: 
  
282 
(a)  reducing the noise component by performing replicate measurements at each 
setting   
(b) maximising the signal, for which we know the most reliable approach is increasing 
the heart rate in some parameters 
(c) being aware that large confidence intervals can cause misinterpretation of the 
reliability of optimisation of CRT.   
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9.3 Biological variability of optimisation using a spectrum 
of echocardiographic parameters 
In this thesis I studied a selection of echocardiographic markers, head-to-head, as 
potential tools for VV optimisation of CRT devices. I have scrutinised each parameter 
looking at the biological variability which impacts on the feasibility of each as a 
potential optimisation tool. I have identified that the advanced modalities of 3D 
echocardiography and tissue Doppler imaging demonstrate a poor signal-to-noise 
ratio yet take longer to acquire and analyse. The more simplistic pulsed Doppler 
methods, namely LVOT VTI and aortic pre-ejection times show a better signal-to-
noise ratio, resulting in a lower spread of results when repeated optimisation 
processes are performed. All parameters improved their signal-to-noise ratio when 
multiple replicates of each setting are used. Time taken, for acquiring and measuring 
each traces at each setting, then becomes the limiting step restricting the level of 
precision that can be achieved.   
Any of the above parameters could, in principle, be used for selection of those 
suitable for CRT and for optimisation of VV delay. But multiple measures would be 
required to achieve adequate signal-to-noise ratio. Recommendations for protocols are 
usually made without regard to how many replicates would be needed to achieve the 
bare minimum level of precision that might be considered clinically adequate. 
Calculating that number of replicates is surprising: it is very much higher indeed than 
the numbers described in protocols or recommended in guidelines. 
Finally, exploring simple opportunities to improve upon conventional parameters, I 
compared the velocity time integral to the peak velocity of LVOT Doppler traces as 
alternatives for optimisation of CRT.  Better signal-to-noise ratio was obtained with 
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peak velocity. Meanwhile, time to analyse was also shorter with peak velocity than 
VTI, so that more replicates could be averaged in the same time frame, making peak 
velocity an even better candidate for optimisation of CRT devices. 
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9.4 The effect of AV delay optimisation on invasive 
pressure and flow measurements: implications for 
the design of AV optimisation protocols 
The detailed invasive study I performed showed, on a beat-by-beat basis, the changes 
which occur when AV delay is altered. Pressure increased initially but then dipped 
away over the subsequent few beats to settle at a lower plateau. This behaviour is 
mirrored closely by the non-invasive blood pressure, which means the non-invasive 
signal is not in error. This opens up the possibility of using non-invasive Finapres -
type signal as a method for CRT optimisation.   
My data showed that flow rises initially with a further rise temporally aligned with a 
fall in pressure. I have explained this secondary dip in pressure and rise in flow, by a  
change in peripheral resistance which I interpret as a favourable phenomenon in heart 
failure patients who are characteristically in a state of pathological vasoconstriction. 
From a practical point of view, for the design of optimisation protocols, my work 
shows that the greatest signal size in pressure is at the first few beats post transition of 
settings. In contrast if flow is used as the optimisation parameter, there is less urgency 
to make the measurements because in later beats the signal is not systematically 
smaller.   
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9.5 Recommendations for performing optimisation of 
Cardiac Resynchronisation Therapy devices 
 
When performing an optimisation process, the aim is to detect small changes in the 
measured parameter as intra cardiac timings are altered. For this to be reliable, i.e. to 
achieve a small scatter on the optima obtained on repeated optimisations requires a 
high intraclass correlation in the measurements being made. My thesis demonstrates 
that this is mathematically possible but would be very laborious and time consuming 
because a large number of replicates will be required. Therefore it is rational to adopt 
a method whose intrinsic signal-to-noise ratio is as high as possible, so that the 
number of replicates needed are as small as possible. For example peak velocity is on 
these grounds a better candidate than VTI.  
 A second consideration is that one should favour methods where the measurement 
and analysis time per beat is small. In clinical practice it is the analysis time which is  
by far the most time consuming component. In future a process of automating some or 
all of this would be likely to increase speed and /or precision of the optimisation 
process. Algorithms which could automatically measure the peak velocities would be 
attractive.  
The difference between beats is a greater source of variability than operator 
uncertainty regarding how to draw round the beats. Therefore I would not expect 
automation of measurement of VTI  to necessarily greatly help through elimination of  
individual-beat measurement error, but by making it possible to average multiple 
beats at little cost in time it could make it clinically realistic to perform high-replicate, 
reliable optimisations in routine practice. 
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A pilot study is already underway to see if VTI can be automatically calculated.  A  
similar algorithm might also be implemented for peak velocity. This would assist 
those using outflow measurements for optimisation of CRT devices in which beat-to-
beat variability can mainly be reduced by multiple replicate measurements.  
There is no reason to be limited to either Peak velocity or VTI as a parameter. Any 
variable would be a possibility but those with  greater noise would require a much 
greater level of repetition to achieve the same level of precision of optimum. For each 
doubling of noise, we know that the number of replicates required increases 4 fold. 
Looked at another way, if the degree of uncertainty of the optimum is considered 
unsatisfactorily wide, the number of replicates can be increased to narrow it. But  
achieving a halving of this uncertainty requires approximately 32 times more 
replicates. 
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9.6 Impact on selection criteria for Cardiac 
Resynchronisation Therapy devices 
As has been demonstrated, signal-to-noise of the advanced echocardiographic 
modalities is poor when single measurements are performed. Therefore despite claims 
made in the literature, it is not plausible that a single assessment of mechanical 
dyssynchrony can tell us anything useful about the patient (since it varies so 
extensively between beats). Many of the claims made for the success of predicting 
response are definitely incorrect and should be withdrawn. 
Current practice and guidelines focus on ECG criteria, and at present there is little 
basis to press for echocardiography to be added as a large contributor. Chapter 5 
demonstrates that QRS duration has a good signal-to-noise ratio which further 
improves upon multiple replicates, and is quick and QRS duration can be 
automatically calculated. However the criteria of biological plausibility of optimum 
obtained is not always fulfilled, even if the criteria of reproducibility and agreement 
with repeated optimisations are met (Kyriacou et al. 2012). For this reason I believe 
that QRS duration alone cannot confidently be used as a selection criterion.  
Additional use of an echocardiographic criterion requires careful thought as  there 
needs to be grounds for confidence in the parameter used. Each department is likely to 
have a preferred method, which, they feel if used carefully could assist with selection.  
However, the record - even amongst carefully argued clinical research papers that 
have undergone peer review - shows that most of these feelings are misplaced 
optimism. Feelings of a local department, without even perfunctory statistical scrutiny 
or peer review, are even less likely to be reliable. Gut instinct should not be believed 
to be reliable, because the record shows clearly that it is unreliable.   
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Proposals for a future selection criterion would need very careful stepwise evaluation. 
The first step would be establishment of the genuine, honest test-retest reproducibility 
of both the marker and the planned marker of response. After this a protocol could be 
designed, to have sufficient replicates. The number of replicates should be determined 
not by just guessing, asking an expert (who in turn guesses), or plucking a number 
from the air but rather by calculation from the marker’s properties and the level of 
precision required (Pabari et al. 2011). 
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9.7 Recommendations for future studies  
Although most optimisations are performed at rest, patients experience their most 
severe symptoms when they are exercising. Therefore, identifying the benefits of 
optimisation during exercise would be the next logical step forward. I have been 
collecting pilot data in 11 patients to demonstrate the effect of AV optimisation on 
peak cardiac power output measured whilst cycling  on a supine bicycle. 
I have demonstrated that in 10/11 patients (91%) an independently established 
optimal AV delay shows individually detectable increases in both flow and pressure. 
In all patients cardiac power output increases when compared with a non-optimal 
delay.  
 
In this thesis I have demonstrated that ultimately, almost any parameter can in 
principle be used for optimisation of CRT but obtaining a sufficiently large signal-to-
noise ratio is essential. This is shown in this thesis when measurements are made at 
rest, and likely to be even more important on measurements taken during exercise 
where noise is only going to be a greater component.  
Beat-to-beat variability, which is inherent and unavoidable, means that a bias resistant 
protocol of systematically averaging multiple replicate measurements is essential. My 
thesis lists strategies for achieving this. 
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10 Appendices 
10.1 Appendix 1: Invitation letter 
 
 
St Mary's Hospital 
International Centre for Circulatory Health, 
59-61 North Wharf Road, 
London 
W2 1LA 
 
Direct Dial: 020 7594 1093 
Direct Fax: 0707 505 5876 
 
 
 
 
 
 
 
 
 
Dear Sir / Madam 
 
You are being invited to participate in a research study. You have been recruited from either a Heart 
failure or Pacemaker clinic where it has been identified that you may be suitable to participate in this 
research project.  
 
Before you decide, it is important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it with others if you 
wish.  Ask us if there is anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part. Thank you for reading this. 
 
Please find attached a Patient Information sheet and contact details should you have any further 
questions 
 
 
Thank you for considering participating in this project 
 
 
Kind Regards 
 
 
 
 
Dr Punam Pabari 
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10.2 Appendix 2: Patient information leaflet 
Non Invasive Haemodynamics to Probe Physiology and Echocardiographic 
Dyssynchrony in Chronic Heart Failure 
 
What is the purpose of the study? 
Patients with heart failure are limited greatly by their symptoms and often require 
emergency admissions to hospital. Day to day activity is restricted and there is an 
increased risk of death associated with the condition. We know that the heart pumping 
mechanism is often not in a coordinated fashion, therefore “dyssynchronous” leading 
to inefficient working of the heart.  
Specialist pacemakers, Cardiac Resynchronisation Therapy, (CRT), have been shown 
to improve the symptoms and survival of certain groups of patients, in addition to 
maximum medical treatment. There are selection methods in place for choosing 
patients who will benefit from these CRT devices; however we are unclear which will 
predict the best long-term outcome. A beneficial response, by improving co 
ordination of ventricle contraction, is seen by an improvement in blood pressure on 
altering pacemaker settings. At present a proportion of patients do not respond as 
predicted after CRT implantations or show the expected benefits. 
This study aims to research the different imaging methods of echocardiography to 
maximise the best outcome in terms of blood pressure response at different pacemaker 
settings. The study will then progress to look at changes in blood pressure once the 
optimal, the best, pacemaker setting had been identified. This will give us a greater 
understanding into the long term benefits of improving pacemaker settings in patients 
with CRT.  
We hope this study will give a greater insight into which methods of selecting patients 
for CRT devices provides greatest benefit, and whether optimising pacemaker settings 
will give long term benefits and therefore a worth while pursuit. 
Why have I been chosen? 
You will probably have been contacted and asked whether you would be interested in 
helping with our research following an outpatients’ appointment at the heart failure 
and / or pacemaker clinic, where we have noted you currently have a CRT pacemaker. 
You can participate in our research providing that you have a Cardiac 
Resynchronisation Therapy pacemaker fitted and heart failure.  
Do I have to take part? 
No. Your decision to participate or not to participate within this study is completely 
free and voluntary. You have the right to refuse as well as to withdraw your 
participation at any time (even if you agree today) without giving a reason. If you 
decide not to participate or to withdraw, it will not affect the quality of your care or 
treatment, nor the relationship you have with your doctor and nursing team. Should 
you withdraw, your doctor will recommend appropriate clinical treatment and follow-
up to ensure your safety. 
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What will happen to me if I take part? 
When you arrive for the testing, we will ask you to lie comfortably on a bed, remove 
your top half clothing, and we will attach several pieces of monitoring equipment 
such as an ECG machine and a blood pressure monitor to your finger.  
The study takes between 2 – 3 hours and you will be asked to lie on your side and 
back while we take various echocardiographic images, specialised ultrasound scans of 
your heart. During this time the pacemaker settings will be altered and the images 
taken at each setting.  We will be taking continuous measurements of blood pressure 
during the testing, and these along with the images taken will give us information to 
analyse.  The pacemaker settings will be changed in the same way as the technicians 
use when you attend the pacemaker clinic, in order to check the pacemakers.  The 
settings will be returned to what they were when you arrived at the hospital, before 
you go home. 
This is a totally painless procedure however, if at any time during the study you feel 
uncomfortable, or wish to stop, then we will terminate immediately. 
What are the side effects of this treatment when taking part? 
This research does not involve any blood tests, drugs or invasive procedures. 
Pacemaker settings will be altered during the study but reset to the original values 
prior to you going home. 
What if something goes wrong? 
Imperial College London holds insurance policies which apply to this study. If you 
experience harm or injury as a result of taking part in this study, you will be eligible 
to claim compensation without having to prove that Imperial College is at fault. This 
does not affect your legal rights to seek compensation. 
If you are harmed due to someone's negligence, then you may have grounds for legal 
action. Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been treated during the course of this study then you 
should immediately inform the 
Investigators (Dr Punam Pabari or Dr Darrel Francis 0207 594 1093).  
The normal National Health Service complaint complaints mechanisms are also 
available to you. If you are still not satisfied with the response, you may contact the 
Imperial College Clinical Research Office. 
What are the possible disadvantages and risks of taking part? 
This research does not involve any blood tests, drugs, contrast dye or invasive 
procedures. 
Some people find undergoing echocardiography uncomfortable as it requires lying on 
the bed in various positions. We will allow for breaks during the scanning periods to 
alleviate this.  
Occasionally the blood pressure measuring device, the Finapres, can cause tingling. 
This is short-lived and stops once removed. 
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What are the possible benefits of taking part? 
This research will not benefit you directly. However, it will contribute to our 
understanding of physiological changes which occur during optimisation of cardiac 
resynchronisation therapy and improve our selection of patients for these devices.  
This may help with the development of treatments and management of heart failure in 
the future. 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment being studied which could influence your willingness to 
participate. If this happens, your research doctor will tell you about it and discuss 
whether you want to or should continue in the study.  If you decide not to carry on, 
your research doctor will make arrangements for your care to continue.  If you decide 
to continue in the study you will be asked to sign an updated consent form. 
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study.  He/she will explain the reasons 
and arrange for your care to continue. 
If the study is stopped for any other reason, you will be told why and your continuing 
care will be arranged. 
What happens when the research study stops? 
By the end of this process we hope to understand more about the physiological 
changes which occur when cardiac resynchronisation devices are optimised, i.e. have 
the settings changed to maximise benefits, and a greater understanding of changes 
which occur for long term benefits. 
What if something goes wrong? 
We will take every care in the course of this study, and the risk involved is minimal. 
However, if through our negligence, you should suffer any harm then you will be 
compensated and a full investigation will be conducted. 
There are no adverse effects expected. 
Will my taking part in this study be kept confidential? 
If you agree to take part in this study, data collected about you will be entered on to a 
computer. However, all data entered will be in an anonymous format and any 
information obtained from this investigation that can be identified will remain 
confidential.  
What will happen to the results of the research study? 
Scientific data from this study may be presented at meetings and published so that the 
information can be used to help others, but your participation in the study will not be 
made known and will be kept strictly confidential. 
Who is organising and funding the research? 
This research is supported by the British Heart Foundation. 
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Who has reviewed the study? 
This study has been reviewed the Brompton, Harefield and NHLI Hospital NHS Trust 
Research Ethics committee.   
 
If you have any further questions please do not hesitate to contact: 
Dr Punam Pabari on 0207 594 1093 
 
 
Thank you for taking the time to consider participating in this study. 
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10.3 Appendix 3: Consent form 
 
 
St Mary's Hospital 
International Centre for Circulatory Health, 
59-61 North Wharf Road, 
London 
W2 1LA 
 
Direct Dial: 020 7594 1093 
Direct Fax: 0707 505 5876 
 
Centre Number: : 
Study Number: 
Patient Identification Number for this trial: 
 
CONSENT FORM 
Title of Project:  Use of Non Invasive Haemodynamics to Probe Physiology of 
Echocardiographic Features of Cardiac Dyssynchrony in Chronic Heart Failure 
 
Name of Researcher:  Dr Punam Pabari                                       Please tick box  
 
 
I confirm that I have read and understand the information sheet dated 22/11/2007          
for the above study. I have had the opportunity to consider the information, ask questions  
and have had these answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at any time  
without giving any reason and without my medical care or legal rights being affected. 
 
I understand that relevant sections of any of my medical notes and data collected during   
the study, may be looked at by responsible individuals from St Mary’s Hospital NHS Trust,  
Imperial College and Regulatory bodies, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.  
 
I understand the risks and benefits of the study and have had any questions answered. I     
am aware of who to contact should I have any further queries. 
 
I agree to my GP being informed of my participation in the study.  
 
I agree to take part in the above study.    
 
 
_____________________ ________________ ____________________ 
Name of Patient  Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date  Signature 
(if different from researcher) 
 
_________________________ ________________ ____________________ 
Researcher   Date  Signature 
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10.4 Appendix 4: Determining the contraction factor 
 
A series of measurements of a variable (x) in a particular patient (e.g. the i’th patient) 
will not always be identical, but rather be scattered randomly with a mean ( ) and 
an error component ( ), i.e. xi  =   + . The same applies for another variable, yi  
=   + .  The statistical term “error” in this context amalgamates observer error, 
equipment error, operator error, and genuine biological variability, all of which 
contribute to the scatter. The combined error in x is described by its variance .  
The size of this error variance in comparison to the size of the variance in the true 
underlying values is an important characteristic of any measured biological 
variable.  This is described by the intraclass correlation coefficient: 
 
The same can be said for y.  If one tries to estimate the correlation between x and y, 
then the observed coefficient of determination R2(xi,yi) will not be the R2 between the 
underlying variables R2(µxi, µyi) but lower: 
R2  (xi, yi)     =   R2 ( , ) × ×  
   =   R2 ( , ) × ×  
The factor × is the maximum R2 that can be observed between xi and yi 
even if there is a perfect correlation between  and . 
In this paper, x is a baseline dyssynchrony marker and y (for example ∆LVEF) is a 
change in response marker over time. In this field unfortunately is not known 
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for most dyssynchrony markers because blinded test-retest studies have not been 
performed, or not been reported. , in contrast, can be estimated from 
randomised controlled trials that performed blinded analysis. The variance of the 
changes over time in the control arm σ2(∆control arm) is , the 
corresponding variance in the intervention arm σ2(∆intervention arm) is   
Although these are not the same individual patients, the randomised trial design 
ensures that they are comparable so that the difference between them, σ2 (∆intervention 
arm)- σ2(∆control arm) is an estimate of the elusive   Thus from an 
individual trial, the estimate of  is 1- 
).  
That last expression relies only to the standard deviation of ∆ in the control and 
device arms, and is therefore easy to calculate in trials that report the distributions of 
∆. It is not sufficient to know the distribution of the initial and final LVEFs.  Rather, 
the distribution of the change, i.e. the standard deviation of ∆, is needed.   
From a single trial, the estimate of  may overestimate or underestimate the true 
value. It will not be reliable in any study where there is a breakdown in blinding. 
Although a breakdown in blinding is not likely to be admitted, it can become obvious 
Estimate of the R2 contraction factor 
caused by  
natural variability in response variable 
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from the pattern of ∆yi. The characteristic features of breakdown in blinding in 
endpoint measurements of a trial are: 
• Unusually narrow σ2∆yi in comparison to those of other trials with ostensibly 
similar methods; 
• Markedly asymmetric ∆ values - for variables whose increase is desirable, the 
upper limit of the 95% confidence interval much further from the median than 
the lower limit is; for variables whose decrease is desirable, the converse. 
Averaging estimates across multiple trials, weighting by their  allows a 
combined estimate for to be developed for each class of response variable yi, 
such as ∆LVEF.  
  
300 
11 References 
 
(1987) Effects of enalapril on mortality in severe congestive heart failure. Results of 
the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The 
CONSENSUS Trial Study Group. N.Engl.J.Med., 316, 1429-1435. 
Abraham, T.P., Dimaano, V.L. & Liang, H.Y. (2007) Role of tissue Doppler and 
strain echocardiography in current clinical practice. Circulation, 116, 2597-2609. 
Abraham, W.T., Fisher, W.G., Smith, A.L., DeLurgio, D.B., Leon, A.R., Loh, E., 
Kocovic, D.Z., Packer, M., Clavell, A.L., Hayes, D.L., Ellestad, M., Trupp, R.J., 
Underwood, J., Pickering, F., Truex, C., McAtee, P. & Messenger, J. (2002) Cardiac 
resynchronization in chronic heart failure. N.Engl.J.Med., 346, 1845-1853. 
Abraham, W.T., Fonarow, G.C., Albert, N.M., Stough, W.G., Gheorghiade, M., 
Greenberg, B.H., O'Connor, C.M., Sun, J.L., Yancy, C.W. & Young, J.B. (2008) 
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights 
from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients 
with Heart Failure (OPTIMIZE-HF). J.Am.Coll.Cardiol., 52, 347-356. 
Abraham, W.T., Young, J.B., Leon, A.R., Adler, S., Bank, A.J., Hall, S.A., 
Lieberman, R., Liem, L.B., O'Connell, J.B., Schroeder, J.S. & Wheelan, K.R. (2004) 
Effects of cardiac resynchronization on disease progression in patients with left 
ventricular systolic dysfunction, an indication for an implantable cardioverter-
defibrillator, and mildly symptomatic chronic heart failure. Circulation, 110, 2864-
2868. 
Adabag, S., Roukoz, H., Anand, I.S. & Moss, A.J. (2011) Cardiac resynchronization 
therapy in patients with minimal heart failure a systematic review and meta-analysis. 
J.Am.Coll.Cardiol., 58, 935-941. 
  
301 
Adams, K.F., Jr., Fonarow, G.C., Emerman, C.L., LeJemtel, T.H., Costanzo, M.R., 
Abraham, W.T., Berkowitz, R.L., Galvao, M. & Horton, D.P. (2005) Characteristics 
and outcomes of patients hospitalized for heart failure in the United States: rationale, 
design, and preliminary observations from the first 100,000 cases in the Acute 
Decompensated Heart Failure National Registry (ADHERE). Am.Heart J., 149, 209-
216. 
Agarwal, R., Beshai, J.F. & Lang, R.M. (2009) Can real-time three-dimensional 
echocardiography be used reliably for the assessment of left ventricular 
dyssynchrony? Arch.Cardiovasc.Dis., 102, 469-472. 
Anselmino, M., Antolini, M., Amellone, C., Piovano, E., Massa, R. & Trevi, G. 
(2009) Optimization of cardiac resynchronization therapy: echocardiographic vs 
semiautomatic device algorithms. Congest.Heart Fail., 15, 14-18. 
Auricchio, A. & Prinzen, F.W. (2011) Non-responders to cardiac resynchronization 
therapy: the magnitude of the problem and the issues. Circ.J., 75, 521-527. 
Auricchio, A., Stellbrink, C., Block, M., Sack, S., Vogt, J., Bakker, P., Klein, H., 
Kramer, A., Ding, J., Salo, R., Tockman, B., Pochet, T. & Spinelli, J. (1999a) Effect 
of pacing chamber and atrioventricular delay on acute systolic function of paced 
patients with congestive heart failure. The Pacing Therapies for Congestive Heart 
Failure Study Group. The Guidant Congestive Heart Failure Research Group. 
Circulation, 99, 2993-3001. 
Auricchio, A., Stellbrink, C., Sack, S., Block, M., Vogt, J., Bakker, P., Mortensen, P. 
& Klein, H. (1999b) The Pacing Therapies for Congestive Heart Failure (PATH-
CHF) study: rationale, design, and endpoints of a prospective randomized multicenter 
study. Am.J.Cardiol., 83, 130D-135D. 
Baldasseroni, S., Opasich, C., Gorini, M., Lucci, D., Marchionni, N., Marini, M., 
Campana, C., Perini, G., Deorsola, A., Masotti, G., Tavazzi, L. & Maggioni, A.P. 
(2002) Left bundle-branch block is associated with increased 1-year sudden and total 
  
302 
mortality rate in 5517 outpatients with congestive heart failure: a report from the 
Italian network on congestive heart failure. Am.Heart J., 143, 398-405. 
Bank, A.J., Kaufman, C.L., Kelly, A.S., Burns, K.V., Adler, S.W., Rector, T.S., 
Goldsmith, S.R., Olivari, M.T., Tang, C., Nelson, L. & Metzig, A. (2009) Results of 
the Prospective Minnesota Study of ECHO/TDI in Cardiac Resynchronization 
Therapy (PROMISE-CRT) study. J.Card Fail., 15, 401-409. 
Barnett, D., Phillips, S. & Longson, C. (2007) Cardiac resynchronisation therapy for 
the treatment of heart failure: NICE technology appraisal guidance. Heart, 93, 1134-
1135. 
Barold, S.S., Ilercil, A. & Herweg, B. (2008) Echocardiographic optimization of the 
atrioventricular and interventricular intervals during cardiac resynchronization. 
Europace., 10 Suppl 3, iii88-iii95. 
Bax, J.J. & Gorcsan, J. (2009) Echocardiography and noninvasive imaging in cardiac 
resynchronization therapy: results of the PROSPECT (Predictors of Response to 
Cardiac Resynchronization Therapy) study in perspective. J.Am.Coll.Cardiol., 53, 
1933-1943. 
Bax, J.J., Marwick, T.H., Molhoek, S.G., Bleeker, G.B., van, E.L., Boersma, E., 
Steendijk, P., van der Wall, E.E. & Schalij, M.J. (2003a) Left ventricular 
dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with 
end-stage heart failure before pacemaker implantation. Am.J.Cardiol., 92, 1238-1240. 
Bax, J.J., Molhoek, S.G., van, E.L., Voogd, P.J., Somer, S., Boersma, E., Steendijk, 
P., Schalij, M.J. & van der Wall, E.E. (2003b) Usefulness of myocardial tissue 
Doppler echocardiography to evaluate left ventricular dyssynchrony before and after 
biventricular pacing in patients with idiopathic dilated cardiomyopathy. 
Am.J.Cardiol., 91, 94-97. 
  
303 
Bertini, M., Valzania, C., Biffi, M., Martignani, C., Ziacchi, M., Pedri, S., 
Domenichini, G., Diemberger, I., Saporito, D., Rocchi, G., Rapezzi, C., Branzi, A. & 
Boriani, G. (2010) Interventricular delay optimization: a comparison among three 
different echocardiographic methods. Echocardiography., 27, 38-43. 
Bertini, M., Ziacchi, M., Biffi, M., Martignani, C., Saporito, D., Valzania, C., 
Diemberger, I., Cervi, E., Frisoni, J., Sangiorgi, D., Branzi, A. & Boriani, G. (2008) 
Interventricular delay interval optimization in cardiac resynchronization therapy 
guided by echocardiography versus guided by electrocardiographic QRS interval 
width. Am.J.Cardiol., 102, 1373-1377. 
Beshai, J.F., Grimm, R.A., Nagueh, S.F., Baker, J.H., Beau, S.L., Greenberg, S.M., 
Pires, L.A. & Tchou, P.J. (2007) Cardiac-resynchronization therapy in heart failure 
with narrow QRS complexes. N.Engl.J.Med., 357, 2461-2471. 
Bleeker, G.B., Mollema, S.A., Holman, E.R., Van, d., V, Ypenburg, C., Boersma, E., 
van der Wall, E.E., Schalij, M.J. & Bax, J.J. (2007a) Left ventricular 
resynchronization is mandatory for response to cardiac resynchronization therapy: 
analysis in patients with echocardiographic evidence of left ventricular dyssynchrony 
at baseline. Circulation, 116, 1440-1448. 
Bleeker, G.B., Schalij, M.J., Boersma, E., Holman, E.R., Steendijk, P., van der Wall, 
E.E. & Bax, J.J. (2007b) Relative merits of M-mode echocardiography and tissue 
Doppler imaging for prediction of response to cardiac resynchronization therapy in 
patients with heart failure secondary to ischemic or idiopathic dilated 
cardiomyopathy. Am.J.Cardiol., 99, 68-74. 
Bleeker, G.B., Yu, C.M., Nihoyannopoulos, P., De, S.J., Van, d., V, Holman, E.R., 
Schalij, M.J., van der Wall, E.E. & Bax, J.J. (2007c) Optimal use of echocardiography 
in cardiac resynchronisation therapy. Heart, 93, 1339-1350. 
Bogert, L.W. & van Lieshout, J.J. (2005) Non-invasive pulsatile arterial pressure and 
stroke volume changes from the human finger. Exp.Physiol, 90, 437-446. 
  
304 
Bordachar, P., Lafitte, S., Reant, P., Reuter, S., Clementy, J., Mletzko, R.U., Siegel, 
R.M., Goscinska-Bis, K., Bowes, R., Morgan, J., Benard, S. & Leclercq, C. (2010) 
Low value of simple echocardiographic indices of ventricular dyssynchrony in 
predicting the response to cardiac resynchronization therapy. Eur J.Heart Fail., 12, 
588-592. 
Boriani, G., Muller, C.P., Seidl, K.H., Grove, R., Vogt, J., Danschel, W., Schuchert, 
A., Djiane, P., Biffi, M., Becker, T., Bailleul, C. & Trappe, H.J. (2006) Randomized 
comparison of simultaneous biventricular stimulation versus optimized 
interventricular delay in cardiac resynchronization therapy. The Resynchronization 
for the HemodYnamic Treatment for Heart Failure Management II implantable 
cardioverter defibrillator (RHYTHM II ICD) study. Am.Heart J., 151, 1050-1058. 
Bristow, M.R., Gilbert, E.M., Abraham, W.T., Adams, K.F., Fowler, M.B., 
Hershberger, R.E., Kubo, S.H., Narahara, K.A., Ingersoll, H., Krueger, S., Young, S. 
& Shusterman, N. (1996) Carvedilol produces dose-related improvements in left 
ventricular function and survival in subjects with chronic heart failure. MOCHA 
Investigators. Circulation, 94, 2807-2816. 
Bristow, M.R., Saxon, L.A., Boehmer, J., Krueger, S., Kass, D.A., De, M.T., Carson, 
P., DiCarlo, L., DeMets, D., White, B.G., DeVries, D.W. & Feldman, A.M. (2004) 
Cardiac-resynchronization therapy with or without an implantable defibrillator in 
advanced chronic heart failure. N.Engl.J.Med., 350, 2140-2150. 
Cappola, T.P., Harsch, M.R., Jessup, M., Abraham, W.T., Young, J.B., Petersen-
Stejskal, S., Plappert, T. & St John, S.M. (2006) Predictors of remodeling in the CRT 
era: influence of mitral regurgitation, BNP, and gender. J.Card Fail., 12, 182-188. 
Carluccio, E., Biagioli, P., Alunni, G., Murrone, A., Pantano, P., Biscottini, E., Zuchi, 
C., Zingarini, G., Cavallini, C. & Ambrosio, G. (2011) Presence of Extensive LV 
Remodeling Limits the Benefits of CRT in Patients With Intraventricular 
Dyssynchrony. JACC.Cardiovasc.Imaging, 4, 1067-1076. 
  
305 
Cazeau, S., Bordachar, P., Jauvert, G., Lazarus, A., Alonso, C., Vandrell, M.C., 
Mugica, J. & Ritter, P. (2003) Echocardiographic modeling of cardiac dyssynchrony 
before and during multisite stimulation: a prospective study. Pacing 
Clin.Electrophysiol., 26, 137-143. 
Cazeau, S., Leclercq, C., Lavergne, T., Walker, S., Varma, C., Linde, C., Garrigue, S., 
Kappenberger, L., Haywood, G.A., Santini, M., Bailleul, C. & Daubert, J.C. (2001) 
Effects of multisite biventricular pacing in patients with heart failure and 
intraventricular conduction delay. N.Engl.J.Med., 344, 873-880. 
Cazeau, S., Ritter, P., Bakdach, S., Lazarus, A., Limousin, M., Henao, L., Mundler, 
O., Daubert, J.C. & Mugica, J. (1994) Four chamber pacing in dilated 
cardiomyopathy. Pacing Clin.Electrophysiol., 17, 1974-1979. 
Cazeau, S.J., Daubert, J.C., Tavazzi, L., Frohlig, G. & Paul, V. (2008) Responders to 
cardiac resynchronization therapy with narrow or intermediate QRS complexes 
identified by simple echocardiographic indices of dyssynchrony: the DESIRE study. 
Eur.J.Heart Fail., 10, 273-280. 
Chung, E.S., Leon, A.R., Tavazzi, L., Sun, J.P., Nihoyannopoulos, P., Merlino, J., 
Abraham, W.T., Ghio, S., Leclercq, C., Bax, J.J., Yu, C.M., Gorcsan, J., III, St John, 
S.M., De, S.J. & Murillo, J. (2008a) Results of the Predictors of Response to CRT 
(PROSPECT) trial. Circulation, 117, 2608-2616. 
Chung, R., Sutton, R. & Henein, M.Y. (2008b) Beyond dyssynchrony in cardiac 
resynchronisation therapy. Heart, 94, 991-994. 
Cleland, J., Freemantle, N., Ghio, S., Fruhwald, F., Shankar, A., Marijanowski, M., 
Verboven, Y. & Tavazzi, L. (2008) Predicting the long-term effects of cardiac 
resynchronization therapy on mortality from baseline variables and the early response 
a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. 
J.Am.Coll.Cardiol., 52, 438-445. 
  
306 
Cleland, J.G., Daubert, J.C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, 
L., Klein, W. & Tavazzi, L. (2001) The CARE-HF study (CArdiac REsynchronisation 
in Heart Failure study): rationale, design and end-points. Eur.J.Heart Fail., 3, 481-
489. 
Cleland, J.G., Daubert, J.C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L. 
& Tavazzi, L. (2005) The effect of cardiac resynchronization on morbidity and 
mortality in heart failure. N.Engl.J.Med., 352, 1539-1549. 
Colocousis, J.S., Huntsman, L.L. & Curreri, P.W. (1977) Estimation of stroke volume 
changes by ultrasonic doppler. Circulation, 56, 914-917. 
Conca, C., Faletra, F.F., Miyazaki, C., Oh, J., Mantovani, A., Klersy, C., Sorgente, A., 
Pedrazzini, G.B., Pasotti, E., Moccetti, T. & Auricchio, A. (2009) Echocardiographic 
parameters of mechanical synchrony in healthy individuals. Am.J.Cardiol., 103, 136-
142. 
Corsi, C., Lang, R.M., Veronesi, F., Weinert, L., Caiani, E.G., MacEneaney, P., 
Lamberti, C. & Mor-Avi, V. (2005) Volumetric quantification of global and regional 
left ventricular function from real-time three-dimensional echocardiographic images. 
Circulation, 112, 1161-1170. 
Cowie, M.R., Wood, D.A., Coats, A.J., Thompson, S.G., Poole-Wilson, P.A., Suresh, 
V. & Sutton, G.C. (1999) Incidence and aetiology of heart failure; a population-based 
study. Eur Heart J., 20, 421-428. 
Cunningham D, Charles R, Cunningham M & de Lange A. (2011) Heart Rhythm 
Devices: UK National Clinical Audit 2009. Network Devices Survey Group: Heart 
Rhythm National Audit Reports. 
  
307 
Davies, L.C., Francis, D., Jurak, P., Kara, T., Piepoli, M. & Coats, A.J. (1999) 
Reproducibility of methods for assessing baroreflex sensitivity in normal controls and 
in patients with chronic heart failure. Clin.Sci.(Lond), 97, 515-522. 
De Boeck, B.W., Meine, M., Leenders, G.E., Teske, A.J., van, W.H., Kirkels, J.H., 
Prinzen, F.W., Doevendans, P.A. & Cramer, M.J. (2008) Practical and conceptual 
limitations of tissue Doppler imaging to predict reverse remodelling in cardiac 
resynchronisation therapy. Eur J.Heart Fail., 10, 281-290. 
Delgado, V., Ypenburg, C., van Bommel, R.J., Tops, L.F., Mollema, S.A., Marsan, 
N.A., Bleeker, G.B., Schalij, M.J. & Bax, J.J. (2008) Assessment of left ventricular 
dyssynchrony by speckle tracking strain imaging comparison between longitudinal, 
circumferential, and radial strain in cardiac resynchronization therapy. 
J.Am.Coll.Cardiol., 51, 1944-1952. 
Deplagne, A., Bordachar, P., Reant, P., Montaudon, M., Reuter, S., Laborderie, J., 
Dos, S.P., Roudaut, R., Jais, P., Haissaguerre, M., Laurent, F., Clementy, J. & Lafitte, 
S. (2009) Additional value of three-dimensional echocardiography in patients with 
cardiac resynchronization therapy. Arch.Cardiovasc.Dis., 102, 497-508. 
Diab, I.G., Hunter, R.J., Kamdar, R., Berriman, T., Duncan, E., Richmond, L., Baker, 
V., Abrams, D., Earley, M.J., Sporton, S. & Schilling, R.J. (2011) Does ventricular 
dyssynchrony on echocardiography predict response to cardiac resynchronisation 
therapy? A randomised controlled study. Heart, 97, 1410-1416. 
Diaz-Infante, E., Sitges, M., Vidal, B., Mont, L., Delgado, V., Marigliano, A., Macias, 
A., Tolosana, J.M., Tamborero, D., Azqueta, M., Roig, E., Pare, C. & Brugada, J. 
(2007) Usefulness of ventricular dyssynchrony measured using M-mode 
echocardiography to predict response to resynchronization therapy. Am.J.Cardiol., 
100, 84-89. 
Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J.J., Ponikowski, P., Poole-
Wilson, P.A., Stromberg, A., van Veldhuisen, D.J., Atar, D., Hoes, A.W., Keren, A., 
  
308 
Mebazaa, A., Nieminen, M., Priori, S.G., Swedberg, K., Vahanian, A., Camm, J., De, 
C.R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., 
Kristensen, S.D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P. 
& Zamorano, J.L. (2008) ESC Guidelines for the diagnosis and treatment of acute and 
chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute 
and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in 
collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by 
the European Society of Intensive Care Medicine (ESICM). Eur.Heart J., 29, 2388-
2442. 
Dorlas, J.C. & Nijboer, J.A. (1985) Photo-electric plethysmography as a monitoring 
device in anaesthesia. Application and interpretation. Br.J.Anaesth., 57, 524-530. 
Duncan, A.M., Lim, E., Clague, J., Gibson, D.G. & Henein, M.Y. (2006) Comparison 
of segmental and global markers of dyssynchrony in predicting clinical response to 
cardiac resynchronization. Eur Heart J., 27, 2426-2432. 
Duvall, W.L., Hansalia, R., Wijetunga, M.N., Buckley, S. & Fischer, A. (2010) 
Advantage of optimizing V-V timing in cardiac resynchronization therapy devices. 
Pacing Clin.Electrophysiol., 33, 1161-1168. 
Ellenbogen, K.A., Gold, M.R., Meyer, T.E., Fernndez, L., I, Mittal, S., Waggoner, 
A.D., Lemke, B., Singh, J.P., Spinale, F.G., Van Eyk, J.E., Whitehill, J., Weiner, S., 
Bedi, M., Rapkin, J. & Stein, K.M. (2010) Primary results from the SmartDelay 
determined AV optimization: a comparison to other AV delay methods used in 
cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing 
empirical, echocardiography-guided, and algorithmic atrioventricular delay 
programming in cardiac resynchronization therapy. Circulation, 122, 2660-2668. 
Faletra, F.F., Conca, C., Klersy, C., Klimusina, J., Regoli, F., Mantovani, A., Pasotti, 
E., Pedrazzini, G.B., De, C.S., Moccetti, T. & Auricchio, A. (2009) Comparison of 
eight echocardiographic methods for determining the prevalence of mechanical 
  
309 
dyssynchrony and site of latest mechanical contraction in patients scheduled for 
cardiac resynchronization therapy. Am.J.Cardiol., 103, 1746-1752. 
Finegold, J.A., Manisty, C.H., Cecaro, F., Sutaria, N., Mayet, J. & Francis, D.P. 
(2012) Choosing between velocity-time-integral ratio and peak velocity ratio for 
calculation of the dimensionless index (or aortic valve area) in serial follow-up of 
aortic stenosis. Int.J.Cardiol. 
Fischer, A., Hansalia, R., Buckley, S., Goldberg, R., Goldman, M., Muntner, P., 
Mehta, D. & Duvall, W.L. (2009) Lack of clinical predictors of optimal V-V delay in 
patients with cardiac resynchronization devices. J.Interv.Card Electrophysiol., 25, 
153-158. 
Flachskampf, F.A. & Daniel, W.G. (2010) Cardiac imaging in the patient with chest 
pain: echocardiography. Heart, 96, 1063-1072. 
Flather, M.D., Yusuf, S., Kober, L., Pfeffer, M., Hall, A., Murray, G., Torp-Pedersen, 
C., Ball, S., Pogue, J., Moye, L. & Braunwald, E. (2000) Long-term ACE-inhibitor 
therapy in patients with heart failure or left-ventricular dysfunction: a systematic 
overview of data from individual patients. ACE-Inhibitor Myocardial Infarction 
Collaborative Group. Lancet, 355, 1575-1581. 
Foley, P.W., Patel, K., Irwin, N., Sanderson, J.E., Frenneaux, M.P., Smith, R.E., 
Stegemann, B. & Leyva, F. (2011) Cardiac resynchronisation therapy in patients with 
heart failure and a normal QRS duration: the RESPOND study. Heart, 97, 1041-1047. 
Francis, D.P. (2011) Precision of a parabolic optimum calculated from noisy 
biological data, and implications for quantitative optimization of biventricular 
pacemakers (cardiac resynchronization therapy) . Applied Mathematics. 
  
310 
Francis, D.P., Coats, A.J. & Gibson, D.G. (1999) How high can a correlation 
coefficient be? Effects of limited reproducibility of common cardiological measures. 
Int.J.Cardiol., 69, 185-189. 
Geibel, A., Gornandt, L., Kasper, W. & Bubenheimer, P. (1991) Reproducibility of 
Doppler echocardiographic quantification of aortic and mitral valve stenoses: 
comparison between two echocardiography centers. Am.J.Cardiol., 67, 1013-1021. 
Ghio, S., Constantin, C., Klersy, C., Serio, A., Fontana, A., Campana, C. & Tavazzi, 
L. (2004) Interventricular and intraventricular dyssynchrony are common in heart 
failure patients, regardless of QRS duration. Eur.Heart J., 25, 571-578. 
Ghio, S., Freemantle, N., Scelsi, L., Serio, A., Magrini, G., Pasotti, M., Shankar, A., 
Cleland, J.G. & Tavazzi, L. (2009) Long-term left ventricular reverse remodelling 
with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J.Heart 
Fail., 11, 480-488. 
Ghio, S., Freemantle, N., Serio, A., Magrini, G., Scelsi, L., Pasotti, M., Cleland, J.G. 
& Tavazzi, L. (2006) Baseline echocardiographic characteristics of heart failure 
patients enrolled in a large European multicentre trial (CArdiac REsynchronisation 
Heart Failure study). Eur J.Echocardiogr., 7, 373-378. 
Gimenes, V.M., Vieira, M.L., Andrade, M.M., Pinheiro, J., Jr., Hotta, V.T. & 
Mathias, W., Jr. (2008) Standard values for real-time transthoracic three-dimensional 
echocardiographic dyssynchrony indexes in a normal population. 
J.Am.Soc.Echocardiogr., 21, 1229-1235. 
Gold, M.R., Niazi, I., Giudici, M., Leman, R.B., Sturdivant, J.L., Kim, M.H., Yu, Y., 
Ding, J. & Waggoner, A.D. (2007) A prospective comparison of AV delay 
programming methods for hemodynamic optimization during cardiac 
resynchronization therapy. J.Cardiovasc.Electrophysiol., 18, 490-496. 
  
311 
Gorcsan, J., Abraham, T., Agler, D.A., Bax, J.J., Derumeaux, G., Grimm, R.A., 
Martin, R., Steinberg, J.S., Sutton, M.S. & Yu, C.M. (2008) Echocardiography for 
cardiac resynchronization therapy: recommendations for performance and reporting--
a report from the American Society of Echocardiography Dyssynchrony Writing 
Group endorsed by the Heart Rhythm Society. J.Am.Soc.Echocardiogr., 21, 191-213. 
Gorcsan, J., Kanzaki, H., Bazaz, R., Dohi, K. & Schwartzman, D. (2004a) Usefulness 
of echocardiographic tissue synchronization imaging to predict acute response to 
cardiac resynchronization therapy. Am.J.Cardiol., 93, 1178-1181. 
Gorcsan, J., Lang, R.M., Picard, M.H., Zoghbi, W.A., Frommelt, P.C. & Gillam, L.D. 
(2004b) Meeting highlights of the 15th annual Scientific Sessions of the American 
Society of Echocardiography: June 26 to 30, 2004. J.Am.Coll.Cardiol., 44, 2111-
2116. 
Gorcsan, J., Tanabe, M., Bleeker, G.B., Suffoletto, M.S., Thomas, N.C., Saba, S., 
Tops, L.F., Schalij, M.J. & Bax, J.J. (2007) Combined longitudinal and radial 
dyssynchrony predicts ventricular response after resynchronization therapy. 
J.Am.Coll.Cardiol., 50, 1476-1483. 
Gras, D., Leclercq, C., Tang, A.S., Bucknall, C., Luttikhuis, H.O. & Kirstein-
Pedersen, A. (2002) Cardiac resynchronization therapy in advanced heart failure the 
multicenter InSync clinical study. Eur.J.Heart Fail., 4, 311-320. 
Hawkins, N.M., Petrie, M.C., Burgess, M.I. & McMurray, J.J. (2009) Selecting 
patients for cardiac resynchronization therapy: the fallacy of echocardiographic 
dyssynchrony. J.Am.Coll.Cardiol., 53, 1944-1959. 
Hawkins, N.M., Wang, D., McMurray, J.J., Pfeffer, M.A., Swedberg, K., Granger, 
C.B., Yusuf, S., Pocock, S.J., Ostergren, J., Michelson, E.L. & Dunn, F.G. (2007) 
Prevalence and prognostic impact of bundle branch block in patients with heart 
failure: evidence from the CHARM programme. Eur.J.Heart Fail., 9, 510-517. 
  
312 
Higgins, S.L., Hummel, J.D., Niazi, I.K., Giudici, M.C., Worley, S.J., Saxon, L.A., 
Boehmer, J.P., Higginbotham, M.B., De, M.T., Foster, E. & Yong, P.G. (2003) 
Cardiac resynchronization therapy for the treatment of heart failure in patients with 
intraventricular conduction delay and malignant ventricular tachyarrhythmias. 
J.Am.Coll.Cardiol., 42, 1454-1459. 
Hochleitner, M., Hortnagl, H., Ng, C.K., Hortnagl, H., Gschnitzer, F. & Zechmann, 
W. (1990) Usefulness of physiologic dual-chamber pacing in drug-resistant idiopathic 
dilated cardiomyopathy. Am.J.Cardiol., 66, 198-202. 
Holloway, C.J., Edwards, L.M., Rider, O.J., Fast, A., Clarke, K., Francis, J.M., 
Myerson, S.G. & Neubauer, S. (2011) A comparison of visual and quantitative 
assessment of left ventricular ejection fraction by cardiac magnetic resonance. 
Int.J.Cardiovasc.Imaging, 27, 563-569. 
Hutcheon, J.A., Chiolero, A. & Hanley, J.A. (2010) Random measurement error and 
regression dilution bias. BMJ, 340, c2289. 
Imholz, B.P., Wieling, W., van Montfrans, G.A. & Wesseling, K.H. (1998) Fifteen 
years experience with finger arterial pressure monitoring: assessment of the 
technology. Cardiovasc.Res., 38, 605-616. 
Inoue, N., Ishikawa, T., Sumita, S., Nakagawa, T., Kobayashi, T., Matsushita, K., 
Matsumoto, K., Ohkusu, Y., Taima, M., Kosuge, M., Uchino, K., Kimura, K. & 
Umemura, S. (2005a) Long-term follow-up of atrioventricular delay optimization in 
patients with biventricular pacing. Circ.J., 69, 201-204. 
Inoue, N., Ishikawa, T., Sumita, S., Nakagawa, T., Kobayashi, T., Matsushita, K., 
Matsumoto, K., Ohkusu, Y., Taima, M., Kosuge, M., Uchino, K., Kimura, K. & 
Umemura, S. (2005b) Long-term follow-up of atrioventricular delay optimization in 
patients with biventricular pacing. Circ.J., 69, 201-204. 
  
313 
Jansen, A.H., Bracke, F.A., van Dantzig, J.M., Meijer, A., van der Voort, P.H., 
Aarnoudse, W., van Gelder, B.M. & Peels, K.H. (2006a) Correlation of echo-Doppler 
optimization of atrioventricular delay in cardiac resynchronization therapy with 
invasive hemodynamics in patients with heart failure secondary to ischemic or 
idiopathic dilated cardiomyopathy. Am.J.Cardiol., 97, 552-557. 
Jansen, A.H., Bracke, F.A., van Dantzig, J.M., Meijer, A., van der Voort, P.H., 
Aarnoudse, W., van Gelder, B.M. & Peels, K.H. (2006b) Correlation of echo-Doppler 
optimization of atrioventricular delay in cardiac resynchronization therapy with 
invasive hemodynamics in patients with heart failure secondary to ischemic or 
idiopathic dilated cardiomyopathy. Am.J.Cardiol., 97, 552-557. 
Jenkins, C., Moir, S., Chan, J., Rakhit, D., Haluska, B. & Marwick, T.H. (2009) Left 
ventricular volume measurement with echocardiography: a comparison of left 
ventricular opacification, three-dimensional echocardiography, or both with magnetic 
resonance imaging. Eur Heart J., 30, 98-106. 
Kapetanakis, S., Bhan, A., Murgatroyd, F., Kearney, M.T., Gall, N., Zhang, Q., Yu, 
C.M. & Monaghan, M.J. (2011) Real-time 3D echo in patient selection for cardiac 
resynchronization therapy. JACC.Cardiovasc.Imaging, 4, 16-26. 
Kapetanakis, S., Kearney, M.T., Siva, A., Gall, N., Cooklin, M. & Monaghan, M.J. 
(2005) Real-time three-dimensional echocardiography: a novel technique to quantify 
global left ventricular mechanical dyssynchrony. Circulation, 112, 992-1000. 
Kass, D.A., Chen, C.H., Curry, C., Talbot, M., Berger, R., Fetics, B. & Nevo, E. 
(1999) Improved left ventricular mechanics from acute VDD pacing in patients with 
dilated cardiomyopathy and ventricular conduction delay. Circulation, 99, 1567-1573. 
Kaufman, C.L., Kaiser, D.R., Burns, K.V., Kelly, A.S. & Bank, A.J. (2010) Multi-
plane mechanical dyssynchrony in cardiac resynchronization therapy. Clin.Cardiol., 
33, E31-E38. 
  
314 
Kuhl, H.P., Schreckenberg, M., Rulands, D., Katoh, M., Schafer, W., Schummers, G., 
Bucker, A., Hanrath, P. & Franke, A. (2004) High-resolution transthoracic real-time 
three-dimensional echocardiography: quantitation of cardiac volumes and function 
using semi-automatic border detection and comparison with cardiac magnetic 
resonance imaging. J.Am.Coll.Cardiol., 43, 2083-2090. 
Kyriacou, A., Pabari, P.A. & Francis, D.P. (2011) Cardiac resynchronization therapy 
is certainly cardiac therapy, but how much resynchronization and how much 
atrioventricular delay optimization? Heart Fail.Rev. 
Lane, R.E., Chow, A.W., Chin, D. & Mayet, J. (2004) Selection and optimisation of 
biventricular pacing: the role of echocardiography. Heart, 90 Suppl 6, vi10-vi16. 
Lane, R.E., Mayet, J., Peters, N.S., Davies, D.W. & Chow, A.W. (2008) Comparison 
of temporary bifocal right ventricular pacing and biventricular pacing for heart 
failure: evaluation by tissue Doppler imaging. Heart, 94, 53-58. 
Lansdorp, B., Ouweneel, D., de, K.A., van der Hoeven, J.G., Lemson, J. & Pickkers, 
P. (2011) Non-invasive measurement of pulse pressure variation and systolic pressure 
variation using a finger cuff corresponds with intra-arterial measurement. 
Br.J.Anaesth. 
Le Cam L. (1986) The Central Limit Theorem Around 1935. Statistical Science, 1, 
78-91. 
Lehmann, K.G. & Platt, M.S. (1999) Improved accuracy and precision of 
thermodilution cardiac output measurement using a dual thermistor catheter system. 
J.Am.Coll.Cardiol., 33, 883-891. 
Linde, C., Abraham, W.T., Gold, M.R. & Daubert, C. (2010) Cardiac 
resynchronization therapy in asymptomatic or mildly symptomatic heart failure 
patients in relation to etiology: results from the REVERSE (REsynchronization 
  
315 
reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. 
J.Am.Coll.Cardiol., 56, 1826-1831. 
Linde, C., Abraham, W.T., Gold, M.R., St John, S.M., Ghio, S. & Daubert, C. (2008) 
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure 
patients and in asymptomatic patients with left ventricular dysfunction and previous 
heart failure symptoms. J.Am.Coll.Cardiol., 52, 1834-1843. 
Linde, C., Leclercq, C., Rex, S., Garrigue, S., Lavergne, T., Cazeau, S., McKenna, 
W., Fitzgerald, M., Deharo, J.C., Alonso, C., Walker, S., Braunschweig, F., Bailleul, 
C. & Daubert, J.C. (2002) Long-term benefits of biventricular pacing in congestive 
heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) 
study. J.Am.Coll.Cardiol., 40, 111-118. 
Liodakis, E., Sharef, O.A., Dawson, D. & Nihoyannopoulos, P. (2009) The use of 
real-time three-dimensional echocardiography for assessing mechanical 
synchronicity. Heart, 95, 1865-1871. 
Lopez-Candales, A. & Edelman, K. (2011) Ratio of right to left ventricular ejection: a 
pilot study using Doppler to detect interventricular dyssynchrony. Clin.Cardiol., 34, 
366-371. 
Lubitz, S.A., Leong-Sit, P., Fine, N., Kramer, D.B., Singh, J. & Ellinor, P.T. (2010) 
Effectiveness of cardiac resynchronization therapy in mild congestive heart failure: 
systematic review and meta-analysis of randomized trials. Eur J.Heart Fail., 12, 360-
366. 
MacRoberts MH & MacRoberts BR. (1984) The Negontional Reference: Or the Art 
of Dissembling. Social Studies of Science, 14, 91-94. 
Marcus, G.M., Rose, E., Viloria, E.M., Schafer, J., De, M.T., Saxon, L.A. & Foster, 
E. (2005) Septal to posterior wall motion delay fails to predict reverse remodeling or 
  
316 
clinical improvement in patients undergoing cardiac resynchronization therapy. 
J.Am.Coll.Cardiol., 46, 2208-2214. 
Marsan, N.A., Bleeker, G.B., Ypenburg, C., Ghio, S., Van de Veire, N.R., Holman, 
E.R., van der Wall, E.E., Tavazzi, L., Schalij, M.J. & Bax, J.J. (2008) Real-time three-
dimensional echocardiography permits quantification of left ventricular mechanical 
dyssynchrony and predicts acute response to cardiac resynchronization therapy. 
J.Cardiovasc.Electrophysiol., 19, 392-399. 
McGowan, J.H. & Cleland, J.G. (2003) Reliability of reporting left ventricular 
systolic function by echocardiography: a systematic review of 3 methods. Am.Heart 
J., 146, 388-397. 
Mele, D., Pasanisi, G., Capasso, F., De, S.A., Morales, M.A., Poggio, D., Capucci, A., 
Tabacchi, G., Sallusti, L. & Ferrari, R. (2006) Left intraventricular myocardial 
deformation dyssynchrony identifies responders to cardiac resynchronization therapy 
in patients with heart failure. Eur Heart J., 27, 1070-1078. 
Minners, J., Allgeier, M., Gohlke-Baerwolf, C., Kienzle, R.P., Neumann, F.J. & 
Jander, N. (2008) Inconsistencies of echocardiographic criteria for the grading of 
aortic valve stenosis. Eur.Heart J., 29, 1043-1048. 
Miyazaki, C., Redfield, M.M., Powell, B.D., Lin, G.M., Herges, R.M., Hodge, D.O., 
Olson, L.J., Hayes, D.L., Espinosa, R.E., Rea, R.F., Bruce, C.J., Nelson, S.M., Miller, 
F.A. & Oh, J.K. (2010) Dyssynchrony indices to predict response to cardiac 
resynchronization therapy: a comprehensive prospective single-center study. 
Circ.Heart Fail., 3, 565-573. 
Monaghan, M.J. (2006) Role of real time 3D echocardiography in evaluating the left 
ventricle. Heart, 92, 131-136. 
  
317 
Mortensen, P.T., Sogaard, P., Mansour, H., Ponsonaille, J., Gras, D., Lazarus, A., 
Reiser, W., Alonso, C., Linde, C.M., Lunati, M., Kramm, B. & Harrison, E.M. (2004) 
Sequential biventricular pacing: evaluation of safety and efficacy. Pacing 
Clin.Electrophysiol., 27, 339-345. 
Moss, A.J., Hall, W.J., Cannom, D.S., Klein, H., Brown, M.W., Daubert, J.P., Estes, 
N.A., III, Foster, E., Greenberg, H., Higgins, S.L., Pfeffer, M.A., Solomon, S.D., 
Wilber, D. & Zareba, W. (2009a) Cardiac-resynchronization therapy for the 
prevention of heart-failure events. N.Engl.J.Med., 361, 1329-1338. 
Moss, A.J., Hall, W.J., Cannom, D.S., Klein, H., Brown, M.W., Daubert, J.P., Estes, 
N.A., III, Foster, E., Greenberg, H., Higgins, S.L., Pfeffer, M.A., Solomon, S.D., 
Wilber, D. & Zareba, W. (2009b) Cardiac-resynchronization therapy for the 
prevention of heart-failure events. N.Engl.J.Med., 361, 1329-1338. 
Muller, R. & Buttner, P. (1994) A critical discussion of intraclass correlation 
coefficients. Stat.Med., 13, 2465-2476. 
Nelson, G.S., Berger, R.D., Fetics, B.J., Talbot, M., Spinelli, J.C., Hare, J.M. & Kass, 
D.A. (2000) Left ventricular or biventricular pacing improves cardiac function at 
diminished energy cost in patients with dilated cardiomyopathy and left bundle-
branch block. Circulation, 102, 3053-3059. 
Nishimura, R.A., Hayes, D.L., Holmes, D.R., Jr. & Tajik, A.J. (1995) Mechanism of 
hemodynamic improvement by dual-chamber pacing for severe left ventricular 
dysfunction: an acute Doppler and catheterization hemodynamic study. 
J.Am.Coll.Cardiol., 25, 281-288. 
Norisada, K., Kawai, H., Tanaka, H., Tatsumi, K., Onishi, T., Fukuzawa, K., Yoshida, 
A. & Hirata, K. (2010) Myocardial contractile function in the region of the left 
ventricular pacing lead predicts the response to cardiac resynchronization therapy 
assessed by two-dimensional speckle tracking echocardiography. 
J.Am.Soc.Echocardiogr., 23, 181-189. 
  
318 
Notabartolo, D., Merlino, J.D., Smith, A.L., DeLurgio, D.B., Vera, F.V., Easley, 
K.A., Martin, R.P. & Leon, A.R. (2004) Usefulness of the peak velocity difference by 
tissue Doppler imaging technique as an effective predictor of response to cardiac 
resynchronization therapy. Am.J.Cardiol., 94, 817-820. 
Otterstad, J.E., Froeland, G., St John, S.M. & Holme, I. (1997) Accuracy and 
reproducibility of biplane two-dimensional echocardiographic measurements of left 
ventricular dimensions and function. Eur Heart J., 18, 507-513. 
Pabari PA, Moraldo M, Mayet J, Kyriacou A, Francis DP & Manisty CH. (2012) 
Validating markers of mechanical dyssynchrony by experimental manipulation of 
interventricular timings: what is needed to make them a reasonable prospect for 
cardiac resynchronisation therapy selection? Heart, 98. 
Pabari, P.A., Willson, K., Stegemann, B., van Geldorp, I.E., Kyriacou, A., Moraldo, 
M., Mayet, J., Hughes, A.D. & Francis, D.P. (2011) When is an optimization not an 
optimization? Evaluation of clinical implications of information content (signal-to-
noise ratio) in optimization of cardiac resynchronization therapy, and how to measure 
and maximize it. Heart Fail.Rev., 16, 277-290. 
Palmieri, V., Russo, C., Buonomo, A., Cimmino, G., Tartaglione, D., Pezzullo, S. & 
Celentano, A. (2010) Test-re-test reproducibility of Doppler echocardiography for 
assessment of electromechanical dyssynchrony: implications for heart failure clinic. 
J.Cardiol., 56, 271-279. 
Park, H.E., Chang, S.A., Kim, H.K., Shin, D.H., Kim, J.H., Seo, M.K., Kim, Y.J., 
Cho, G.Y., Sohn, D.W., Oh, B.H. & Park, Y.B. (2010) Impact of loading condition on 
the 2D speckle tracking-derived left ventricular dyssynchrony index in nonischemic 
dilated cardiomyopathy. Circ.Cardiovasc.Imaging, 3, 272-281. 
Parreira, L., Santos, J.F., Madeira, J., Mendes, L., Seixo, F., Caetano, F., Lopes, C., 
Venancio, J., Mateus, A., Ines, J.L. & Mendes, M. (2005) Cardiac resynchronization 
  
319 
therapy with sequential biventricular pacing: impact of echocardiography guided VV 
delay optimization on acute results. Rev.Port.Cardiol., 24, 1355-1365. 
Penaz, J. (1973) Photoelectric measurement of blood pressure, volume and flow in the 
finger. Digest of the international Conference on Medicine and Biological 
Engineering, 104. 
Penicka, M., Bartunek, J., De, B.B., Vanderheyden, M., Goethals, M., De, Z.M., 
Brugada, P. & Geelen, P. (2004) Improvement of left ventricular function after 
cardiac resynchronization therapy is predicted by tissue Doppler imaging 
echocardiography. Circulation, 109, 978-983. 
Penzel, T., Mayer, J., Peter, J.H., Podszus, T., Voigt, K.H. & von, W.P. (1992) 
Continuous non-invasive blood pressure monitoring in patients with sleep disorders. 
Physiol Res., 41, 11-17. 
Perego, G.B., Chianca, R., Facchini, M., Frattola, A., Balla, E., Zucchi, S., Cavaglia, 
S., Vicini, I., Negretto, M. & Osculati, G. (2003) Simultaneous vs. sequential 
biventricular pacing in dilated cardiomyopathy: an acute hemodynamic study. 
Eur.J.Heart Fail., 5, 305-313. 
Pitt, B., Poole-Wilson, P.A., Segal, R., Martinez, F.A., Dickstein, K., Camm, A.J., 
Konstam, M.A., Riegger, G., Klinger, G.H., Neaton, J., Sharma, D. & Thiyagarajan, 
B. (2000) Effect of losartan compared with captopril on mortality in patients with 
symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival 
Study ELITE II. Lancet, 355, 1582-1587. 
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., 
Neaton, J., Roniker, B., Hurley, S., Burns, D., Bittman, R. & Kleiman, J. (2001) The 
EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction 
complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure 
Efficacy and Survival Study. Cardiovasc.Drugs Ther., 15, 79-87. 
  
320 
Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J. & 
Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients 
with severe heart failure. Randomized Aldactone Evaluation Study Investigators. 
N.Engl.J.Med., 341, 709-717. 
Pitzalis, M.V., Iacoviello, M., Romito, R., Guida, P., De, T.E., Luzzi, G., Anaclerio, 
M., Forleo, C. & Rizzon, P. (2005) Ventricular asynchrony predicts a better outcome 
in patients with chronic heart failure receiving cardiac resynchronization therapy. 
J.Am.Coll.Cardiol., 45, 65-69. 
Pitzalis, M.V., Iacoviello, M., Romito, R., Massari, F., Rizzon, B., Luzzi, G., Guida, 
P., Andriani, A., Mastropasqua, F. & Rizzon, P. (2002) Cardiac resynchronization 
therapy tailored by echocardiographic evaluation of ventricular asynchrony. 
J.Am.Coll.Cardiol., 40, 1615-1622. 
Pope, B.B. (2002) How to perform 3- or 5-lead monitoring. Nursing., 32, 50-52. 
Porciani, M.C., Dondina, C., Macioce, R., Demarchi, G., Cappelli, F., Lilli, A., 
Pappone, A., Ricciardi, G., Colombo, P.C., Padeletti, M., Jelic, S. & Padeletti, L. 
(2006a) Temporal variation in optimal atrioventricular and interventricular delay 
during cardiac resynchronization therapy. J.Card Fail., 12, 715-719. 
Porciani, M.C., Lilli, A., Macioce, R., Cappelli, F., Demarchi, G., Pappone, A., 
Ricciardi, G. & Padeletti, L. (2006b) Utility of a new left ventricular asynchrony 
index as a predictor of reverse remodelling after cardiac resynchronization therapy. 
Eur Heart J., 27, 1818-1823. 
Raphael CE., Kyriacou, A., Pabari, P.A., Cole G, Baruah R, Hughes, A.D. & Francis, 
D.P. (2011) Multinational evaluation of the interpretability of the iterative method of 
optimization of AV delay for CRT. ESC. 
  
321 
Reuter, S., Garrigue, S., Barold, S.S., Jais, P., Hocini, M., Haissaguerre, M. & 
Clementy, J. (2002) Comparison of characteristics in responders versus 
nonresponders with biventricular pacing for drug-resistant congestive heart failure. 
Am.J.Cardiol., 89, 346-350. 
Ritter, P., Padeletti, L., Gillio-Meina, L. & Gaggini, G. (1999) Determination of the 
optimal atrioventricular delay in DDD pacing. Comparison between echo and peak 
endocardial acceleration measurements. Europace., 1, 126-130. 
Sassone, B., Capecchi, A., Boggian, G., Gabrieli, L., Sacca, S., Vandelli, R., Petracci, 
E. & Mele, D. (2007) Value of baseline left lateral wall postsystolic displacement 
assessed by M-mode to predict reverse remodeling by cardiac resynchronization 
therapy. Am.J.Cardiol., 100, 470-475. 
Sawhney, N.S., Waggoner, A.D., Garhwal, S., Chawla, M.K., Osborn, J. & Faddis, 
M.N. (2004) Randomized prospective trial of atrioventricular delay programming for 
cardiac resynchronization therapy. Heart Rhythm., 1, 562-567. 
Scharf, C., Li, P., Muntwyler, J., Chugh, A., Oral, H., Pelosi, F., Morady, F. & 
Armstrong, W.F. (2005) Rate-dependent AV delay optimization in cardiac 
resynchronization therapy. Pacing Clin.Electrophysiol., 28, 279-284. 
Schutte, A.E., Huisman, H.W., van Rooyen, J.M., Malan, N.T. & Schutte, R. (2004) 
Validation of the Finometer device for measurement of blood pressure in black 
women. J.Hum.Hypertens., 18, 79-84. 
Shamim, W., Francis, D.P., Yousufuddin, M., Varney, S., Pieopli, M.F., Anker, S.D. 
& Coats, A.J. (1999) Intraventricular conduction delay: a prognostic marker in 
chronic heart failure. Int.J.Cardiol., 70, 171-178. 
  
322 
Smith, N.T., Wesseling, K.H. & de, W.B. (1985) Evaluation of two prototype devices 
producing noninvasive, pulsatile, calibrated blood pressure measurement from a 
finger. J.Clin.Monit., 1, 17-29. 
Sogaard, P., Egeblad, H., Pedersen, A.K., Kim, W.Y., Kristensen, B.O., Hansen, P.S. 
& Mortensen, P.T. (2002) Sequential versus simultaneous biventricular 
resynchronization for severe heart failure: evaluation by tissue Doppler imaging. 
Circulation, 106, 2078-2084. 
Soliman, O.I., Geleijnse, M.L., Theuns, D.A., van Dalen, B.M., Vletter, W.B., 
Jordaens, L.J., Metawei, A.K., Al-Amin, A.M. & Ten Cate, F.J. (2009) Usefulness of 
left ventricular systolic dyssynchrony by real-time three-dimensional 
echocardiography to predict long-term response to cardiac resynchronization therapy. 
Am.J.Cardiol., 103, 1586-1591. 
Soliman, O.I., Krenning, B.J., Geleijnse, M.L., Nemes, A., Bosch, J.G., van Geuns, 
R.J., Kirschbaum, S.W., Anwar, A.M., Galema, T.W., Vletter, W.B. & Ten Cate, F.J. 
(2007a) Quantification of left ventricular volumes and function in patients with 
cardiomyopathies by real-time three-dimensional echocardiography: a head-to-head 
comparison between two different semiautomated endocardial border detection 
algorithms. J.Am.Soc.Echocardiogr., 20, 1042-1049. 
Soliman, O.I., Theuns, D.A., Geleijnse, M.L., Anwar, A.M., Nemes, A., Caliskan, K., 
Vletter, W.B., Jordaens, L.J. & Cate, F.J. (2007b) Spectral pulsed-wave tissue 
Doppler imaging lateral-to-septal delay fails to predict clinical or echocardiographic 
outcome after cardiac resynchronization therapy. Europace., 9, 113-118. 
Solomon, S.D., Foster, E., Bourgoun, M., Shah, A., Viloria, E., Brown, M.W., Hall, 
W.J., Pfeffer, M.A. & Moss, A.J. (2010) Effect of cardiac resynchronization therapy 
on reverse remodeling and relation to outcome: multicenter automatic defibrillator 
implantation trial: cardiac resynchronization therapy. Circulation, 122, 985-992. 
  
323 
St John Sutton, M.G., Plappert, T., Abraham, W.T., Smith, A.L., DeLurgio, D.B., 
Leon, A.R., Loh, E., Kocovic, D.Z., Fisher, W.G., Ellestad, M., Messenger, J., 
Kruger, K., Hilpisch, K.E. & Hill, M.R. (2003) Effect of cardiac resynchronization 
therapy on left ventricular size and function in chronic heart failure. Circulation, 107, 
1985-1990. 
Stewart, R.A., Young, A.A., Anderson, C., Teo, K.K., Jennings, G. & Cowan, B.R. 
(2011) Relationship between QRS duration and left ventricular mass and volume in 
patients at high cardiovascular risk. Heart. 
Suffoletto, M.S., Dohi, K., Cannesson, M., Saba, S. & Gorcsan, J., III. (2006) Novel 
speckle-tracking radial strain from routine black-and-white echocardiographic images 
to quantify dyssynchrony and predict response to cardiac resynchronization therapy. 
Circulation, 113, 960-968. 
Sutton, M.G., Plappert, T., Hilpisch, K.E., Abraham, W.T., Hayes, D.L. & Chinchoy, 
E. (2006a) Sustained reverse left ventricular structural remodeling with cardiac 
resynchronization at one year is a function of etiology: quantitative Doppler 
echocardiographic evidence from the Multicenter InSync Randomized Clinical 
Evaluation (MIRACLE). Circulation, 113, 266-272. 
Sutton, M.G., Plappert, T., Hilpisch, K.E., Abraham, W.T., Hayes, D.L. & Chinchoy, 
E. (2006b) Sustained reverse left ventricular structural remodeling with cardiac 
resynchronization at one year is a function of etiology: quantitative Doppler 
echocardiographic evidence from the Multicenter InSync Randomized Clinical 
Evaluation (MIRACLE). Circulation, 113, 266-272. 
Tamborero, D., Vidal, B., Tolosana, J.M., Sitges, M., Berruezo, A., Silva, E., Castel, 
M., Matas, M., Arbelo, E., Rios, J., Villacastin, J., Brugada, J. & Mont, L. (2011) 
Electrocardiographic versus Echocardiographic Optimization of the Interventricular 
Pacing Delay in Patients Undergoing Cardiac Resynchronization Therapy. 
J.Cardiovasc.Electrophysiol. 
  
324 
Thomas, D.E., Yousef, Z.R. & Fraser, A.G. (2009) A critical comparison of 
echocardiographic measurements used for optimizing cardiac resynchronization 
therapy: stroke distance is best. Eur.J.Heart Fail., 11, 779-788. 
Tribouilloy, C., Shen, W.F., Rey, J.L., Adam, M.C. & Lesbre, J.P. (1994) Mitral to 
aortic velocity-time integral ratio. A non-geometric pulsed-Doppler regurgitant index 
in isolated pure mitral regurgitation. Eur.Heart J., 15, 1335-1339. 
Turcott, R.G. & Pavek, T.J. (2008) Hemodynamic sensing using subcutaneous 
photoplethysmography. Am.J.Physiol Heart Circ.Physiol, 295, H2560-H2572. 
Turcott, R.G., Witteles, R.M., Wang, P.J., Vagelos, R.H., Fowler, M.B. & Ashley, 
E.A. (2010) Measurement precision in the optimization of cardiac resynchronization 
therapy. Circ.Heart Fail., 3, 395-404. 
Valzania, C., Eriksson, M.J., Boriani, G. & Gadler, F. (2008) Cardiac 
resynchronization therapy during rest and exercise: comparison of two optimization 
methods. Europace., 10, 1161-1169. 
van Bommel, R.J., Gorcsan, J., III, Chung, E.S., Abraham, W.T., Gjestvang, F.T., 
Leclercq, C., Monaghan, M.J., Nihoyannopoulos, P., Peraldo, C., Yu, C.M., Demas, 
M., Gerritse, B. & Bax, J.J. (2010a) Effects of cardiac resynchronisation therapy in 
patients with heart failure having a narrow QRS Complex enrolled in PROSPECT. 
Heart, 96, 1107-1113. 
van Bommel, R.J., Ypenburg, C., Borleffs, C.J., Delgado, V., Marsan, N.A., Bertini, 
M., Holman, E.R., Schalij, M.J. & Bax, J.J. (2010b) Value of tissue Doppler 
echocardiography in predicting response to cardiac resynchronization therapy in 
patients with heart failure. Am.J.Cardiol., 105, 1153-1158. 
Van de Veire, N.R., Bleeker, G.B., De, S.J., Ypenburg, C., Holman, E.R., van der 
Wall, E.E., Schalij, M.J. & Bax, J.J. (2007) Tissue synchronisation imaging 
  
325 
accurately measures left ventricular dyssynchrony and predicts response to cardiac 
resynchronisation therapy. Heart, 93, 1034-1039. 
van Gelder, B.M., Bracke, F.A., Meijer, A., Lakerveld, L.J. & Pijls, N.H. (2004) 
Effect of optimizing the VV interval on left ventricular contractility in cardiac 
resynchronization therapy. Am.J.Cardiol., 93, 1500-1503. 
van Geldorp, I.E., Delhaas, T., Hermans, B., Vernooy, K., Broers, B., Klimusina, J., 
Regoli, F., Faletra, F.F., Moccetti, T., Gerritse, B., Cornelussen, R., Settels, J.J., 
Crijns, H.J., Auricchio, A. & Prinzen, F.W. (2011) Comparison of a non-invasive 
arterial pulse contour technique and echo Doppler aorta velocity-time integral on 
stroke volume changes in optimization of cardiac resynchronization therapy. 
Europace., 13, 87-95. 
van, E.J., Hasenbos, M. & Crul, J.F. (1985) Invasive v. non-invasive measurement of 
arterial pressure. Comparison of two automatic methods and simultaneously measured 
direct intra-arterial pressure. Br.J.Anaesth., 57, 434-444. 
Vanderheyden, M., De, B.T., Rivero-Ayerza, M., Geelen, P., Bartunek, J., Verstreken, 
S., De, Z.M. & Goethals, M. (2005) Tailored echocardiographic interventricular delay 
programming further optimizes left ventricular performance after cardiac 
resynchronization therapy. Heart Rhythm., 2, 1066-1072. 
Vesely, M.R., Li, S., Kop, W.J., Reese, A., Marshall, J., Shorofsky, S.R., Gottlieb, 
S.S., Mehra, M.R. & Gottdiener, J.S. (2008) Test-retest reliability of assessment for 
intraventricular dyssynchrony by tissue Doppler imaging echocardiography. 
Am.J.Cardiol., 101, 645-650. 
Vidal, B., Tamborero, D., Mont, L., Sitges, M., Delgado, V., Berruezo, A., Diaz-
Infante, E., Tolosana, J.M., Pare, C. & Brugada, J. (2007) Electrocardiographic 
optimization of interventricular delay in cardiac resynchronization therapy: a simple 
method to optimize the device. J.Cardiovasc.Electrophysiol., 18, 1252-1257. 
  
326 
Wang, C.L., Wu, C.T., Yeh, Y.H., Wu, L.S., Chang, C.J., Ho, W.J., Hsu, L.A., 
Luqman, N. & Kuo, C.T. (2010) Recoordination rather than resynchronization 
predicts reverse remodeling after cardiac resynchronization therapy. 
J.Am.Soc.Echocardiogr., 23, 611-620. 
Wesseling, K.H., Settels, J.J., van der Hoeven, G.M., Nijboer, J.A., Butijn, M.W. & 
Dorlas, J.C. (1985) Effects of peripheral vasoconstriction on the measurement of 
blood pressure in a finger. Cardiovasc.Res., 19, 139-145. 
Whinnett, Z.I., Davies, J.E., Nott, G., Willson, K., Manisty, C.H., Peters, N.S., 
Kanagaratnam, P., Davies, D.W., Hughes, A.D., Mayet, J. & Francis, D.P. (2008) 
Efficiency, reproducibility and agreement of five different hemodynamic measures for 
optimization of cardiac resynchronization therapy. Int.J.Cardiol., 129, 216-226. 
Whinnett, Z.I., Davies, J.E., Willson, K., Chow, A.W., Foale, R.A., Davies, D.W., 
Hughes, A.D., Francis, D.P. & Mayet, J. (2006a) Determination of optimal 
atrioventricular delay for cardiac resynchronization therapy using acute non-invasive 
blood pressure. Europace., 8, 358-366. 
Whinnett, Z.I., Davies, J.E., Willson, K., Manisty, C.H., Chow, A.W., Foale, R.A., 
Davies, D.W., Hughes, A.D., Mayet, J. & Francis, D.P. (2006b) Haemodynamic 
effects of changes in atrioventricular and interventricular delay in cardiac 
resynchronisation therapy show a consistent pattern: analysis of shape, magnitude and 
relative importance of atrioventricular and interventricular delay. Heart, 92, 1628-
1634. 
Whinnett, Z.I., Nott, G., Davies, J.E., Willson, K., Manisty, C.H., Kanagaratnam, P., 
Peters, N.S., Davies, D.W., Hughes, A.D., Mayet, J. & Francis, D.P. (2011) 
Maximizing efficiency of alternation algorithms for hemodynamic optimization of the 
AV delay of cardiac resynchronization therapy. Pacing Clin.Electrophysiol., 34, 217-
225. 
  
327 
Wikstrom, G., Blomstrom-Lundqvist, C., Andren, B., Lonnerholm, S., Blomstrom, P., 
Freemantle, N., Remp, T. & Cleland, J.G. (2009) The effects of aetiology on outcome 
in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur 
Heart J., 30, 782-788. 
Xiao, H.B., Lee, C.H. & Gibson, D.G. (1991) Effect of left bundle branch block on 
diastolic function in dilated cardiomyopathy. Br.Heart J., 66, 443-447. 
Young, J.B., Abraham, W.T., Smith, A.L., Leon, A.R., Lieberman, R., Wilkoff, B., 
Canby, R.C., Schroeder, J.S., Liem, L.B., Hall, S. & Wheelan, K. (2003) Combined 
cardiac resynchronization and implantable cardioversion defibrillation in advanced 
chronic heart failure: the MIRACLE ICD Trial. JAMA, 289, 2685-2694. 
Yu, C.M., Bax, J.J., Monaghan, M. & Nihoyannopoulos, P. (2004a) 
Echocardiographic evaluation of cardiac dyssynchrony for predicting a favourable 
response to cardiac resynchronisation therapy. Heart, 90 Suppl 6, vi17-vi22. 
Yu, C.M., Bax, J.J., Monaghan, M. & Nihoyannopoulos, P. (2004b) 
Echocardiographic evaluation of cardiac dyssynchrony for predicting a favourable 
response to cardiac resynchronisation therapy. Heart, 90 Suppl 6, vi17-vi22. 
Yu, C.M., Chau, E., Sanderson, J.E., Fan, K., Tang, M.O., Fung, W.H., Lin, H., 
Kong, S.L., Lam, Y.M., Hill, M.R. & Lau, C.P. (2002) Tissue Doppler 
echocardiographic evidence of reverse remodeling and improved synchronicity by 
simultaneously delaying regional contraction after biventricular pacing therapy in 
heart failure. Circulation, 105, 438-445. 
Yu, C.M., Fung, J.W., Zhang, Q., Chan, C.K., Chan, Y.S., Lin, H., Kum, L.C., Kong, 
S.L., Zhang, Y. & Sanderson, J.E. (2004c) Tissue Doppler imaging is superior to 
strain rate imaging and postsystolic shortening on the prediction of reverse 
remodeling in both ischemic and nonischemic heart failure after cardiac 
resynchronization therapy. Circulation, 110, 66-73. 
  
328 
Yu, C.M., Fung, W.H., Lin, H., Zhang, Q., Sanderson, J.E. & Lau, C.P. (2003) 
Predictors of left ventricular reverse remodeling after cardiac resynchronization 
therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. 
Am.J.Cardiol., 91, 684-688. 
Yu, C.M., Gorcsan, J., III, Bleeker, G.B., Zhang, Q., Schalij, M.J., Suffoletto, M.S., 
Fung, J.W., Schwartzman, D., Chan, Y.S., Tanabe, M. & Bax, J.J. (2007) Usefulness 
of tissue Doppler velocity and strain dyssynchrony for predicting left ventricular 
reverse remodeling response after cardiac resynchronization therapy. Am.J.Cardiol., 
100, 1263-1270. 
Yu, C.M., Zhang, Q., Fung, J.W., Chan, H.C., Chan, Y.S., Yip, G.W., Kong, S.L., 
Lin, H., Zhang, Y. & Sanderson, J.E. (2005) A novel tool to assess systolic 
asynchrony and identify responders of cardiac resynchronization therapy by tissue 
synchronization imaging. J.Am.Coll.Cardiol., 45, 677-684. 
Yu, Y.M., Chen, M., Xiong, Y., Chau, M.M., Li, R.S. & Lau, T.K. (2009) 
Comparison of conventional and PureWave Crystal transducer in obstetric 
sonography. J.Matern.Fetal Neonatal Med., 22, 616-621. 
Zhang, Q., Fung, J.W., Chan, Y.S., Chan, H.C., Lin, H., Chan, S. & Yu, C.M. (2008) 
The role of repeating optimization of atrioventricular interval during interim and long-
term follow-up after cardiac resynchronization therapy. Int.J.Cardiol., 124, 211-217. 
Zhang, Q., Liang, Y.J., Zhang, Q.H., Li, R.J., Chua, Y., Xie, J.M., Lee, P.W. & Yu, 
C.M. (2011) Impact of a Dedicated Training Program on the Reproducibility of 
Systolic Dyssynchrony Measures Using Tissue Doppler Imaging. 
J.Am.Soc.Echocardiogr. 
Zuber, M., Toggweiler, S., Quinn-Tate, L., Brown, L., Amkieh, A. & Erne, P. (2008) 
A comparison of acoustic cardiography and echocardiography for optimizing 
pacemaker settings in cardiac resynchronization therapy. Pacing Clin.Electrophysiol., 
31, 802-811. 
  
329 
 
 
 
